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Abstract 	  
Purple acid phosphatases (PAPs) are binuclear metallohydrolases that have been isolated from 
various mammals, plants, fungi and bacteria. They catalyse phosphoric ester hydrolysis under acidic 
to neutral conditions by utilising two closely spaced heterovalent metal ions in their active sites. In 
mammals, PAP activity is associated with bone resorption, which can lead to bone diseases such as 
osteoporosis. For instance, osteoporosis patients are observed to have elevated PAP serum levels. 
Furthermore, research has shown that transgenic mice that over-expressed the PAP gene developed 
mild osteoporosis. These observations therefore make human PAP an attractive target to develop 
anti-osteoporotic drugs. 
This project employed the strategy of using a substrate analogue, where the lead compound (as 
shown below) with Ki value of 8 µM against pig PAP was chosen as the basis in this rational drug 
design. Therefore acyl derivatives of α-aminoarylmethylphosphonic acids (as shown below) were 
designed as potential new potent PAP inhibitors. Docking studies suggested that the derivatives 
would have high binding affinity due to the phosphonate moiety (substrate mimic) binding to the 
binuclear metal centre, which are as intended. Furthermore, the long acyl chains make favourable 
interactions with the long hydrophobic groove adjacent to the dimetal centre, and depending on the 
size and substitutions on the aromatic ring, the ring might occupy the space in any of the small 
pockets in the vicinity of the active site; all of which contribute to the predicted high binding 
affinities of the derivatives to the enzyme. 
 
The lead compound: (naphthalene-1-yl(tetradecanamido)methyl)phosphonic acid 
 
R1 = , , , ,  
R2 = Me(CH2)m-, Me(CH2)nOCH2-; m = 8, 10, 12, 14, 16; n = 7, 15, 17. 
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The derivatives were synthesised in three or four steps method in good yields and then tested as pig 
PAP inhibitors. The kinetic studies in this project were performed using newly extracted and 
purified pig PAP. The extraction and purification of pig PAP from the allantoic fluid of a pregnant 
pig was successfully carried out using fast protein liquid chromatography (FPLC) by adapting a 
well-established protocol. Kinetic analysis showed that the derivatives have high inhibition 
potencies against pig PAP with Ki values in the low micromolar to nanomolar range. The most 
potent pig PAP inhibitor within this series was the octadecyl-derivative of α-
(phenyl(amido)methyl)phosphonic acid with Ki value of 168 nM. This is the most potent pig PAP 
inhibitor to date. 
Screening tests on a hundred other compounds were also performed to identify new possible 
alternative PAP inhibitors. Most of the compounds have metal-binding moieties as they were 
developed as inhibitors of a metallo-β-lactamase, which is also a binuclear metallohydrolase. 
Therefore it was thought that they might have inhibition properties against PAPs. However, they 
were found to have little or no inhibition against pig PAP. Nonetheless, these results provide 
valuable information, where phosphonic acid is a better choice to be employed as the metal-binding 
component, compared with other metal-ligating motifs such as thiol, carboxylate, imidazole, nitrile, 
or pyrrole groups, in the future design of potential PAP inhibitors. 
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Chapter 1  INTRODUCTION 
1.1  Osteoporosis 
Osteoporosis is a systemic skeletal disease that is more common among elderly people, although it 
does strike at any age without the patients’ awareness. It is therefore termed as a ‘silent’ disease as 
it is not clinically evident (no sign or symptom), until a bone fracture occurs.1-2 A person is 
diagnosed to have osteoporosis when he or she has bone mineral density (BMD) levels at the hip or 
spine of more than 2.5 standard deviations below the young-adult reference population (T-score of  
-2.5 or less).1,3 The risk of bone fracture increases when the bone becomes more fragile due to an 
osteoporosis patient having low BMD and microarchitectural deterioration of bone tissue.1,3-7 
Therefore, osteoporosis is a risk factor for fracture. 
Osteoporosis develops as a result of extensive bone loss, which is due to many factors such as the 
thinning of bone cortex, the increasing porosity of cortical bone and also the destruction of 
trabeculae through thinning and perforation. Although bone loss is attributable to many factors, it is 
primarily caused by higher level of bone resorption than bone formation, thus interrupting the 
balance of the dynamic bone remodelling process.1,3,6 This dynamic process is essential to ensure 
healthy bones in humans. However, as we age, bone resorption by osteoclasts (bone-resorbing cells) 
starts to exceed bone formation by osteoblasts (bone-forming cells). Therefore, the occurrence and 
progression of osteoporosis increases with age due to age-dependent bone loss.1 
Women approaching menopause usually have lower “peak bone mass” and changes in their 
hormonal system, thus making them more susceptible to osteoporosis. This therefore increases the 
prevalence of osteoporosis in women by approximately three times more than that of men.1 
Furthermore, an estimated one in two American3,8 and Australian9 women will suffer an 
osteoporotic fracture in their lifetime, as compared to one in four American men3,8 and one in three 
Australian men.9 Although the most common osteoporosis-related fractures are usually at the hip, 
vertebrae and distal forearm (wrist),1,7,9 but they can also occur at other sites such as ribs and upper 
arm,9-10 or at any other bone in the body.3,8  
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1.1.1  Osteoporosis and its importance 
Osteoporotic fractures can cause significant morbidity such as kyphosis (severe rounding of the 
back), muscle weakness, height loss, vertebral deformity, chronic pain, disability and dependence,9 
and even some mortality, where approximately 20% of osteoporosis patients with a hip fracture die 
within the next one year.1,3,11 Although osteoporotic fractures at other sites are considered less 
serious, osteoporosis fractures also have the ‘cascade effect’, where 50% of osteoporosis patients 
with a fracture will have another, and the risk of future fractures is amplified with each new 
fracture.3 Therefore, the risk of fractures in patients needs to be reduced in order to manage 
osteoporosis. 
The consequences of osteoporosis not only impact the patients and their families, but also the 
economy due to healthcare expenditure and loss of working days. For example, in 2005, the US 
suffered a total loss of US$17 billion due to approximately 2 million osteoporotic fractures,8,10 and 
the incidences of fracture and annual cost are projected to increase by almost 50% by 2025.8,12 In 
Europe, an increase from €31.7 billion in 2005 to a staggering €76.7 billion in 2050 is projected for 
the total direct cost for osteoporosis-related fractures.11 On the other hand, the impact of 
osteoporosis costs Australia as much as AU$7 billion due to loss of working days, and AU$1.9 
billion for direct osteoporosis-healthcare costs, per annum.10  
Osteoporosis is highly prevalent; more than 75 million people are diagnosed with osteoporosis in 
Europe, Japan and the US.1 In the US alone, it is estimated that there will be a dramatic increase 
from 44 million in 20088 to 61 million in 202011 in the number of osteoporosis and osteopenia 
(those with high risk of developing osteoporosis) patients. In addition, more than 2.3 million 
osteoporosis-related fractures are reported to occur in the US and Europe, annually.1 Furthermore, 
in a global scale, the incidence of hip fractures alone in 1990 was estimated to be about 1.5 million, 
and is projected to increase to a substantial 4.5-6.3 million in 2050.1 The significant increase in the 
estimated number of osteoporosis patients and osteoporosis-related fractures poses a substantial 
global health threat. Therefore, there is an urgent need to manage osteoporosis.  
1.1.2  Current osteoporosis treatments 
The main aim of osteoporosis treatments is to prevent or reduce bone loss and to promote bone 
formation in osteoporosis patients, or individuals with low BMD, who are therefore at risk of 
developing osteoporosis or osteopenia. Prevention or reduction in bone loss will consequently 
decrease the risk and the occurrence of osteoporosis-related fractures1 and increase in bone 
formation will result in higher BMD levels in the patients. There are several classes of osteoporosis 
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medications that are currently available: (1) antiresorptive therapies, (2) anabolic agents such as 
parathyroid hormones, and (3) dual action bone agents (DABAs) such as strontium ranelate. Of the 
three classes of osteoporosis treatments, the most widely prescribed medications are the 
antiresorptive agents, which mainly focus on reducing or stopping net bone loss.2 Antiresorptives 
include (1) bisphosphonates, (2) selective oestrogen receptor modulator (SERM), (3) hormone 
replacement therapies (HRTs) and (4) RANK (receptor activator of nuclear factor κ B) signalling 
inhibitors.3 Patients with especially low BMD levels and who are bisphosphonate-intolerant are 
usually prescribed the anabolic agent, parathyroid hormone. In addition, lifestyle changes such as 
increasing calcium intake and the weekly amount of exercise, decreasing alcohol intake, and 
smoking cessation can also assist in preventing the development of osteoporosis.1,9 
The bisphosphonate drugs, which are the synthetic analogues of pyrophosphates (Figure 1), are the 
current gold standard treatment for osteoporosis. Two types of bisphosphonates exist, which are (1) 
non-nitrogenous bisphosphonates,1,13-15 and (2) nitrogenous bisphosphonates (Table 1).14-16 Both 
types of bisphosphonates exert their anti-resorptive effects by destroying the bone-resorbing cells 
(osteoclasts) by inducing apoptosis,17-21 however they differ in the mechanism by which they induce 
osteoclast apoptosis. Non-nitrogenous bisphosphonates are postulated to have a direct toxic effect 
on osteoclasts by interrupting the cellular energy metabolism of osteoclasts by incorporating into 
adenosine triphosphate (ATP), the cell energy source. The accumulation of the resulting metabolites 
that are resistant to hydrolysis results in osteoclast apoptosis.18-20 On the other hand, nitrogen-
containing bisphosphonates act by inhibiting the enzyme farnesyl pyrophosphate synthase in the 
cholesterol mevalonic pathway. This results in the disruption of the cytoskeletal integrity of 
osteoclasts, hence inducing apoptosis.14-15,19-20,22-23 Thus, the overall effect of the bisphosphonate 
drugs is decreased bone resorption.1,13  
  
Figure 1: General structure of a) bisphosphonates and b) pyrophosphates. R1 and R2 side chains for 
bisphosphonates are shown in Table 1. 
Although bisphosphonates have been shown to reduce fracture risk and increase BMD,24-32 non-
compliance is high due to various reasons such as safety concerns and their strict daily dosage 
regimens.1-3 The safety issues of bisphosphonates include the risk of excessive inhibition of bone 
remodelling from its prolonged use, which increases the accumulation of bone microdamage, thus 
delaying the healing of fractures and reducing bone strength.33-35 Bisphosphonates that are taken 
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orally can cause intestinal disturbances due to them having poor intestinal absorption.1 The more 
common side effects of this class of drugs include nausea, vomiting, diarrhoea, muscle pain, joint 
pain and headache, as well as oesophagitis and inflammations of the stomach and digestive system.1 
Furthermore, some cases of long-term use of bisphosphonates have been associated with 
osteonecrosis of the jaw (ONJ).36-37 Osteoporosis patients prescribed with bisphosphonates have 
also been shown to have higher risk of atrial fibrillation38-40 and, peculiarly, higher incidence of 
atypical femoral shaft fractures.40-45 
Table 1: R1 and R2 side chains for non-nitrogenous and nitrogenous bisphosphonates.19 
Type of bisphosphonate Agent R1 side chain R2 side chain 
Non-nitrogenous 
Clodronate -Cl -Cl 
Etidronate -OH -CH3 
Tiludronate -H 
 
Nitrogenous 
Alendronate -OH -(CH2)3NH2 
Ibandronate -OH 
 
Neridronate -OH -(CH2)5NH2 
Olpadronate -OH -(CH2)2N(CH3)2 
Pamidronate -OH -(CH2)2NH2 
Risedronate -OH 
 
Zoledronate -OH 
 
None of the currently prescribed anti-osteoporotic drugs have high efficacies in restoring lost bone 
mass, and the effectiveness of the current medications in preventing fracture incidences are still less 
than 50%.3,24-29,31-32,46-47 In addition, the BMD increases attributable to these drugs are only 
moderate and are only due to bone tissue mineralisation rather than to the desired increase in bone 
tissue. Furthermore, the numerous side effects from taking the medications1,3,33-46 make them 
unfavourable. These unmet needs of osteoporosis patients from the currently available treatments 
signify the need for the development of new drugs with high efficacies and better safety profiles. 
S
Cl
N (CH2)4Me
Me
N
N N
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1.1.3  Purple acid phosphatase (PAP) and osteoporosis 
It is apparent that efforts should be put into developing new pharmacological treatments for 
osteoporosis that are effective and safe. The best strategy to prevent bone loss is to halt or delay 
bone resorption. One way to approach this is to inactivate the bone resorbing cells, osteoclasts, such 
as the actions of the bisphosphonates. However, as discussed in Section 1.1.2, there is a need to find 
a new target to develop new chemotherapeutics for osteoporosis with high efficacies and better 
safety profiles. One appropriate target is purple acid phosphatase (PAP),48-55 a hydrolase that is 
highly expressed in osteoclasts, activated macrophages and dendritic cells.49,56-57 
PAP is a suitable and attractive target for the development of anti-osteoporotic drugs as it has long 
been postulated to play a crucial role in bone resorption.21,49,55,58-69 PAP expressed in osteoclasts is 
actively involved in bone degradation by dephosphorylating bone matrix proteins such as 
osteopontin.61,63,70 PAP’s role in bone resorption is further supported by studies which have shown 
that transgenic PAP-knockout mice developed osteopetrosis (increased bone mineral content)58,70. 
Although these mice still has fully functional osteoclasts, it was observed that bone resorption was 
significantly reduced in the transgenic mice compared to mice with wild type osteoclasts.70 
Conversely, transgenic mice with osteoclasts that over-expressed the PAP gene developed mild 
osteoporosis.58 These therefore suggest that PAP might have a role in the development of 
osteoporosis.  Furthermore, PAP serum levels are found to be elevated in patients with 
osteoporosis.52 Using PAP as the target for osteoporosis chemotherapeutics is further suggested by 
studies that showed that osteoclastic bone resorption was hindered in in vitro bone resorptive assays 
by either a PAP specific antibody, or if molybdate, a potent PAP inhibitor, was used in the assays.62-
63 
Bone remodelling maintains skeletal integrity by constantly replacing old bone with new bone. It is 
a dynamic process of bone resorption, which is followed by bone formation.1 The dynamic process 
requires the interaction between the newly activated osteoclasts with cells of osteoblastic lineage 
(bone-forming cells). It occurs in three steps; (1) the bone resorption phase, which is driven by the 
activated osteoclasts, (2) the reversal phase, and (3) the bone formation phase by osteoblasts, which 
takes a longer duration than the first two steps.13 Therefore in bone remodelling process, bone 
resorption will inherently lead to bone formation, however active osteoclasts are required to send a 
signal to osteoblasts to promote bone formation.71 Therefore, inhibiting PAP activity while still 
keeping osteoclasts fully functional could potentially increase and regenerate bone mass, while still 
repressing bone resorption. 
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1.2  Purple acid phosphatases (PAPs) 
1.2.1  Overview 
Important cellular processes in organisms are highly regulated by reversible protein 
phosphorylation. The kinases regulate protein phosphorylation, while the phosphatases control 
protein dephosphorylation. There are two superfamilies of phosphatases, which are the protein 
tyrosine phosphatases (PTPs) and the protein phosphatases (PPs), that include PP1, PP2, PP2B (or 
calcineurin), and the structurally related purple acid phosphatases (PAPs),72-75 which is this 
project’s enzyme of interest. Although both of the gene superfamilies catalyse the hydrolysis of 
phosphoesters, each of the enzyme superfamilies has different structural arrangements, and utilises 
distinct mechanisms of action.72 
PAPs are binuclear metallohydrolases65,72-73,75 that require and utilise two closely spaced (< 4 Å) 
heterovalent metal ions (Fe(III)M(II); M = Fe (mammals), Zn or Mn (plants))64,67,76-78 in their active 
sites49,65,79-80 to carry out phosphoric ester hydrolysis according to equation 1,53 at neutral to acidic 
pH.64,73,81 PAPs are N-glycosylated proteins,79,82-87 and are typically purple due to a metal-ligand 
charge transfer from a tyrosine phenolate to a chromophoric Fe(III) in PAPs’ active sites (see 
Figure 3),64,78,88-90 which makes them discernible from other acid phosphatases. In addition, PAPs 
are also characteristically resistant to inhibition by L-tartrate, thus they are also called tartrate-
resistant acid phosphatases (TRAPs).66,91  
(RO)PO32- + H2O ! HPO42- + ROH                           (equation 1) 
PAPs are found and have been characterised from numerous organisms, such as animals (porcine, 
bovine, human, mouse and rat),57,65,77,92-105 plants (red kidney bean,80,83,106-108 soybean,84 sweet 
potato,84,109-113 tomato,114-116 duckweed,113,117-118 potato,119 and Arabidopsis thaliana120-121), fungi, 
and also some microorganisms.122-124 Within kingdoms, PAPs are very similar, where animal PAPs 
share at least 80% of the amino acid sequence,123-125 while plant PAPs share ~70% sequence 
homology.84,123-124 However between kingdoms, PAPs share very little similarity, with only ~20% 
overall sequence homology.123-124 Analysis of amino acid sequence alignment of several known 
PAPs from different sources shows that the ~20% similarity is due to five conserved motifs, and 
these motifs contain seven highly conserved amino acid residues that ligate the dinuclear centre 
across the enzyme sources21,64-65,77-78 (see Table 2). Hence, the active sites of all PAPs are 
remarkably similar, which will be discussed further in Section 1.2.2.  
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The more extensively studied PAPs are the monomeric mammalian enzymes weighing 35 kDa, and 
the larger plant enzymes that are homodimers with a disulfide bridge connecting the two subunits, 
having molecular weights of approximately 110-120 kDa.49,65,82 There are also smaller 35 kDa plant 
PAPs that are more “mammalian-like”123 (see Table 2) although they have been little explored. 
Two isoforms of mammalian PAPs exist, which are isoform 5a (intact polypeptide chain) and 
isoform 5b (product of a proteolytic cleavage of an exposed loop).65,97 While there are only two 
isoforms of the mammalian proteins; the plant counterpart on the other hand has numerous genes 
that encode for different isoforms of plant PAPs that are expressed in different tissues according to 
environmental factors.77,82,84,120-121,123,126-128 
Table 2: The five conserved motifs in animal, plants, and microbial PAPsa.21,49 
 Sources Motif 1  Motif 2  Motif 3  Motif 4  Motif 5 Length Accession 
Animals Human GDWG 34 GDNFY 34 GNHD 87 VAGH 33 GHDH 325 P13686 
 Mouse GDWG 34 GDNFY 34 GNHD 89 VAGH 33 GHDH 327 Q05117 
 Rat GDWG 34 GDNFY 34 GNHD 89 VAGH 33 GHDH 327 P29288 
 Pig GDWG 34 GDNFY 34 GNHD 89 VAGH 33 GHDH 338 P09889 
 Cowb GDWG - GDNFY - GNHD - VAGH 33 GHDH - Not available 
 Zebrafishc GDWG 34 GDNFY 33 GNHD  -  - - AI415792 
 C. elegans GDTG 34 GDNIY 33 GNHD 98 ISGH 32 GHDH 382 Z81494 
Plants35 Red kidney bean GDWG 29 GDNFY 33 GNHD 88 VGHH 32 GHDH 331 AF236109 
 Soybean GDWG 29 GDNFY 33 GNHD 89 VIGH 33 GHDH 332 AF236108 
 Sweet potato GDWG 29 GDNFY 33 GNHD 89 VIGH 33 GHDH 313 AF236107 
 A. thaliana GDWG 29 GDNFY 33 GNHD 89 VVGH 33 GHDH 338 AY818189 
 Easter lily GDWG 29 GDNFY 29 GNHD 89 VGHH 33 GHDH 329 - 
Plants55 Red kidney bean GDLG 25 GDLSY 32 GNHE 79 VLMH 35 GHVH 459 AJ001270 
 Soybean GDLG 25 GDLSY 32 GNHE 79 VLMH 35 GHVH 464 AF200824 
 Sweet potato  GDIG 25 GDLSY 32 GNHE 79 VLVH 35 GHVH 473 AF200825 
 Onion GDLG 23 GDLSY 32 GNHE 79 VLMH 35 GHVH 481 AB052619 
 Rice GDLG 23 GDLSY 32 GNHE 79 VLMH 35 GHVH 476 AF356352 
 A. thaliana GDMG 23 GDLSY 33 GNHE 79 VLMH 35 GHVH 475 AY050812 
Microorganisms Aspergillus ficuum NDMG 25 GDLSY 84 GBHE 151 VMSH 33 GHIH 614 UI8554 
 M. tuberculosis GDQS 40 GDLCY 31 GNHE 89 VCMH 35 GHEH 529 NP217093 
 Synechocystis 6803 GDIA 38 GDNQY 27 GNHE 72 AYWH 32 GHDH 326 D90900 
aThe seven invariant metal-ligating residues are shown in blue. These five conserved motifs contribute to the ~20% 
sequence homology across the enzyme sources. The numbers between the motif blocks indicate the numbers of amino 
acid residues between each motif, and ‘length’ shows the total number of amino acid residues of each PAP. Plants35 and 
Plants55 are small and large forms of plant PAPs, respectively. 
bIncomplete determination by amino acid sequencing. 
cOnly partial sequence is available. 
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1.2.2 Structural and active site properties of PAPs 
Crystal structures of the homodimeric red kidney bean and sweet potato PAPs with 55 kDa 
subunits,81,84,106-107,111 and the monomeric 35 kDa animal PAPs from pig,125,129 human,130 and rat131-
132 (Figure 2)65 have been solved. Each subunit of the plant PAPs contains a C-terminal domain that 
includes the catalytically active site, and a smaller N-terminal domain with unknown function. The 
N-terminal domain is not apparent in the mammalian enzymes, and does not show any interaction 
either between the two subunits or with the active site.82 Conversely, the C-terminal domain of plant 
PAPs bears structural similarity with the 35 kDa mammalian PAPs.65,77 
As discussed in Section 1.2.1, there are seven invariant metal-ligating residues in the active sites of 
all PAPs, which give them structural similarity in that region (Figure 3).65,133-134 The ferric ion is 
more tightly bound in the high affinity site (Site M1) by coordinating to the imidazole of a histidine, 
a phenoxide of a tyrosine, and two oxygen atoms from two aspartate residues. One of the oxygen 
atoms bridges the two heterovalent metal ions. The divalent metal ion coordinates to the bridging 
oxygen of an aspartate residue, two imidazole groups of hystidine residues, and an oxygen atom of 
an asparagine residue.65,80-81,107,111,125,130-132  
In addition to the seven conserved metal-coordinating residues, there are also water ligands that are 
believed to coordinate the metal ions. However, the number and identities of these solvent derived 
ligands are still under investigation. The resolution at 2.9 Å of the only available crystal structure of 
a PAP in the resting state, which was isolated from red kidney bean, was too low to identify the 
water ligands. However, three water ligands were modelled into the active site to complete the 
coordination sphere of the dinuclear centre, where one is coordinated to each of the metal ions, and 
another one bridging them.106 Nonetheless, several PAP crystal structures in complex with either 
phosphate or sulfate107,125,130-131 and other spectroscopic methods90,134-139 have confirmed the 
existence of a bridging water ligand. The pKa for the protonation equilibrium of these bridging 
water ligands depends on the metal ion composition, which is evident from magnetisation and 
electron paramagnetic resonance (EPR) measurements. For instance, the diiron centre in pig PAP 
(pPAP) is weakly antiferromagnetically coupled at pH 4.9 due to the presence of a µ-hydroxo 
bridge. On the other hand, the Fe(III)Mn(II) centre in sweet potato PAP (spPAP) is strongly 
coupled at pH 4.9, which shows the existence of a µ-oxo bridge instead.65,97,133,140-141 
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Figure 2: Crystal structure representatives of (A) plant PAPs and (B) animal PAPs. (A) Plant PAPs 
are ~110 kDa homodimer proteins with each 55 kDa subunit consisting of an N-terminal domain 
(blue) with unknown function and a C-terminal domain (blue) that contains the catalytic dimetal 
center. The disulfide bridge that connects the two domains is not shown. The metal ions are shown 
as coloured spheres: Fe(III) in orange and M(II) in magenta. (B) Mammalian PAPs are 35 kDa 
monomeric proteins that resemble the C-terminal domain in plant PAPs. The two orange spheres 
are representative of the diiron centre, and the stick model represents the bound phosphate.65 
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Figure 3: The active site of red kidney bean PAP (rkbPAP), which is representative of both animal 
and plant PAPs. The high-affinity metal site (M1) contains Fe(III), while the low-affinity metal site 
(M2) contains Zn(II) or  Fe(II) or Mn(II). The seven metal-ligated amino acid residues and the two 
histidine residues (His202 and His296) are highly conserved across all known PAPs. The hydroxide 
anion bridging the two metal ions, and the two solvent derived ligands that are terminally bound to 
each metal ion are also shown. Charge transfer from Tyr167 to the chromophoric Fe(III) gives 
PAPs the characteristic purple colour. The residue numbers shown refer to the sequences of 
rkbPAP.65 
The crystal structures of isoform 5a of mammalian PAPs also show an exposed loop near the active 
site, as shown in Figure 4. The flexible exposed loop, or the “repression loop” is believed to 
regulate the enzyme’s activity by blocking or unblocking the active site.92,130 Upon proteolytic 
cleavage of the “repression loop”, the enzyme becomes an open, active form, and has significantly 
increased phosphatase activity.64,67,96,130,142 Thus, it is speculated that isoform 5a is a proenzyme that 
undergoes proteolytic activation upon secretion in osteoclasts, where it is involved in bone 
resorption.62-63,65,68-69 For instance, the activity of reduced recombinant human PAP (hPAP) cleaved 
by trypsin (isoform 5b) increased to 1370 U/mg from 365 U/mg for the reduced intact recombinant 
hPAP (isoform 5a).142 In addition, mammalian PAP activity can also be regulated through reversible 
redox process and the enzymes exist in equilibrium between the active form that has significant 
phosphatase activity, which is pink (λmax = 515 nm, ε = 4450 M-1 cm-1) and in the reduced state 
(Fe(III)Fe(II));143 and an inactive form, which is purple (λmax = 550 nm, ε = 4300 M-1 cm-1) and in 
the oxidised state (Fe(III)Fe(III)).81 Conversely, since plant PAPs contain redox-inactive binuclear 
metal ion combinations in their catalytically relevant active sites, the enzymes’ activity cannot be 
regulated by reversible redox processes. 
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Figure 4: A ribbon diagram of recombinant human PAP expressed in Pichia pastoris. The central 
β-sheets are coloured in green, α-helices in red, and polypeptide loops in blue. The diiron centre is 
presented as magenta spheres and the hydrolysis product phosphate as blue sticks. The regulatory 
loop or the ‘repression’ loop near the active site is presented in yellow.130 
1.2.3  Mechanism of action 
All PAPs are believed to use a similar catalytic mechanism65,81,133,144 due to the structural 
resemblance of the active sites (Figure 3). Furthermore, the seven invariant metal-ligating residues 
and the two highly conserved histidine residues further substantiate this theory. The catalytic 
mechanism of PAPs is deduced based on combined kinetic, crystallographic and spectroscopic data. 
Schenk and co-workers have proposed a comprehensive 8-step mechanism of phosphoester 
hydrolysis employed by PAPs as shown in Figure 5.81       
The overall catalytic step involves a direct transfer of the phosphate moiety of the substrate to a 
nucleophilic solvent molecule that is coordinated to a metal ion.55,65,72-73,76-77,107 The first step 
involves the binding of the substrate to PAP to form a pre-catalytic complex. There is no 
experimental data of this structure currently available, however the crystal structure of red kidney 
bean PAP (rkbPAP)-sulfate complex solved by Schenk and co-workers at 2.4 Å (Figure 6) shows 
that instead of binding directly to the metal ions, the sulfate is positioned in the second coordination 
sphere, and is stabilised via hydrogen bonds with the µ-hydroxide, His202, His295, His296 and 
	   12	  
Asn201 (residue numbers refer to the sequence of rkbPAP).81,140,145 This structure can be used as a 
plausible model to show how the substrate might bind to PAP in the pre-catalytic state.      
      
 
Figure 5: The proposed comprehensive 8-step catalytic mechanism of PAPs. (a) The binding of 
phosphorylated substrate in the second coordination sphere of the active site (interactions between 
phosphate and the two histidine residues (His202 and His296) are not shown) forming the pre-
catalytic complex, is followed by the (b) monodentate binding of the substrate to the divalent metal 
ion. Structural rearrangements then result in (c) “quasi-monodentate” coordination of the µ-
hydroxide and bidentate binding of the phosphate moiety in a µ-1,3 bridging mode to the dimetal 
centre, which facilitate the nucleophilic attack of the µ-hydroxide on the phosphorous atom (d-h) 
The alcohol leaving group is released, and the active site is regenerated when the bound phosphate 
moiety is replaced by at least two water molecules.81  
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Figure 6: Diagram of the rkbPAP with bound sulfate at the active site. The sulfate moiety is shown 
to bind in the second coordination sphere and is stabilized via extensive hydrogen bond network 
(shown as dashed lines). Fe(III) is shown as tan sphere and Zn(II) as grey sphere.81 
The next step requires substrate movement to then bind to the divalent metal ion in a monodentate 
fashion.81,107,140,145 The catalysis then requires a nucleophilic attack on the phosphorous atom. 
Although the identity of the nucleophile is still subject to debate,81,90,111-112,137,139,144 the only 
apparent nucleophile candidate, the µ-hydroxide has low nucleophilicity to make a viable attack. 
Nonetheless, monodentate binding of the substrate to the divalent metal ion shifts the µ-hydroxide 
towards the divalent metal ion, thus changing its bidentate coordination mode towards a “quasi-
monodentate” coordination, which in turn increases its nucleophilicity.81,90,137,139,146 The vacant 
position on the ferric ion allows the substrate to now bind bidentately to the metal ions in a µ-1,3 
bridging mode, which both increases the electrophilicity of the phosphorous atom, and orienting it 
in an ideal position for a nucleophilic attack by the µ-hydroxide.55,81,137 This theory was supported 
by the observation of this bidentate bridging mode of the substrate in pig PAP (pPAP) at its 
optimum pH (pH 4.9)52,145 through a combination of EPR, extended X-ray absorption fine structure 
(EXAFS) and resonance Raman spectroscopic data.136,138-139,147  
The nucleophilic attack of the µ-hydroxide on the phosphorous atom in the substrate allows the 
release of an alcohol leaving group77 that is protonated by an adjacent histidine residue (His195, His 
195, His295 and His296 in hPAP, pPAP, spPAP and rkbPAP, respectively).55,65,72 Following that, 
the final step requires the regeneration of the active site by removal of the phosphate group,49,64,72,81 
formation of a new µ-hydroxide bridge, and reprotonation of the proton donor (histidine residue)148 
for PAPs to be active for the next catalytic cycle. However, this final step is the least understood in 
the catalytic mechanism of PAPs. A possible mechanism is that the incorporation of two water 
molecules allows the expulsion of the phosphate moiety (Figure 5f-h). Zhang and co-workers have 
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shown that calculations using hybrid density functional theory method with a B3LYP functional 
support the speculation that the identity of the two water molecules are the µ-H2O that bridges the 
metal ions, and another water molecule (termed M-H2O) that usually bridges the µ-hydroxide 
bridge and histidine residue that acts as the proton donor (His195, His 195, His295 and His296 in 
hPAP, pPAP, spPAP and rkbPAP, respectively) via strong hydrogen bonds.148 Their calculations 
support the theory that a simultaneous process of proton transfers from the µ-H2O to the histidine 
residue which deprotonates the µ-H2O thus forming the µ-OH bridge, and reprotonate the histidine 
proton donor, respectively, is mediated by the M-H2O.148 This M-H2O mediated proton transfers 
activation mechanism regenerates PAPs for the next catalytic cycle. 
1.2.4  PAPs’ biological functions 
PAPs’ main function is protein dephosphorylation, which is the main mechanism in cell signal 
transduction pathways72-73,75 and hence important cellular processes in general. Thus, PAPs have 
many significant biological functions. However, as there are many isoforms of plant PAPs that are 
expressed intra- and extracellularly, according to environmental factors, it is difficult to assign 
specific functions of plant PAPs.82,114-116,119-121,123 Nonetheless, they are postulated to participate in 
mobilising inorganic phosphate in the soil during seed germination.49,77,114-116,128,149-150 
 As well as their function as phosphatases, mammalian PAPs play a role in iron transport during 
pregnancy,151 and macrophage-specific generation of reactive oxygen species (ROS) in response to 
pathogen invasion of hosts.152 ROS generation is believed to be of the iron catalysed Haber/Weiss-
Fenton reactions (equations 2 and 3) by the redox-active diiron centre in mammalian PAPs, as was 
shown in vitro.49 Therefore mammalian PAPs are classed as bifunctional enzymes, as they are able 
to catalyse both hydrolytic reactions and peroxidations.57,152-153 
Fe3+-Fe2+ + H2O2 ! Fe3+-Fe3+ + OH" + OH-           (equation 2) 
Fe3+-Fe3+ + O2"- ! Fe3+-Fe2+ + O2            (equation 3) 
The biological role of mammalian PAPs that is of interest in this research project is its crucial 
involvement in bone resorption,62-69,154-155 as discussed in section 1.1.3. Increased bone resorption 
that exceeds bone formation creates an imbalance in the dynamic bone remodelling process,1,6 
which is the major factor in osteoporosis development.1 This therefore makes human PAP (hPAP) a 
very attractive target for the development of anti-osteoporotic drugs.48-55,156 
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1.3  PAP inhibitors 
1.3.1  Existing PAP inhibitors 
Several tetrahedral oxoanions such as phosphate (PO43-), arsenate (AsO43-), vanadate (VO43-),157 
tungstate (WO42-) and molybdate (MoO42-),62,158 and simple anion such as fluoride (F-)139,159 are 
known to inhibit PAP activity. However, most of these compounds are too toxic to be used in vivo, 
as they are non-specific inhibitors and thus their potential as therapeutics is limited.  
Valizadeh et al.52 have developed good inhibitors by exploiting the specificity of PAPs for 
phosphotyrosyl (pTyr) proteins. They have measured the inhibition constant (Ki) values of pTyr-
containing tripeptides 1-4 that are Fmoc-protected, in the general form of Fmoc-Glu-X-Ala (X 
represents pTyr analogues) against several animal (recombinant human, recombinant mouse, and 
pig) and plant (sweet potato and red kidney bean) PAPs (selected data are shown in Table 3).52 The 
inhibitors are moderately potent PAP ihibitors with Ki values in low to mid-micromolar range, and 
have a general trend of higher potencies (lower Ki values) at lower pH (pH 3.3) than at higher but 
optimal pH in PAP (pH 4.9). Most of the compounds are competitive inhibitors of PAPs at both pH 
3.3 and 4.9. However, compounds 3 and 4 show pH dependent inhibition against PAPs. For 
instance, compound 3 inhibits rkbPAP in a mixed mode (Kic similar to Kiuc, where Kic and Kiuc 
represent competitive and uncompetitive inhibition constants, respectively) at pH 3.3, but is a fully 
competitive inhibitor against rkbPAP at pH 4.9; while compound 4 exhibits a mixed inhibition 
mode against both hPAP and pPAP at pH 3.3, but inhibits both PAPs in a fully competitive mode at 
pH 4.9.  
In addition to compounds 1-4, Valizadeh et al.52 have also tested the inhibitory activities of several 
analogues of Fmoc-protected tripeptides with the carboxylate of the C-terminal alanine changed to 
amide (compounds 5-10), against pPAP (Table 4). This modification did not result in significant 
changes in inhibition potencies for this class of inhibitors, although they exhibit fully competitive 
inhibition mode (no considerable Kiuc values) against pPAP at both pH 3.3 and 4.9. Although these 
compounds (1-10) have considerable potency against PAPs, their high molecular weights, poor 
solubilities and, more importantly, their susceptibility to proteolytic cleavage by proteases in vivo 
limit their therapeutic potential. 
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Table 3: pTyr analogues (X) substituted in Fmoc-Glu-X-Ala (1-4) and their inhibition properties on 
PAPs52 (Ki values are in µM)a,b. 
 
Inhibitor, X = 
Human PAP Pig PAP Red kidney bean PAP 
pH 3.3 pH 4.9 pH 3.3 pH 4.9 pH 3.3 pH 4.9 
Kic Kiuc Kic Kiuc Kic Kiuc Kic Kiuc Kic Kiuc Kic Kiuc 
 
1 
ND ND ND ND 53 - 85 - 77 - 66 - 
 
2 
67 - 63 - 14 - 87 - 7 - 29 - 
 
3 
14 - 26 - 1.9 - 47 - 0.9 6.8 41 - 
 
4 
36 23 74 - 12 38 50 - 31 - 15 - 
ND	  –	  not	  determined.	  aKic	  and	  Kiuc	  represent	  competitive	  and	  uncompetitive	  inhibition	  constants,	  respectively.	  bNo	  value	  indicates	  that	  the	  value	  found	  is	  too	  large	  (more	  than	  ten-­‐fold	  of	  Kic	  values),	  thus	  is	  irrelevant,	  hence	  neglected.	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Table 4: PTyr analogues (X) substituted in Fmoc-Glu-X-Ala-amide (5-10) and their inhibition 
properties on pig PAP.52 
 
Inhibitor, X = 
pH 3.3 pH 4.9 
Kic (µM) Kic (µM) 
 
5 
201 279 
 
6 
112 146 
 
7 
413 777 
 
8 
100 
 
 
161 
 
9 
6 38 
 
10 
8 49 
 
O N
N
N
NH2
O
H
OHO
O
H
X
O
H O
COOH
COOH
O
COOH
COOH
O
OAc
COOH
COOH
COOH
COOH
COOH
COOH
F
	   18	  
Efforts into developing PAP inhibitors have also focused on using the approach of mimicking the 
PAPs’ substrate phosphoesters, by replacing the hydrolysable O-P bond in phosphoric esters with 
non-cleavable C-P bond in phosphonates.48,51,53-54,156 However, the replacement of the ester oxygen 
with a methylene group can potentially lead to loss of interaction between the compound and an 
acid or metal ion in PAP’s active site. Nonetheless, this approach has led to several anti-
osteoporotic drug leads. To overcome this potential loss of interaction, Myers et al. has employed 
the strategy of using metal-ligating pendant groups such as thiols, phosphonic acids and carboxylate 
groups incorporated into simple phosphonic acids.51 They found that these compounds 11-17 had 
greater inhibition potencies than the simple unfunctional phosphonic acid 18 when tested against 
rkbPAP (see Table 5). The results also showed that increasing chain length (12-13, 15-16) can 
potentially increase inhibition potencies.51 Although these compounds have modest PAP inhibitory 
potencies, with Ki and IC50 (the concentration of the compound required to inhibit the enzyme 
activity by 50% in vitro) values between mid micromolar and low milimolar range, the findings 
have shown that this approach can increase the potencies of PAP inhibitors by up to two orders of 
magnitude.  
Table 5: Inhibition constants and IC50 values for compound 11-18 against rkbPAP.51 
Inhibitor Ki (µM) Inhibitor Ki (µM) 
 
11 
80a  
15 
590 
 
12 
3000a  
16 
160 
 
13 
160a 
 
17 
350a 
 
14 
140  
18 
7600 
aIC50 values are shown as these compounds exhibit non-linear kinetics. 
Schwender and co-workers have also used the approach of using PAP substrate mimics in 
developing PAP inhibitors. They have screened analogues of phosphonates against human PAP 
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isolated from the spleen of a patient with hairy cell leukaemia which contained both isozymes (5a 
and 5b), and have established a series of phosphonate inhibitors (19, 22-24) with IC50 values in the 
micromolar range.48 Their results are shown in Table 6. They found that inhibitors with a 1-
naphthylmethyphosphonic acid scaffold (19) show significant inhibition, and the most potent 
inhibitors in this series have highly bulky groups substituted at the α-position (22-24). This results 
suggest that: (1) there is a large hydrophobic or sterically tolerant region, and possibly, (2) a 
preference for acyl substituents (as shown by the high PAP inhibition potency of 23 and 24), near 
the dimetal centre where the phosphonic acid moiety is believed to bind to PAPs.48 It must be noted 
that although the α-hydroxy derivative 20 was found to be inactive by this research group, later 
work by McGeary and co-workers showed that compound 20 has modest inhibition against 
rkbPAP53 (see Table 7). 
Table 6: IC50 values for inhibitors 19-24 against hPAP extracted from the spleen of a patient with 
hairy cell leukaemia.48 
Inhibitor IC50 (µM)a Inhibitor IC50 (µM)a 
 
19 
30 
 
22 
6.3 
 
20 
Inactive 
 
23 
6.0 
 
21 
Inactive 
 
24 
1.4 
Ph – phenyl.  
aIC50 values represent the concentration of the compound required to inhibit the enzyme activity by 50% in vitro.  
Based on the findings from Schwender and co-workers,48 the 1-naphthylmethylphosphonic acid 
scaffold (19) was used by McGeary et al. as the basis to design new series of inhibitors.53 Using 
computational modelling to dock several analogues of 19, it was predicted that the phosphonate 
moiety would bind to the dinuclear centre, and a long groove adjacent to the active site was found 
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to be a potential point of interactions that can be exploited to design new potential PAP inhibitors. 
Hence, the α-(alkoxy(naphthyl)methyl)phosphonic acids (25) (Figure 7) were designed and docked 
to hPAP (PDB code 1WAR130,160) using the computational modelling software GOLD. The decyl 
derivative of 25 was predicted to bind as intended, where the phosphonate moiety binds to the 
dimetal centre, and the long alkyl chain fits in the adjacent groove (Figure 8).53 These inhibitors 
have low to sub-micromolar inhibitory potencies against pPAP and rkbPAP and, consistent with the 
findings of Myers et al.,51 the inhibition potencies of inhibitors 25 also increase with increasing 
alkyl chain length, up to 18 carbons in the aliphatic chain (see Table 7 for details).53,156  
	  
25 
Figure 7: The general chemical structure of α-alkoxynaphthylmethylphosphonic acid (25), where R 
is an alkyl chain with different lengths. 
	  
Figure 8: Predicted binding orientation of the R-isomer of decyl derivative of α-
alkoxynaphthylmethylphosphonic acid (25c) to hPAP active site (PDB code 1WAR130,160) as 
predicted by docking study using GOLD. The long alkyl chain is seen to bind in the adjacent 
groove.53 
P OR
HO
HO O
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Table 7:  Inhibition properties of 19, 20, 25a-c,53 and 25d-i156 on both rkbPAP and pPAP, at pH 4.9 
and pH 6.2, respectively. 
Inhibitor Structure or R group 
pPAP (pH 4.9) rkbPAP (pH 6.2) 
Kic (µM)a Kiuc (µM)a,b Kic (µM)a Kiuc (µM)a,b 
19 
 
ND ND >7c NA 
20 
 
ND ND 5c NA 
25a Me(CH2)5- 430c NA 1470 1430 
25b Me(CH2)7- 23 44 50 129 
25c Me(CH2)9- 17 20 4 3 
25d Me(CH2)11- 0.684 - 4.450d - 
25e Me(CH2)13- 1.070 - 0.186d - 
25f Me(CH2)15- 0.579 - 0.423d - 
25g Me(CH2)17- 0.203 - 0.470d - 
25h Me(CH2)19- 4.430 - 0.783d - 
25i Me(CH2)21- 61.7 - 14.1d - 
ND – not determined. 
NA – not applicable, as only IC50 value was measured. aKic	  and	  Kiuc	  represent	  competitive	  and	  uncompetitive	  inhibition	  constants,	  respectively.	  bNo	  value	  indicates	  that	  the	  value	  found	  is	  too	  large	  (more	  than	  ten-­‐fold	  of	  Kic	  values),	  thus	  is	  irrelevant,	  hence	  neglected. 
cIC50 value is measured instead of Ki value, which represents the concentration of the compound required to inhibit the 
enzyme activity by 50% in vitro. 
dKinetic assays were carried out at pH 4.9. 
As inhibitors 25 are chiral and were synthesised and tested as racemates, it is intriguing to find out 
which of the enantiomer contributes towards the high potency of these inhibitors. Therefore, 
McGeary and co-workers have isolated individual enantiomers of 25f using analytical 
enantioselective high performance liquid chromatography (HPLC) with a normal phase chiral 
column, and investigated their inhibitory properties against pPAP and rkbPAP.156 Interestingly, 
each of the enantiomer has comparable IC50 values against both PAPs between each other, and what 
is more fascinating is that the racemic 25f is more potent than the individual enantiomers (see 
Table 8 for details).156 
P
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Table 8: Inhibitory properties of 25f and its individual enantiomers against pPAP and rkbPAP.156 
Inhibitor pPAP, IC50a (µM) rkbPAP, IC50a (µM) 
25f (R = Me(CH2)15-) racemic 0.61 ± 0.03 0.43 ± 0.05 
(+)-25f 5.0 ± 0.21 3.5 ± 0.37 
(-)-25f 6.8 ± 0.48 7.1 ± 0.39 
aIC50 values represent the concentration of the compound required to inhibit the enzyme activity by 50% in vitro. 
Based on the high inhibitory properties of 25, McGeary and co-workers have put in efforts towards 
improving the potency of compounds 25, and therefore designed yet another series of PAP 
inhibitors 26 (Figure 9), where the ether bond in 25 was replaced with a secondary amide bond in 
26.54 This modification was chosen as the amide bond in compound 26 is expected to improve the 
water solubility of the inhibitors and also be easier to synthesise than 25.54 Scheme 1 shows the 
four-step synthetic method to synthesise 25 from 1-naphthaldehyde (27), and Scheme 2 shows the 
three-step synthetic method to synthesise 26 from the same starting material 1-naphthaldehyde (27). 
To synthesise 25, an extra step is required (compared with the synthesis of 26), where the hydroxyl 
group in α-(hydroxy(naphthyl)methyl)phosphonate diester (28) was transformed into a better 
leaving group by reacting 28 with methanesulfonyl chloride (MsCl) thus converting 28 to its 
methanesulfonate ester (29), to be easily displaced with long chain alcohols to incorporate the 
desired ether group in 30 (see Scheme 1).53,156 Whereas to synthesise the final compound 26, the 
introduction of an amide group into 31 (see Scheme 2) was carried out in only one step by reacting 
31 with long chain acid chlorides in the presence of a base (DIPEA – N,N-diisopropylethylamine) 
in mild conditions to yield the desired α-(alkylamido(naphthyl)methyl)phosphonate diester (32) in 
good yields.54 The cleavage of the phosphonate ester groups in both 30 and 32 to yield the final 
phosphonic acids 25 and 26, respectively, was achieved using the same conditions using 
trimethylsilyl iodide (TMSI), formed in situ from trimethylsilyl chloride (TMSCl) and sodium 
iodide (NaI) in acetonitrile (MeCN).53-54,156 
 
26 
Figure 9: General structure of α-(amido(naphthyl)methyl)phosphonic acid (26), where R is an alkyl 
chain with different lengths. 
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Scheme 1: Synthesis of α-alkoxynaphthylmethylphosphonic acid (25), where R is an alkyl chain 
with different lengths, from 1-naphthaldehyde (27).53,156 
	  	  
Scheme 2: Synthesis of α-alkylamidomethylnaphthylphosphonic acid (26), where R is an alkyl 
chain with different lengths, from 1-naphthaldehyde (27).54 
Inhibitors 26 were also quite potent PAP inhibitors, with low micromolar inhibition potencies 
against both pPAP and rkbPAP (see Table 9 for details). Both inhibitors 25 and 26 have similar 
inhibition trend, whereby increasing their alkyl chain lengths significantly improves their inhibition 
potencies on PAP.  This might be attributable to the predicted interactions between the long alkyl 
chain in the inhibitor and the groove in the vicinity of the enzymes’ active sites53 according to 
computational docking simulations. Figure 10 shows the predicted binding orientation of the R-
isomer of 26f in hPAP calculated by using Molegro Virtual Docker (MVD).54 Furthermore, as 
mentioned before, Schwender et al. have suggested that there might be a preference for an acyl 
group near PAPs’ active sites for strong binding,48 suggesting that there might be favourable 
interactions between the carbonyl group in 26 and the surface residue proximal to the active site, 
thus explaining the strong inhibitory effects of 26 on PAPs. 
P OR
HO
HO O
O P OH
EtO
EtO O
P OMs
EtO
EtO O
P OR
EtO
EtO O
HPO(OEt)2, DIPEA
neat, rt, 18 h
MsCl, DIPEA, DCM
rt, 3 d
ROH, DIPEA, MeCN
reflux, 18 h
TMSCl, NaI, MeCN
40 oC, 18 h
25
27 28 29
30
P
H
N
HO
HO O
O P NH2.HCl
EtO
EtO O
P
H
N
EtO
EtO O
1. HPO(OEt)2, NH4OAc, EtOH, 60 oC, 44 h
2. HCl (gas), EtOH-Et2O
ROCl, DIPEA, DCM
rt, 18 h
TMSCl, NaI, MeCN
40 oC, 18 h
26
27 31
32
R
O
R
O
	   24	  
Table 9: Inhibition properties of inhibitors 26a-g obtained from kinetic assays performed on pPAP 
and rkbPAP at pH 4.9.54 
Inhibitor R 
Pig PAP Red kidney bean PAP 
Kic (µM)a Kiuc (µM)a,b Kic (µM)a Kiuc (µM)a,b 
26a Me(CH2)2- 363 1439 238 654 
26b Me(CH2)5- 116 349 222 446 
26c Me(CH2)6- 44 - 195 443 
26d Me(CH2)8- 10 - 57 102 
26e Me(CH2)10- 21 - 5 - 
26f Me(CH2)12- 8 - 11 - 
26g Me(CH2)14- 13 - 31 - aKic	  and	  Kiuc	  represent	  competitive	  and	  uncompetitive	  inhibition	  constants,	  respectively.	  
bNo	  value	  indicates	  that	  the	  value	  found	  is	  too	  large	  (more	  than	  ten-­‐fold	  of	  Kic	  values),	  thus	  is	  irrelevant,	  hence	  neglected. 
 
Figure 10: Predicted binding orientation of the R-isomer of 26f in hPAP by Molegro Virtual 
Docker (MVD).54 The long alkyl chain of 26f was predicted to bind to the groove in the vicinity of 
the enzyme’s active site. 
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1.3.2  Current lead compound 
Based on the discussion in Section 1.3.1, the most potent PAP inhibitors to date are inhibitors 25g 
against pPAP (Kic = 203 nM), and 25e against rkbPAP (Kic = 186 nM).156 Nonetheless, inhibitors 26 
are also promising candidates as anti-osteoporotic drug leads as they have low micromolar 
inhibition constants against PAPs (see Table 9 for details). In addition, the inhibitory properties of 
the longer alkyl chain derivatives of 26 are yet to be explored. Therefore, it cannot be concluded 
that the inhibition potency of 25 is superior to that of 26. 
Computational modelling is a very useful tool to predict and visualise the binding orientations of 
the inhibitors to the enzymes based on energy minimisations. Nonetheless, experimentally 
measured data by X-ray crystallography is required as they provide the precise binding interactions 
between the inhibitors and enzymes. Therefore our group has carried out crystallographic studies 
and has solved X-ray data of rkbPAP crystals with bound 25g (Kic = 470 nM)156 and 26a (Kic = 238 
µM).161 Although hPAP is the clinically relevant target, mammalian PAPs are innately hard to 
crystallise,162-163 and pPAP can only be crystallised with phosphate directly bound to the dimetal 
centre.125 On the contrary, rkbPAP can be obtained in large quantities from its natural sources83,107 
and crystallises more readily,81,106,108 thus it was chosen to be used in the crystallographic studies. 
The use of rkbPAP as a valid hPAP model is supported by the observations that: (1) the residues are 
highly conserved in the active sites of PAPs across different sources,65 (2) the substrates binding 
pockets are similar,80,92,107,111,125,130 and (3) a range of structurally different PAP inhibitors were 
reported to have similar inhibition constants for several mammalian and plant PAPs.52-
54,65,83,92,111,156,159,164 
Figure 11 and Figure 12 show the crystal structures of rkbPAP-25g (2.2 Å)156 and rkbPAP-26a 
(2.0 Å)161 complexes. Although the kinetic results showed that PAP was inhibited more strongly by 
the racemates of 25 than individual enantiomers (at least for 25f), the crystal data of rkbPAP-25g 
(2.2 Å) and rkbPAP-26a (2.0 Å) complexes did not show simultaneous binding of both 
enantiomers; only the S-isomers can be fitted to the electron density. Both crystal structures show 
that the S-isomers of 25g and 26a bind to the active site of rkbPAP in a similar manner. However, 
as opposed to the docking results where the phosphonate moieties of 25 and 26 bind directly to the 
dimetal ions (the distances between phosphonate oxygens and the metal ions ~ 2.0 Å suggest that 
the compounds bind to PAP in the first coordination sphere), surprisingly, the crystal structures 
show that inhibitors 25g and 26a bind to rkbPAP in the second coordination sphere. The crystal 
structure of rkbPAP-25g complex shows that the oxygen atoms in the phosphonate group form 
hydrogen bonds with the side-chain imidazole nitrogens of His295 and His296, with distances of 
2.5 Å and 2.8 Å, respectively; and the crystal structure of rkbPAP-26a complex shows that one of 
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the phosphonate oxygen atoms binds to the µ-hydroxide in the active site (2.3 Å). This hydrogen-
bonding interactions are similar to that observed in the rkbPAP-sulfate complex, which is proposed 
to be the pre-catalytic complex, as discussed in Section 1.2.3. But while sulfate binds to rkbPAP via 
the µ-hydroxide, this bridging hydroxide molecule was displaced upon binding of 25g to rkbPAP, 
as it was not observed in the crystal structure.156 An interesting observation between the inhibitors 
25g and 26a with rkbPAP was that the amide nitrogen atom in 26a was observed to make 
hydrogen-bonding interaction (2.8 Å) with a water molecule that also bridges the hydroxyl group of 
Tyr365 near the active site,161 while the ether oxygen atom in 25g was not observed to make any 
interaction with the enzyme.156  
	  
Figure 11: Stereo image of the 2Fo-Fc electron density (1.0 σ) for rkbPAP active site and 
compound 25g. The magenta and black spheres represent the Fe(III) and Zn(II) ions, respectively, 
while the cyan and yellow stick models represent the inhibitors’ and rkbPAP’s carbons, 
respectively. Oxygen atoms of the phosphonate moiety are labeled O1, O2 and O3.156 
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Figure 12: Stereo image of the 2Fo-Fc electron density (1.0 σ) for rkbPAP active site and 
compound 26a (0.9 σ). The magenta and black spheres represent the Fe(III) and Zn(II) ions, 
respectively, while the cyan and yellow stick models represent the inhibitors’ and rkbPAP’s 
carbons, respectively. Water molecules and the µ-hydroxide are shown as red spheres.161 
The crystal structures also show that there are hydrophobic interactions between the alkyl chains of 
both inhibitors with the hydrophobic rkbPAP surface residues,156 however the longer alkyl chain 
(C18H37) in 25g contribute to additional hydrophobic interactions, thus resulting in tighter binding 
of 25g to the enzyme compared with the much shorter alkyl chain (C3H7) of inhibitor 26a. This 
observation is also in agreement with the PAP inhibition properties of both inhibitors. In addition, 
the naphthalene ring in 26a is also observed to be more loosely bound to rkbPAP compared with the 
naphthalene ring in 25g, although both are shown to bind to the enzyme via π-cation and 
hydrophobic interactions with the imidazole rings of His295 and His296 (rkbPAP sequence).156 
This might also be attributable to the shorter alkyl chain in 26a thus making the compound to be 
less “fixed” to the enzyme, due to the smaller amount of binding interactions.  
It is also important to note that although the long alkyl chains in the designs of inhibitors 25 and 26 
are predicted to bind to the hydrophobic groove in the vicinity of the active site of mammalian PAP, 
the same groove is absent in rkbPAP. Nonetheless, both crystal data and kinetic analysis show that 
the long aliphatic chain is an important feature in the inhibitors that dramatically improves the 
binding and inhibition potencies of both classes of inhibitors. 
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1.4  Research aims 
This project aims to complete the following, with the approaches to achieve the aims explained in 
Section 1.5: 
• To design new PAP inhibitors. 
• To use computational modelling software to dock the potential inhibitors on PAPs and to 
visualise the predicted binding orientations of the potential inhibitors on PAPs. 
• To extract and purify PAP, namely pPAP from the allantoic fluid of a pregnant pig. 
• To synthesise the newly designed PAP inhibitors. 
• To investigate the inhibition properties of the new potential PAP inhibitors against pPAP, 
which is readily available, and is used as a model of the human enzyme. The target human 
enzyme is not readily available as hPAP can only be produced in minute quantities using the 
baculoviral expression system. This will be discussed further in Section 1.5.3. 
• To determine the actual binding modes of the newly designed PAP inhibitors by obtaining 
crystal structures of PAPs (pPAP, rkbPAP or both) with bound inhibitors. 
• To use the knowledge gained from all of the studies in this work to aid in the design of new-
generation of PAP inhibitors. 
• To screen available compounds to identify new series or classes of potent PAP inhibitors 
that can be used as new lead compounds. 
1.5  Research approach 
1.5.1  Design of new inhibitors based on lead compound 
The lead compounds 25 and 26 have similar key structural features, namely, a 1-naphthyl 
component, a long aliphatic chain, and a phosphonate moiety, which is postulated to bind to the 
diiron metal centre in PAPs in a similar way to their endogenous substrate. However, the stable C-P 
bond (unlike the hydrolysable P-O bond in phosphoesters) cannot be hydrolysed by PAP, thus 
inhibiting PAP to carry out the dephosphorylation of bone matrix proteins.  
The only difference in the structures of 25 and 26 is the ether and amide bond, respectively. As 
discussed in Section 1.3.2, the rkbPAP crystal structures with bound 25g and 26a showed that the 
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ether oxygen in compound 25g did not contribute to any interaction with the enzyme,156 while the 
amide nitrogen atom in 26a was hydrogen-bonded to a water molecule that also bridges the 
hydroxyl group of Tyr365 near the active site of rkbPAP.161 Therefore, compared with compound 
25, the increased potential of hydrogen bonding interactions with PAPs in 26 (due to the nature of 
amides as both H-bond donors and acceptors) and the ease of synthesis of 26 make 26 as the 
preferred choice to be used as the lead compound in this project. In addition, Schwender et al. have 
reported the enzyme’s preference for acyl substituents,48 suggesting potential H-bond interactions 
between the carbonyl and the residues near the active site region. Hence, inhibitors with chemical 
structure such as 33 (Figure 13) were chosen to be the next series of PAP inhibitor. Schwender et 
al. have also reported that having a 1-naphthyl instead of other aryl substituents such as 2-naphthyl 
or phenyl increases the compounds’ PAP inhibition potencies dramatically.48 Nonetheless, due to 
the long alkyl chains in the inhibitors, having a smaller rigid component in the compound might 
contribute to a better affinity to the enzyme, hence increased inhibition potency.  Furthermore, 
compound 33 can be easily modified due to the greater variety of substituted benzaldehydes 
available, thus analogues of 33 can be highly explored for their PAP inhibition potential. 
 
33 
Figure 13: General structure of α-(amido(phenyl)methyl)phosphonic acid (33), where R is an alkyl 
or 2-alkoxymethyl chain with different lengths. 
1.5.2  Computational modelling 
Computational modelling is a useful tool to identify any potential interaction sites between potential 
inhibitors and enzymes. This therefore can assist in chemical modifications to be performed on 
existing lead compounds to determine the appropriate functional groups that will form interactions 
with the desired enzyme. Hence, this will result in increased binding affinities of the compounds to 
the enzyme. All compounds designed and synthesised (both isomers in the case of chiral 
compounds) will be docked on both the target human enzyme and pig PAP (hPAP, PDB ID = 
1WAR;130 pPAP, PDB ID = 1UTE125)160 by using a molecular docking software. 
 Molegro Virtual Docker (MVD)165 was chosen to be used as the docking software in this work to 
visualise the predicted binding interactions between the compounds and the enzymes. This is 
because it has noticeably higher accuracy when predicting binding orientations of flexible ligands 
P
H
N
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on enzymes, compared with other docking software, such as GOLD, Surflex, Glide, and 
FlexX.156,166 The docking simulations will be performed on pPAP as kinetic assays will be 
performed using pPAP as hPAP model, while docking on hPAP is useful as hPAP is the main target 
of the inhibitors, and thus the docking results can be compared to predict the potency of the 
inhibitors against hPAP. This computational modelling has proven to be a very useful tool in 
recognising new inhibitors and predicting the inhibitory effects of new compounds based on the 
interactions observed.52-53 
1.5.3  Kinetic assays 
Kinetic assays will be performed to determine the inhibition constants (Ki values) and the inhibition 
modes of the inhibitors against the readily available pPAP. Kinetic assays could not be performed 
on the target enzyme hPAP, as the current method for hPAP expression using baculoviral 
expression system only produces recombinant hPAP in small quantities,130  thus they could not be 
acquired at the time of the study. Nonetheless, the use of pPAP as hPAP model still produces valid 
results due to the high conservation of the seven invariant metal-ligating residues in the active sites, 
the same catalytic mechanism,52-53,64,81,142 and the similar inhibition constants for different inhibitors 
against both PAPs.52,65,108,142,167 The kinetic results provide useful knowledge of the inhibition 
modes and potencies of the new inhibitors and thus would validate the computational modelling 
results. 
1.5.4  PAP preparation and purification 
pPAP will first be extracted and purified to be used in enzyme kinetic assays. pPAP will be 
prepared according to standard literature procedure by Campbell et al.93 
1.5.5  X-ray crystallography 
X-ray crystallographic study is crucial to determine the accurate binding orientations of the new 
inhibitors to PAPs. Therefore, the inhibitors will be crystallised with the enzymes either by co-
crystallisation or soaking of the inhibitors into the enzyme crystals. X-ray data collection and model 
refinements will then be undertaken to determine the actual binding modes of the inhibitors on 
PAPs. 
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Chapter 2  ACYL DERIVATIVES OF α-
(AMINO(PHENYL)METHYL)PHOSPHONIC ACID  
2.1  Introduction 
As discussed in Chapter 1, osteoporosis is a highly prevalent disease worldwide.1-3 The high 
morbidity and mortality rates caused by osteoporosis-related fractures do not only have impacts to 
the patients and their families, but also to the economy due to direct and indirect healthcare costs.1-3 
Furthermore, the efficacies of the current osteoporosis treatments are still less than desirable,4-16 and 
with a number of side effects that are associated with them (see Section 1.1.2),1,17-29 there is a need 
to develop new anti-osteoporotic drugs with high efficacies and better safety profiles. 
As discussed in Section 1.1.3, PAP is a suitable and attractive target for the development of new 
osteoporosis chemotherapeutics. There has been evidence that suggests a strong link between PAP 
and the development of osteoporosis30-32 in the literature, due to mammalian PAP’s postulated role 
in bone resorption.16,30,33-45 Therefore, this work aims to develop new PAP inhibitors for the 
development of anti-osteoporotic chemotherapeutics using the approaches discussed in Section 1.5. 
As discussed in Section 1.5.1, new compounds with the chemical structure 33 (Figure 14) were 
chosen to comprise the next series of PAP inhibitors. The inhibition potencies of the lead 
compounds 25 and 26 were greatly improved with long alkyl chains and only started to have 
considerable inhibition potencies against PAPs when there were at least ten carbons in the alkyl 
chains (see Table 7 and Table 9 in Section 1.3.1 for details). Therefore, the derivatives of 33 were 
also designed and synthesised to have increasing chain lengths, with the derivative with the shortest 
alkyl chain to have nine carbons. In addition, several derivatives of 33 with oxygen containing 
carbon tails were also synthesised and tested to investigate whether the oxygen atoms would 
contribute to increased binding interactions with the enzymes, and hence improved inhibition 
potencies.   
 
33 
Figure 14: General structure of α-(amido(phenyl)methyl)phosphonic acid (33), where R is an alkyl 
or alkoxymethyl chain with different lengths. 
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Previously, a visiting Assistant Professor of Organic Chemistry to the McGeary group, Dr Hadi 
Adibi from Kermanshah University of Medical Sciences, Iran, synthesised and tested a number of 
derivatives of compound 34, which have a similar chemical structure to that of compound 33, but 
with a 4-methoxy substituted phenyl ring (Figure 15).46 The inhibition properties of the derivatives 
of 34 against pPAP will be discussed later in Section 2.2.4.  
 
34 
Figure 15: General structure of ((4-methoxyphenyl)(alkylamido)methyl)phosphonic acid (34), 
where R is an alkyl or alkoxymethyl chain with different lengths. 
Thus, this chapter will present and discuss the work done and the results obtained from the 
predicted binding orientations of the derivatives of compound 33 using in silico simulations, the 
syntheses, and the inhibition properties of this new series of compounds against pPAP. 
2.2  Results and Discussion 
2.2.1  Molecular Modelling 
The availability of the crystal structures of PAPs greatly assisted in the development of new PAP 
inhibitors as the potential binding points for the inhibitors to PAPs can be visualised, and can be 
used in in silico docking studies. The aim of this work is to develop new potent PAP inhibitors, 
with the clinically relevant target to be the human enzyme.  However, as discussed in Section 1.5.3, 
human PAP (hPAP) can only be obtained in very small quantities using the baculoviral expression 
system,47 therefore all in vitro testings in this work were performed on the readily available pig PAP 
(pPAP) as a hPAP model (see Section 2.2.4 later for details of kinetic studies). As previously 
discussed in Chapter 1, all PAPs have seven highly conserved metal-ligating residues in the active 
sites,33,40-41,48-49 and as animal PAPs are highly homologous in their amino acid sequences (> 
80%),50-52 the active sites of hPAP and pPAP are nearly identical. Therefore, pPAP is a good hPAP 
model to be used in the kinetic studies. Accordingly, docking simulations for the new inhibitors 
were performed on both hPAP and pPAP. The results obtained can be compared and could provide 
useful information in the design of potential potent hPAP inhibitors. 
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Crystal structures of hPAP (PDB ID = 1WAR)47 and pPAP (PDB ID = 1UTE)52 were downloaded 
from the protein data bank (PDB).53 Figure 16 shows the surface at the active sites of hPAP and 
pPAP. It can be observed that the shapes of the surface of both enzymes are highly similar, where 
both hPAP and pPAP have common potential binding points that can be exploited to design 
potential potent hPAP inhibitors, namely: (1) the diiron metal centres, (2) the long groove adjacent 
to the active sites, and (3) two small pockets that are proximal to the dimetal centres. This suggests 
that the inhibitory properties of the new compounds obtained from the kinetic studies performed on 
pPAP (discussed later in Section 2.2.4) can be extrapolated to hPAP. Furthermore, previous studies 
have shown that different inhibitors have similar inhibition constants against both PAPs,31,41,54-56 
which was likely due to the highly conserved seven invariant metal-ligating residues in the active 
sites and the same catalytic mechanism,31,40,54,57-58 therefore further supporting the use of pPAP as a 
hPAP model in this work. 
Derivatives of compound 33 (Figure 14) were designed as the first series of novel potential PAP 
inhibitors. Compound 33 has a chiral centre, and all the derivatives were synthesised as racemates 
(see Section 2.2.2 for details). Subsequently, both the R and S isomers were docked in the crystal 
structure coordinates of both hPAP and pPAP by using Molegro Virtual Docker (MVD59). The 
search space was constrained to a sphere with 14 Å radius, with the metal centre set as the sphere 
origin. All water molecules were omitted from all the crystal structure coordinates prior to docking. 
All of the enzymes and the inhibitors were standardly prepared by MVD, and the phosphonic acid 
moieties were set to have two negative charges delocalised over three oxygen atoms, such as at pH 
4.9 (the optimum pH of mammalian PAPs, and the pH of the assay conditions performed in this 
work). The binding affinities of the compounds to the enzymes are represented by MolDock scores 
(docking scores), where larger negative values represent higher binding affinities. MolDock score, 
Escore is defined by the following equation: 
Escore = Einter + Eintra                  (equation 4) 
Where Einter is the protein-ligand interaction energy and Eintra is the ligand’s internal energy.59  
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Figure 16: The highly similar surface of the active sites of (a) hPAP and (b) pPAP with 
electrostatic representation where red = negative, blue = positive and white = hydrophobic. Possible 
binding points between inhibitors and the enzymes are also shown. The two yellow spheres in (a) 
and (b) represent the two iron metals, and the red sphere in (b) represents the µ-hydroxo bridge. 
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Table 10 summarises the structures of the R and S isomers of all the derivatives of 33 and 34g, and 
the respective docking scores as calculated by MVD based on energy minimisation of the inhibitor-
enzyme complexes. 
Table 10: The chemical structure of the compounds 33a-g and 34g that were docked in hPAP and 
pPAP, and the respective docking scores as calculated by MVD.  
 
R-33 
 
S-33 
MolDock Scorea (kcal/mol) 
hPAP pPAP 
Compound R = R isomer S isomer R isomer S isomer 
33a Me(CH2)8- -112 -123 -198 -126 
33b Me(CH2)10- -136 -145 -177 -220 
33c Me(CH2)12- -153 -109 -189 -208 
33d Me(CH2)14- -93 -92 -165 -200 
33e Me(CH2)16- -123 -107 -124 -196 
33f Me(CH2)7OCH2- -116 -70 -193 -196 
33g Me(CH2)15OCH2- -42 -45 -177 -218 
 
R-34 
 
S-34 
-143 -147 -163 -179 
34g Me(CH2)15OCH2- 
aThe binding affinities of the inhibitors to the enzymes are calculated based on energy minimisation and given a 
MolDock Score. Larger negative values indicate higher binding affinities of the inhibitors to the enzymes. 
Generally, comparable docking scores were obtained between the two isomers for most of the 
compounds for both hPAP and pPAP (see Table 10 for details). This might be due to the similar 
predicted interactions between the isomers for all derivatives and the two enzymes. This was in 
agreement with the kinetic result obtained from previous studies as discussed in Section 1.3.1, 
where the individual enantiomers for compound 25f had similar IC50 values against both pPAP and 
red kidney bean PAP (rkbPAP). Therefore, this suggests that both isomers of compounds 33 and 
34g would also have similar inhibition properties against hPAP and pPAP.  
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From Table 10, it can be observed that all of the compounds that were docked in hPAP and pPAP 
were calculated to have higher binding affinities to pPAP than hPAP. This was an unexpected 
result, as it was hypothesised that the compounds would have similar binding affinities to hPAP and 
pPAP, due to the high similarities (>80%) in their amino acid sequence50-52 and the seven invariant 
metal-ligating residues in the active sites.33,40-41,48-49 Furthermore, as previously mentioned, both 
hPAP and pPAP employ the same catalytic mechanism, and different inhibitors were found to have 
similar inhibition constants against both PAPs.31,41,54-56 This suggests that the calculated docking 
scores might not be accurate, as was found and concluded based on both the docking and kinetic 
results obtained throughout this work. 
The design of the derivatives of the new PAP inhibitor series 33 with increasing chain length was 
according to the hypothesis that the potencies of the compounds in inhibiting PAP would increase 
as the chain length increases; similar to that observed for the lead compounds 25 and 26. However, 
there was no actual trend between increasing chain length and the docking scores (binding 
affinities) that was observed for these new compounds (see Table 10 for details). Nonetheless, the 
inhibition assays for these compounds against pPAP suggested otherwise, which would be 
discussed later in Section 2.2.4. 
All of the predicted binding orientations for compounds 33a-g and 34g to hPAP and pPAP can be 
found in Appendix D.1. All of the compounds were observed to bind to both hPAP and pPAP 
through strong electrostatic interactions between one or two of the phosphoryl oxygen atoms and 
the diiron centre, which contributed to the considerably good docking scores for almost all of the 
compounds. Notably, both isomers of compound 33g have very low binding affinities to hPAP. 
This was due to the predicted binding orientation of both isomers of 33g, where the phosphonate 
moieties were pointing out from the active site of hPAP, and not binding to the dimetal centre as 
intended (see Appendix D.1). This suggests that the phosphonate moiety is a crucial metal-binding 
component that should be present in the structure of PAP inhibitors in order to have significant 
potencies.  
Based on the summary of the calculated binding affinities of the compounds on hPAP and pPAP as 
listed in Table 10, compound R-33c was calculated to have the highest binding affinity to hPAP, 
while compound S-33b was calculated to have the highest binding affinity to pPAP. Figure 17 
shows the predicted binding orientation of R-33c in hPAP. The iron ions in the active site were 
predicted to be bridged by one oxygen atom in the phosphonate moiety, each with a distance of 2.0 
Å between them, and have weak electrostatic interactions with the other two phosphoryl oxygen 
atoms (more than 3.4 Å). In addition, hydrogen-bonding interaction was also observed between the 
amide oxygen of R-33c and the NH imidazole of His219, with a distance of 3.0 Å. Interestingly, the 
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long alkyl chain of R-33c was not observed to bind to the groove as hypothesised, but made 
hydrophobic interactions with the backbone of the surface residues near the active site, and curled 
back, covering the cavity of the active site. The long alkyl chains of both isomers of all of the 
derivatives of 33a-g and 34g were predicted to bind to both hPAP and pPAP in a similar manner, 
except for several S-isomers in pPAP (see Figure 18 and Appendix D.1). Another common pattern 
of the binding orientation of the two isomers for this class of compounds on both hPAP and pPAP 
was that the phenyl ring was observed to fit into the small pocket adjacent to the active site (see 
Figure 17).  
Compound S-33b was calculated to have the highest binding affinity to pPAP. Figure 18 shows the 
predicted binding orientation of S-33b in pPAP. Like all other compounds, S-33b was also 
predicted to have strong electrostatic interactions between the phosphoryl oxygen atoms and the 
diiron centre. One of the phosphoryl oxygen atoms was predicted to bridge both Fe(II) and Fe(III) 
(both at 2.0 Å), and one other oxygen atom in the phosphonate moiety was predicted to ligate only 
Fe(II), with a distance of 2.0 Å apart between them as well. Hydrogen-bonding interactions were 
also observed between the phosphoryl oxygen atoms and the side chains of Asn89, and Tyr55 with 
distances of 3.5 Å and 2.5 Å respectively. One of the phosphoryl oxygen atoms was also predicted 
to make electrostatic interaction with the side chain of Asp52 with a distance of 2.5 Å. The long 
carbon chain of S-33b was predicted to bind to the groove (see Figure 18), along with the carbon 
chains of S-33a-c, S-33e and S-34g that were also predicted to bind in a similar manner to pPAP 
(see Appendix D.1). 
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R-33c 
 
Figure 17: Predicted binding orientation of compound R-33c in hPAP. The phosphonate moiety 
was observed to bind to the diiron centre (shown as faint yellow spheres). 
 
S-33b 
 
Figure 18: Predicted binding orientation of compound S-33b in pPAP. The phosphonate moiety 
was observed to bind to the diiron centre (shown as faint yellow spheres). 
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Although compound S-33b was calculated to have the best binding affinity to pPAP, the kinetic 
results showed that compound 33e was the most potent pPAP inhibitor, followed by compound 34g 
(see Section 2.2.4 for detailed results and discussion), which was supported by the considerably 
high docking scores as well. Figure 19 shows the predicted binding orientation of compound R-34g 
in pPAP. It can be observed that the long chain binds to the pocket and to the groove, which might 
explain the high potency of 34g (see Section 2.2.4 for details). Furthermore, the ether oxygen was 
predicted to make a hydrogen bond with the amine proton of the side chain of Asn91 with a 
distance of 3.1 Å. Interestingly, it was observed that the methoxy group at the para-position of the 
phenyl ring fits nicely into one of the pockets near the dimetal centre. This might also be one of the 
contributing factors to the high potency of compound 34g in inhibiting pPAP. This was a similar 
observation, where the phenyl rings of the other compounds were also predicted to bind to one of 
the small pockets adjacent to the active site.  
  
R-34g 
 
Figure 19: Predicted binding orientation of compound R-34g in pPAP. The phosphonate moiety 
was observed to bind to the diiron centre (shown as faint yellow spheres). 
Although all of the compounds 33a-g and 34g have slightly different binding orientations and the 
calculated binding affinities (Table 10) between hPAP and pPAP, previous studies have shown that 
pPAP is a valid hPAP model due to the highly homologous amino acid sequence between the two 
enzymes (> 80%) and the highly similar surface at the active sites (Figure 16). Furthermore, high 
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conservation of the seven invariant metal-ligating residues in the active sites, the same catalytic 
mechanism,31,40,54,57-58 and the similar inhibition constants found for different inhibitors against both 
PAPs31,41,54-56 in previous studies further substantiate the hypothesis that the kinetic studies results 
against pPAP can be extrapolated to hPAP.  
It is important to note that these docking results were only predictions from calculations that were 
based on energy minimisations. Therefore, they will not represent the actual binding affinities and 
the interactions between the inhibitors and the enzymes. Several studies in the literature have also 
demonstrated that the calculated binding affinities of the inhibitors to the enzymes do not accurately 
reflect the true binding affinities and the inhibition potencies of the tested compounds.60-63 
Experimentally determined kinetic results would provide more reliable data in terms of the 
potencies and the inhibition modes of the compounds; while X-ray crystallographic data would 
provide the actual binding modes of these inhibitors to the enzymes, at least in the solid state. 
Nonetheless, computational modelling is still a useful tool to be employed in the design of PAP 
inhibitors because, when combined with kinetic analyses, it provides useful guidance in the design 
of future inhibitors.  
2.2.2 Syntheses of (Alkylamido(phenyl)methyl)phosphonic acids (33a-g) and ((2-
(hexadecyloxy)acetamido)(4-methoxyphenyl)methyl)phosphonic acid (34g) 
The synthetic route to yield new PAP inhibitors 33 is shown in Scheme 3, using the established 
methods to synthesise the lead compounds 26;64 where diethyl (amino(phenyl)methyl)phosphonate 
hdyrochloride (36) was produced from starting material benzaldehyde (35),65 followed by the 
introduction of an amide bond at the free amine using acid chlorides (37).64,66 However, the last step 
of the cleavage of the diethyl groups to yield the lead compounds 26 using trimethylsilyl iodide 
(TMSI) formed in situ from trimethylsilyl chloride (TMSCl) and sodium iodide resulted in very low 
yields. Another standard method described in the literature for the cleavage of the diethyl groups in 
phosphonates using bromotrimethylsilane (TMSBr) and subsequent methanolysis was shown to 
produce near quantitative yields of phosphonic acids.67 Therefore, this method was used to 
dealkylate phosphonates 38, and quantitative yields were achieved for almost all of the derivatives 
of the desired phosphonic acids 33 (see Table 12). 
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Scheme 3: Synthetic route from benzaldehyde (35) to α-(amido(phenyl)methyl)phosphonic acids 
(33). 
The conversion of benzaldehyde (35) into diethyl (amino(phenyl)methyl)phosphonate 
hydrochloride (36) in two steps was achieved by heating 35 with a mixture of ammonium acetate 
and diethyl phosphite over activated molecular sieves using ethanol as a solvent according to 
standard procedure described in the literature;65  followed by introducing hydrogen chloride gas to 
give its corresponding hydrochloride salt in 36% overall yield (refer Scheme 3).65 The 1H NMR 
spectrum of 36 was consistent with that reported in the literature.65  
Amide bonds were then introduced to 36 by reacting 36 with acyl chlorides to yield 38a-g. Acid 
chlorides (37a-g) were first prepared by refluxing carboxylic acids (39a-g) with thionyl chloride 
(see Scheme 4).64,66 The conversion of 36 into its corresponding amides (38a-g) was achieved by 
reacting 36 with 37a-g and DIPEA (N,N-diisopropylethylamine) using dichloromethane as the 
solvent (see Scheme 3). Purification by flash column chromatography gave 38a-g in good yields 
(Table 11).  
 
Scheme 4: Synthesis route of acyl chlorides (37a-g).64,66 
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Table 11: Yields obtained for diethyl (alkylamido(phenyl)methyl)phosphonates (38a-g). 
Compound 
number R 
Yield 
% 
38a Me(CH2)8- 93 
38b Me(CH2)10- 89 
38c Me(CH2)12- 82 
38d Me(CH2)14- 84 
38e Me(CH2)16- 89 
38f Me(CH2)7OCH2- 48 
38g Me(CH2)15OCH2- 37 
 
The identities of 38a-g were confirmed by nuclear magnetic resonance (NMR) spectroscopy, 
namely one-dimensional (1D) NMR spectroscopy such as 1H, 13C, 13C-DEPT (distortionless 
enhancement by polarisation transfer), and two-dimensional (2D) NMR spectroscopy such as 
correlation spectroscopy (COSY) and heteronuclear single-quantum correlation spectroscopy 
(HSQC) (NMR spectra are not included) and low- and high-resolution mass spectrometry (LRMS 
and HRMS, respectively). Figure 20 shows the 1H NMR spectrum of 38e, which is representative 
for all derivatives of 38, and all the diethyl phosphonates synthesised in this work. Similar to that 
observed in the 1H NMR spectrum of 36, complex multiplet signals were also observed for the 
methylene protons in the ethoxy groups in 38a-g with each proton having different chemical shifts. 
This was due to the methylene protons being diastereotopic. Hence, each of the methylene protons 
of the ethoxy groups has different chemical and electronic environment, resulting in them 
producing NMR signals at different chemical shifts. Each methylene proton of each ethoxy group 
has three different couplings: (1) geminal coupling, (2) coupling with the phosphorous atom, and 
(3) their coupling with the methyl protons; thus giving rise to the complex multiplet signals 
observed. Another characteristic 1H NMR peak for all derivatives of 38 was the doublet of doublets 
at around 5.5 ppm, which was attributable to the methine proton coupled with the phosphorous 
atom as well as with the amide proton. Figure 21 shows the 13C NMR spectrum of 38c, which is 
representative for all derivatives of 38, and all the diethyl phosphonates synthesised in this work.  
All of the carbon signals in 13C NMR spectra for all derivatives of 38 correlate with the number of 
carbon atoms, although some overlapping signals were observed for the methylene protons in the 
long carbon chain. Similar to the methine proton, the methine carbon also gave rise to a doublet 
peak at around 50 ppm with a coupling constant of around 155 Hz, due to one-bond coupling with 
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the phosphorous atom.68 Furthermore, the appearance of the doublet peak for the carbonyl carbon in 
38 further proved that the introduction of the amide bond in 36 was successful. The carbonyl carbon 
peak was also split into a doublet due to the three-bond coupling with the phosphorous atom. The 
other carbon peaks that were also split into doublets were the methylene carbons in the ethoxy 
groups, and the carbons in the phenyl group due to two-, three- and four-bond couplings, 
respectively, to the phosphorous atom.  
	  
Figure 20: 1H NMR spectrum of 38e, which is representative for all derivatives of 38, and all the 
diethyl phosphonates synthesized in this work. The characteristic doublet of doublet peak for the 
methine proton at around 5.5 ppm and the characteristic complex multiplet signals for the protons in 
the ethoxy groups are shown. 
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Figure 21: 13C NMR spectrum of 38c, which is representative for all derivatives of 38, and all the 
diethyl phosphonates synthesized in this work. The characteristic doublet peak for the methine 
carbon at around 50 ppm and the characteristic doublet peak for the carbonyl carbon (172 ppm) can 
be observed.  
Carboxylic acids 39a-e are commercially available. However, 2-(octyloxy)acetic acid 39f was first 
synthesised according to the procedure described in the literature,69 where the octan-1-ol (40f) was 
stirred with sodium hydride and bromoacetic acid (41) in dry THF, as shown in Scheme 5. The 2-
(hexadecyloxy)acetic acid 39g was synthesised by Dr Waleed Hussein.70 
   
Scheme 5: Synthesis of 2-(octyloxy)acetic acid (39f). 
The final step to produce the newly designed inhibitors 33 and its derivatives required the cleavage 
of the diester bonds of the phosphonates in 38a-g to give their corresponding phosphonic acids 33a-
g in quantitative yields (Table 12). This was achieved by stirring 38a-g with TMSBr in dry 
40f
1. NaH, dry THF, 0 oC, argon, 15 min
2.                          , rt, argon, 2 dBr OH
O
41
39f
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chloroform as the solvent according to the standard procedure described in the literature67 (refer 
Scheme 3).  
Table 12: Yields obtained for the synthesis of (alkylamido(phenyl)methyl)phosphonic acids (33a-
g) from compounds 38a-g. 
Compound 
number R 
Yield 
% 
33a Me(CH2)8- 91 
33b Me(CH2)10- 97 
33c Me(CH2)12- 100 
33d Me(CH2)14- 100 
33e Me(CH2)16- 100 
33f Me(CH2)6CH2OCH2- 100 
33g Me(CH2)14CH2OCH2- 99 
 
All spectral data acquired for 33a-g (1D and 2D NMR, LRMS and HRMS) were used to 
characterise and confirm the structures of 33a-g. All of the peaks in both the 1H and 13C NMR 
spectra for all derivatives of 33 were consistent with that observed for their corresponding 
precursors, 38a-g, with the disappearance of the ethoxy signals, hence confirming that the cleavage 
of the diester bonds in the phosphonates in 38a-g was successfully achieved.  
In addition to the synthesis of 33a-g, the final step of the dealkylation of the diesters in 42 (obtained 
from Dr Hadi Adibi) to yield 34g according to Scheme 6 was also carried out using the same 
procedure as in Scheme 3. Due to time constraint, he could not complete this step himself. 
However, it was interesting to synthesise and measure the inhibition potency of 34g so that direct 
comparison could be done between the derivatives of 33 and 34, thus would provide useful 
guidance towards improving the inhibition potencies of the new PAP inhibitors. 
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Scheme 6: Synthesis of ((2-(hexadecyloxy)acetamido)(4-methoxyphenyl)methyl)phosphonic acid 
(34g) from diethyl ((2-(hexadecyloxy)acetamido)(4-methoxyphenyl)methyl)phosphonate (42). 
2.2.3  pPAP extraction and purification 
To test the potencies of the new inhibitors on PAP, kinetic assays were performed on pPAP, as the 
clinically relevant target hPAP could not be attained in sufficient quantities to carry out the study. 
pPAP was first extracted and purified from the allantoic fluid of a pregnant pig, using the method 
that was adapted from a well-established protocol,71 with slight modifications to the procedure, 
using fast protein liquid chromatography (FPLC). The detailed procedure can be found in Section 
2.4.2. The first step was to extract pPAP from allantoic fluid by chromatography on a 
carboxymethyl (CM)-cellulose column using FPLC. Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) analysis on the collected fractions with para-nitrophenyl phosphate 
(p-NPP) (PAP substrate) activity showed that the 35 kDa pPAP and another two higher molecular 
weight proteins were successfully extracted from the allantoic fluid. Figure 22 shows the SDS-
PAGE analysis with three visible bands for the three proteins. 
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Figure 22: SDS-PAGE analysis of the fractions collected from the chromatography of allantoic 
fluid on a CM-cellulose column, stained using Bio-Safe Coomassie G-250. Three proteins were 
seen, which are the 35 kDa pPAP (in the box) and another two higher molecular weight proteins 
(two bands above that of pPAP). Track 1: marker proteins with the molecular weights shown on the 
left, tracks 2-6: collected fractions with p-NPP activity. 
The two contaminant proteins were then removed by a gel filtration chromatography using 
Sephacryl S-200 also on FPLC. Analysis by both SDS-PAGE (see Figure 23) and kinetic analysis 
on p-NPP activity confirmed the purity of the extracted pPAP. This method yielded pPAP of high 
purity in large amount (306 mg) from two litres of allantoic fluid from a pregnant pig. 
The purified pPAP had similar spectral properties with that as described in literature.71 Both redox 
forms of pure pPAP had a sharp peak at 280 nm, the absorption maximum of proteins. The purple 
form of pPAP had an intense broad absorption maximum in the visible range around 545 nm, as 
well as a near-UV shoulder at around 320 nm. Upon treatment with β-mercaptoethanol (BME) and 
ferrous ammonium sulfate, the pink form of pPAP had an absorption maximum at 510 nm, with a 
marked decrease in the 320 nm shoulder, consistent with that in the literature.55,71-73  
Pig PAP was reduced to convert it into its active, pink form (Fe(III)Fe(II)) by incubating it with 
BME and ferrous ammonium sulfate for ten minutes at 37 °C to be used in the kinetic assays. 
Detailed procedure is described in Section 2.4.2. The most active preparation of the freshly 
extracted and purified pPAP had specific activity of 437 U/mg. The specific activity of the reduced 
enzyme differed from one preparation to another, but increased two- to four-fold from the specific 
activity of non-reduced pPAP. This is in agreement with previous studies.72-73  
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Figure 23: SDS-PAGE analysis of the fractions collected from the chromatography of allantoic 
fluid on a gel filtration, Sephacryl S200 column, stained using Bio-Safe Coomassie G-250. The 
fractions contain pure pPAP as shown by the single band for each fraction (in the box). Track 1: 
marker proteins with the molecular weights shown on the left, tracks 2-6: collected fractions with p-
NPP activity. 
2.2.4  Kinetic Assays 
All of the new compounds (33 and 34) synthesised were tested to see if they were potent PAP 
inhibitors as suggested by the docking results (see Section 2.2.1 for details). Ideally, inhibition 
properties of the new compounds were tested on the clinically relevant hPAP. However, as 
previously mentioned, hPAP could not be acquired at the time of study. Therefore, all kinetic assays 
in this work were performed on pPAP. pPAP was the enzyme of choice, as several studies have 
shown that it is a valid model for hPAP as previously discussed. Furthermore, pPAP was also easily 
obtained, as the extraction and purification of pPAP from the allantoic fluid of a pregnant pig were 
successfully carried out in this work, yielding high amount of pure pPAP (see Section 2.2.3).  
All kinetic assays were performed in 25% dimethyl sulfoxide (DMSO) as it assisted in the solubility 
of the compounds, especially the derivatives with the longer aliphatic chains. Furthermore, it was 
shown that the maximum activity of PAP was achieved when kinetic assays were performed in 25% 
DMSO.74 All of the compounds were initially screened against pPAP with 5 mM substrate (para-
nitrophenyl phosphate (p-NPP)) concentration at pH 4.9, with the compounds’ concentrations of 1 
µM, 10 µM and 100 µM (data not shown). Screening assays were essential to determine whether 
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the compounds inhibit pPAP with considerable potencies, before carrying out the more time-
consuming inhibition assays. Fortunately, all of the derivatives 33a-g were considerably potent 
against pPAP. Therefore, inhibition constants (Ki) for 33a-g against pPAP were measured as these 
values provide more information about the inhibition properties of the compounds, such as their 
potencies and also their inhibition modes, i.e., competitive, uncompetitive, or mixed-mode 
inhibition. 
Figure 24 to Figure 31 show the steady-state inhibition data for compounds 33a-g and 34g on 
pPAP at pH 4.9. 
 
33a 
 
Figure 24: Steady-state inhibition of pPAP by compound 33a at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 33a concentrations ranged from 0 to 30 µM (as shown on the right 
of the curves). Values are mean of duplicate measurements ± standard error of the mean (SEM). 
Data was analysed by non-linear regression using equation 5 (see Section 2.4.3). 	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33b 
 
Figure 25: Steady-state inhibition of pPAP by compound 33b at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 33b concentrations ranged from 0 to 10 µM (as shown on the right 
of the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-
linear regression using equation 5 (see Section 2.4.3). 
 
33c 
 
Figure 26: Steady-state inhibition of pPAP by compound 33c at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 33c concentrations ranged from 0 to 30 µM (as shown on the right 
of the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-
linear regression using equation 5 (see Section 2.4.3). 
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33d 
 
Figure 27: Steady-state inhibition of pPAP by compound 33d at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 33d concentrations ranged from 0 to 5 µM (as shown on the right of 
the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-linear 
regression using equation 5 (see Section 2.4.3). 
 
33e 
 
Figure 28: Steady-state inhibition of pPAP by compound 33e at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 33e concentrations ranged from 0 to 1 µM (as shown on the right of 
the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-linear 
regression using equation 5 (see Section 2.4.3) 
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33f	  
 
Figure 29: Steady-state inhibition of pPAP by compound 33f at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 33f concentrations ranged from 0 to 100 µM (as shown on the right 
of the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-
linear regression using equation 5 (see Section 2.4.3). 
	  
33f	  
 
Figure 30: Steady-state inhibition of pPAP by compound 33g at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 33g concentrations ranged from 0 to 3 µM (as shown on the right of 
the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-linear 
regression using equation 5 (see Section 2.4.3). 
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34g	  
 
Figure 31: Steady-state inhibition of pPAP by compound 34g at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 34g concentrations ranged from 0 to 1 µM (as shown on the right of 
the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-linear 
regression using equation 5 (see Section 2.4.3). 
Table 13 and Table 14 summarise the inhibition assay results obtained for 33a-g and 34a-e, 34g, 
respectively, against pPAP. Kic and Kiuc represent the competitive and uncompetitive inhibition 
constants, respectively. Kic values represent the dissociation constants for the interactions between 
the inhibitor and the free enzyme, where they compete with the substrate to bind to the same site, 
while Kiuc values represent the dissociation constants for the interactions between the inhibitor and 
the enzyme substrate (ES) complex, indicating uncompetitive binding. The scheme for inhibited 
reaction is shown in Scheme 8 later in Section 2.4.3. 
In contrast with the docking results described in Section 2.2.1, an inhibition trend was observed for 
inhibitors 33a-e, where inhibition increased as the length of the alkyl chain increased, similar to that 
observed for the lead compounds 25 and 26 (see Table 7 and Table 9 in Chapter 1 for 
details).58,64,74 The inhibitor 33a with the short aliphatic chain inhibited pPAP in mixed-competitive 
mode (Kic similar to Kiuc75),  and the derivatives with the longer aliphatic chains 33b-e, inhibit PAP 
solely in a competitive mode (see Table 13). Although this trend could not be explained based on 
the modelling results, but it might be due to the hypothesis that the alkyl chains of the inhibitors 33 
bind to the groove next to the active site. Longer chain length provides more hydrophobic 
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interactions with the hydrophobic groove, thus resulting in increased inhibition potency with 
increased chain length.  
Table 13: Inhibition properties of inhibitors 33a-g obtained from kinetic assays performed on pPAP 
at pH 4.9. 
 
33 
kcat (s-1)a KM (mM)b Kic (µM)c Kiuc (µM)c,d 
Inhibitor R = 
33a Me(CH2)8- 110 ± 15 9.8 ± 2.5 19 ± 8 30 ± 21 
33b Me(CH2)10- 126 ± 9.5 2 ± 0.6 31 ± 30 - 
33c Me(CH2)12- 226 ± 15 6.4 ± 0.9 0.320 ± 0.07 - 
33d Me(CH2)14- 195 ± 42 10 ± 4 0.320 ± 0.195 - 
33e Me(CH2)16- 125 ± 3.5 1.3 ± 0.2 0.168 ± 0.038 - 
33f Me(CH2)7OCH2- 118 ± 3.5 1.2 ± 0.2 56 ± 18 254 ± 66 
33g Me(CH2)15OCH2- 183 ± 15 2.8 ± 0.7 0.545 ± 0.197 1.97 ± 0.52 
akcat represents the maximum rate. 
bKM represents the Michaelis constant. 
cKic and Kiuc represent competitive and uncompetitive inhibition constants, respectively. 
dNo value indicates that the value found is too large (more than ten-fold of Kic values), thus is irrelevant, hence 
neglected. 
All of the derivatives of 33 exhibited potent pPAP inhibition with Ki values in the low micromolar 
and nanomolar range. The most potent pPAP inhibitor in this series was compound 33e, which 
competitively inhibit pPAP with Kic value of 168 nM. This compound is the most potent pPAP 
inhibitor ever reported, and it is 50 times more potent than the most potent pPAP inhibitor from the 
previous series of lead compound 26f (Kic value of 8 µM), and slightly more potent than the 
previous most potent pPAP inhibitor, compound 25g (Kic value of 203 nM). This marked 
improvement in potency compared to compound 26f (the direct lead compound) might be due to the 
observation from the modelling results that the phenyl ring in compounds 33 bind to the small 
pocket adjacent to the active site in both pPAP and hPAP; compared with the larger naphthalene 
component in compounds 26 that do not fit in the pocket. As this observation was similar in the 
docking results for the compounds 33 in both pPAP and hPAP, this suggests that the kinetic results 
obtained for the derivatives of 33 can be extrapolated to hPAP.  
Notably, compound 33g has an oxygen atom in the long chain, and the length of the chain is one 
carbon longer than the length of the carbon chain in compound 33e, but compound 33g did not have 
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superior inhibition potency than compound 33e. This suggests that the maximum potency that could 
be reached for this series of compounds might be when the length of the chain was 17 carbons. 
However, this was not conclusive as derivatives of compound 33 with longer chains were not 
synthesised and tested for PAP inhibition. Another point to take from this result was that the 
oxygen atom in the chain might not play a role in contributing to increased interaction between the 
inhibitor and PAP. This was in contrast with the docking results, where the ether oxygen was 
predicted to make a hydrogen bond with the amine proton of the side chain of Asn91 in pPAP (see 
Section 2.2.1 for details). However, this is also not conclusive as the chain in compound 33f that 
also has an oxygen atom was too short to result in significant inhibition. Therefore, having the 
inhibition data for compounds with the same length between the alkyl chain and the oxygen 
containing chain would provide better information in regard to the role of the oxygen in 
contributing to the binding interactions between the inhibitors and PAP. 
Table 14 summarises the inhibition data for the derivatives of 34 that were synthesised and tested 
by Dr Hadi Adibi46 and Dr Waleed Hussein.70 Compounds 34a-e exhibited highly comparable 
pPAP inhibition potencies with those of compounds 33a-e in the low micromolar and nanomolar 
range, and also similar inhibition trend to that observed for compounds 33a-e. The most interesting 
point that could be obtained from this result was that when direct comparison were made between 
compounds 33g and 34g, compound 34g (Kic value of 269 nM) was at least two times more potent 
than compound 33g (Kic value of 545 nM). Compound 34g was shown to be a competitive inhibitor, 
while compound 33g had a mixed inhibition mode, but was predominantly a competitive inhibitor. 
Both compounds have almost all of the same components, except 34g has a para-methoxy 
substituted phenyl ring. The docking results from Section 2.2.1 suggested that this methoxy group 
at the para-position of the phenyl ring might contribute to increased binding affinity to PAP as it 
fits nicely into one of the small pockets near the active site. Both the kinetic and modelling results 
for the series of compounds 33 and 34 provide valuable information and guidance for the next 
round of rational PAP inhibitor design. 
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Table 14: Inhibition properties of inhibitors 34a-e and 34g obtained from kinetic assays performed 
on pPAP at pH 4.9. 
 
34 
kcat (s-1)a KM (mM)b Kic (µM)c Kiuc (µM)c,d 
Inhibitor R = 
34ae Me(CH2)8- 121 ± 19 9.7 ± 2.8 - 686 ± 506 
34be Me(CH2)10- 119 ± 13 6.9 ± 1.7 3.027 ± 1.363 - 
34ce Me(CH2)12- 162 ± 31 10.8 ± 3.7 0.403 ± 0.188 - 
34de Me(CH2)14- 190 ± 29 13.2 ± 3.4 0.339 ± 0.112 - 
34ee Me(CH2)16- 227 ± 24 6.5 ± 1.5 0.186 ± 0.061 - 
34g Me(CH2)15OCH2- 183 ± 15 2.8 ± 0.7 0.269 ± 0.103 - 
akcat represents the maximum rate. 
bKM represents the Michaelis constant. 
cKic and Kiuc represent competitive and uncompetitive inhibition constants, respectively. 
dNo value indicates that the value found is too large (more than ten-fold of Kic values), thus is irrelevant, hence 
neglected. 
eKinetic assays were performed by Dr Hadi Adibi46 and Dr Waleed Hussein.70 
2.3  Conclusion 
New series of potent PAP inhibitors 33 and 3446,70 were successfully developed in this work and the 
unpublished work by Dr Hadi Adibi46 and Dr Waleed Hussein70 using the strategy of design, 
synthesis and testing. The design of the new series based on a lead compound yielded very 
promising results with marked improvement in PAP inhibition potencies of the compounds. 
Although the computational modelling results did not really correlate to the hypothesis that 
increasing chain length would result in increased binding affinity, it was demonstrated that when 
both the kinetic results and the modelling results were compared, valuable information were 
gathered that could be exploited for further rational PAP inhibitor design.  
A total of eight new PAP inhibitors 33a-g and 34g were designed and successfully synthesised 
according to the methods described in the literature. Kinetic analysis showed that these new 
compounds were potent pPAP inhibitor with Ki values in the low micromolar and nanomolar range, 
and the derivatives with the longer chains inhibited pPAP in mostly competitive mode. This agreed 
with the design of the compounds, where the phosphonate moiety was employed as a substrate 
mimic to be the metal-binding component in the compounds, and the long chains were hypothesised 
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to bind to the groove adjacent to the active site, thus the new inhibitors would be competing with 
the substrate to bind to the active site. 
The most potent pPAP inhibitor described in this chapter was compound 33e with Kic value of 168 
nM, which was a tremendous improvement in potency compared with the previous lead compound 
26f that had a similar chemical structure but with a larger aromatic component; a naphthalene 
instead of the smaller phenyl ring. Direct comparison between compounds 33g (Kic value of 269 
nM) and 34g (Kic value of 545 nM) also showed that a substitution at the para-position of the 
phenyl ring might contribute to improved inhibition potency of the compounds. The modelling 
results suggested that the components in the compounds that were modified (the phenyl ring instead 
of naphthalene, and the methoxy group at the para-position) bind or fit nicely to the small pockets 
near the active site in both pPAP and hPAP.  
In summary, the main important conclusions that could be made from both the docking and kinetic 
results are (1) the two pockets near the active site of PAP (refer Figure 16 in Section 2.2.1) would 
be a good target to design inhibitors that could fit into those pockets, (2) having a smaller aromatic 
component in the compound (phenyl instead of naphthalene) resulted in marked improvement in 
inhibition potency, and (3) having a substitution at the para-position of the phenyl ring improved 
the inhibition potencies of the compounds compared with the compound without a substituent at the 
phenyl ring. This important information was used as a guide in the design of the next generations of 
PAP inhibitors, which will be described later in Chapters 3, 4 and 5. Another important point to 
note however is that the modelling results were only predictions, and until the crystal structure of 
PAP-inhibitor complex could be solved, the actual binding orientations of the inhibitors could not 
be determined. The efforts towards obtaining this valuable information will be described later in 
Appendix B. 
2.4  Experimental 
2.4.1 Syntheses 
All chemical reagents are of analytical grade unless stated otherwise. Chloroform was dried by 
distillation from phosphorous pentoxide. Molecular sieves (4 Å) were activated by heating them in 
a domestic microwave oven (3 x 2 min) at high power.  Light petroleum (LP, b.p. 40-60 °C) was 
distilled before use. Flash column chromatography was carried out with Merck Kieselgel 60 as 
described in the literature.41 NMR experiments were recorded on 500 MHz spectrometer (Bruker, 
Rheinstetten, Germany). Chemical shifts are reported in parts per million (ppm) on a δ scale, 
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relative to the solvent peak (CDCl3 δH 7.24, δC 77.0; CD3OD δH 3.30, δC 49.0; D2O δH 4.79). 
Coupling constants (J) are reported in hertz and peak multiplicities described as singlet (s), doublet 
(d), doublet of doublets (dd), triplet (t), quartet (q), pentet (p), multiplet (m), or broad (br). High-
resolution electrospray ionisation accurate mass measurements were recorded in positive and 
negative modes on a quadrupole – time of flight instrument (Bruker) with an ESI source. Accurate 
mass measurements were carried out with external calibration using sodium formate as reference 
calibrant and/or Agilent tune mix (molecular weight (mw) > 500). Low and high-resolution electron 
impact ionization mass measurements were recorded using perfluorokerosene-H as reference 
calibrant. Melting points were determined with DigiMelt MPA161 (Stanford Research Systems). 
Diethyl (amino(phenyl)methyl)phosphonate hydrochloride (36)65  
 
This compound was prepared according to the general procedure described in the literature.65 The 
reaction was carried out under anhydrous conditions. Ammonium acetate (7.70 g, 0.10 mol) was 
added to EtOH (20 mL) in a round-bottomed flask containing activated molecular sieves (4 Å) (2.0 
g), followed by the addition of benzaldehyde (35) (10.61 g, 0.10 mol) and diethyl phosphite (12.90 
mL, 0.10 mol). The reaction mixture was stirred at 60 °C under nitrogen atmosphere for 44 hours. 
Once it has cooled to room temperature, conc. HCl was added to the resulting mixture to acidify it 
to pH 1, and neutral materials were then removed by washing with Et2O (50 mL). Addition of 2 M 
NaOH to the aqueous layer changed the pH to 11, and the product was extracted with CH2Cl2 (100 
mL) to give the resulting diethyl (amino(phenyl)methyl)phosphonate hydrochloride (36) as yellow 
oil. The product was then treated with HCl gas in Et2O (10 mL) and the solvent was evaporated to 
obtain the hydrochloride salt of diethyl compound 36 as white solid (36%). 1H NMR (500MHz, 
(CD3)2SO) δ 0.79 (3H, t, J 7.1 Hz, OCH2CH3), 1.02 (3H, t, J 7.1, OCH2CH3), 3.58-3.62 (1H, m, 
OCH2CH3), 3.67-3.74 (1H, m, OCH2CH3), 3.84-3.89 (1H, m, OCH2CH3), 3.93-3.97 (1H, m, 
OCH2CH3), 5.08 (1H, d, J 18.0 Hz, NHCHP), 7.44-7.64 (5H, m, ArH), 9.56 (2H, br s, NH2) (in 
agreement with that described in the literature.65 IR (cm-1): 2865, 2589, 2038, 1606, 1520, 1236.  
General procedure for the preparation of acid chlorides (37a-g). All acid chlorides were prepared 
according to the procedure described by Hussein et al.66 Reactions were carried out under 
anhydrous conditions. Carboxylic acids 39a-g (2 eq., 4 mmol) were refluxed in thionyl chloride (3 
mL) for three hours. Excess thionyl chloride was evaporated using a water aspirator. Co-
P NH2.HCl
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evaporation of the resulting reaction mixture with toluene (3 x 5 mL) until dryness gave the 
corresponding acid chlorides 37a-g.  
2-(Octyloxy)acetic acid (39f)76 
 
This compound was prepared according to the general procedure described in the literature.77 The 
reaction was carried out under anhydrous conditions. To NaH (8.0 g of 60% suspension in mineral 
oil, 200 mmol) in dry THF (100 mL) was added 1-octanol (40f) (10.3 mL, 65 mmol) dropwise 
under stirring at 0 °C in argon atmosphere and the reaction mixture was stirred for 15 minutes. 
Bromoacetic acid (41) (7.0 g, 50 mmol) in dry THF (5 mL) was then carefully added dropwise over 
a period of 20 minutes at 0 °C under stirring and argon atmosphere, during which effervescence 
was observed. The reaction mixture was further stirred for 2 days at room temperature. The reaction 
mixture was quenched with water, THF evaporated, and the aqueous phase was acidified to 
between pH 4 and 5 using conc. HCl. The resulting mixture was then extracted with Et2O (3 x 50 
mL), and the combined Et2O phases were then extracted with 1 M NaOH (50 mL). The aqueous 
phase was then washed with Et2O (2 x 50 mL), and the pH adjusted to between 4 and 5 using conc. 
HCl. The product was then extracted with Et2O (2 x 50 mL), and the organic phases was dried with 
Na2SO4, and evaporated in vacuo to afford 39f as yellow oil (0.96 g, 10%). 1H NMR (500 MHz, 
CDCl3) δ 0.85 (3H, t, J 6.9 Hz, CH3CH2), 1.24-1.33 (10H, m, CH3(CH2)5(CH2)2O), 1.60 (2H, p, 
CH2CH2O), 3.52 (2H, t, J 6.7 Hz, CH2O), 4.09 (2H, s, OCH2CO), consistent with that reported in 
the literature.76 
General procedure for the preparation of diethyl phosphonates (38a-g).  
 
The reaction was carried out under anhydrous conditions. To the acid chlorides 37a-g (2 mmol), a 
solution of DIPEA (1.7 mL, 10 mmol) and the hydrochloride salt 36 (0.28 g, 1.00 mmol) in CH2Cl2 
(5 mL) was added dropwise to the acid chlorides 37a-g and the reaction mixture was stirred under 
argon atmosphere at room temperature for 18 h. The reaction was stopped and concentrated in 
vacuo. The solid was then dissolved in minimum amount of 10% EtOAc in LP and gravity filtered 
to get rid of the salt of DIPEA. The solvent was evaporated and the crude product was then purified 
using silica flash column chromatography (10-70% EtOAc in LP) to give 38a-g as solid products. 
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Diethyl (decanamido(phenyl)methyl)phosphonate (38a) 
 
White solid (0.37 g, 93%), m.p. 47.2-48.4 °C. Rf: 0.56 (60% EtOAc in LP, KMnO4 dip). ESI-MS, 
m/z: 420 [M + Na]+. HRMS calculated for C21H36NNaO4P+ 420.2280, found 420.2275. 1H NMR 
(500 MHz, CDCl3) δ 0.84 (3H, t, J 7.0 Hz, CH3(CH2)8CO), 1.04 (3H, t, J 7.1 Hz, OCH2CH3), 1.20-
1.21 (12H, m, CH3(CH2)6(CH2)2CO), 1.30 (3H, t, J 7.0 Hz, OCH2CH3), 1.56-1.60 (2H, m, 
CH2CH2CO), 2.20 (2H, t, J 7.6 Hz, CH2CO) 3.60-3.68 (1H, m, OCH2CH3), 3.83-3.91 (1H, m, 
OCH2CH3), 4.05-4.17 (2H, m, OCH2CH3), 5.51 (1H, dd, J 9.6, J 21.0 Hz, NHCHP), 6.96 (1H, m, 
br, NH), 7.26 (1H, t, J 8.0 Hz, ArH), 7.31 (2H, t, J 7.4 Hz, ArH),  7.43 (2H, d, J 8.1 Hz, ArH);  13C 
NMR (125 MHz, CDCl3) δ 14.1, 16.1 (d, 3JPC 5.7 Hz), 16.4 (d, 3JPC 6.0 Hz), 22.6, 25.6, 29.17, 
29.20, 29.28, 29.4, 31.8, 36.4, 49.9 (d, 1JPC 153 Hz), 62.9 (d, 2JPC 7.1 Hz), 63.3 (d, 2JPC 6.9 Hz), 
128.0 (d, 4JPC 2.5 Hz), 128.1 (d, 3JPC 6.1 Hz), 128.5, 135.3, 172.5 (d, 3JPC 7.3 Hz). IR (cm-1): 3246, 
3058, 2973, 2921, 2853, 1668, 1647, 1547, 1244.  
Diethyl (dodecanamido(phenyl)methyl)phosphonate (38b) 
 
White solid (0.38 g, 89%), m.p. 59.9-60.7 °C. Rf: 0.56 (60% EtOAc in LP, KMnO4 dip). ESI-MS, 
m/z: 448 [M + Na]+. HRMS calculated for C23H40NNaO4P+ 448.2587, found 448.2574. 1H NMR 
(500 MHz, CDCl3) δ 0.85 (3H, t, J 7.0 Hz, CH3(CH2)10CO), 1.04 (3H, t, J 7.2 Hz, OCH2CH3), 
1.20-1.21 (16H, m, CH3(CH2)8(CH2)2CO), 1.28 (3H, t, J 7.1 Hz, OCH2CH3), 1.56-1.59 (2H, m, 
CH2CH2CO), 2.20 (2H, t, J 7.6 Hz, CH2CO) 3.61-3.66 (1H, m, OCH2CH3), 3.84-3.89 (1H, m, 
OCH2CH3), 4.07-4.16 (2H, m, OCH2CH3), 5.51 (1H, dd, J 9.6, J 21.1 Hz, NHCHP), 7.06 (1H, s, 
br, NH), 7.26-7.32 (3H, t (overlapped), ArH),  7.44 (2H, d, J 7.1 Hz, ArH);  13C NMR (125 MHz, 
CDCl3) δ 14.1, 16.1 (d, 3JPC 5.6 Hz), 16.4 (d, 3JPC 5.9 Hz), 22.6, 25.6, 29.19, 29.28, 29.29, 29.45, 
29.55, 31.9, 36.4, 50.0 (d, 1JPC 153 Hz), 62.9 (d, 2JPC 7.1 Hz), 63.4 (d, 2JPC 6.9 Hz), 128.0 (d, 4JPC 
2.5 Hz),  128.1 (d, 3JPC 6.0 Hz), 128.5, 135.3, 172.6 (d, 3JPC 7.4 Hz). 
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Diethyl (phenyl(tetradecanamido)methyl)phosphonate (38c)  
 
White solid (0.67 g, 82%), m.p. 65.2-66.9 °C. Rf: 0.57 (80% EtOAc in LP, KMnO4 dip). ESI-MS, 
m/z: 476 [M + Na]+. HRMS calculated for C25H44NNaO4P+ 476.2900, found 476.2900. 1H NMR 
(500 MHz, CDCl3) δ 0.85 (3H, t, J 7.0 Hz, CH3(CH2)12CO), 1.05 (3H, t, J 7.1 Hz, OCH2CH3), 
1.21-1.23 (20H, m, CH3(CH2)10(CH2)2CO), 1.30 (3H, t, J 7.1 Hz, OCH2CH3), 1.56-1.61 (2H, m, 
CH2CH2CO), 2.21 (2H, t, J 7.6 Hz, CH2CO) 3.84-3.88 (1H, m, OCH2CH3), 3.89-3.91 (1H, m, 
OCH2CH3), 4.06-4.15 (2H, m, OCH2CH3), 5.49 (1H, dd, J 9.5, J 21.1 Hz, NHCHP), 6.70 (1H, m, 
br, NH), 7.27 (1H, t, J 8.0 Hz, ArH), 7.30 (2H, t, J 7.4 Hz, ArH),  7.40 (2H, d, J 8.1 Hz, ArH);  13C 
NMR (125 MHz, CDCl3) δ 14.1, 16.1 (d, 3JPC 5.7 Hz), 16.4 (d, 3JPC 5.6 Hz), 22.7, 25.6, 29.2, 29.31, 
29.34, 29.5, 29.58, 29.63, 29.65, 31.9, 36.6, 50.0 (d, 1JPC 153 Hz), 62.9 (d, 2JPC 7.1 Hz), 63.5 (d, 
2JPC 7.0 Hz), 128.0 (d, 4JPC 2.5 Hz), 128.12 (d, 3JPC 6.0 Hz), 128.6, 135.2, 172.4 (d, 3JPC 7.6 Hz). 
Diethyl (hexadecanamido(phenyl)methyl)phosphonate (38d)  
 
White solid (0.51 g, 84%), m.p. 74.7-75.3 °C. Rf: 0.66 (80% EtOAc in LP, KMnO4 dip). ESI-MS, 
m/z: 504 [M + Na]+. HRMS calculated for C27H48NNaO4P+ 504.3213, found 504.3205. 1H NMR 
(500 MHz, CDCl3) δ 0.85 (3H, t, J 7.0 Hz, CH3(CH2)14CO), 1.05 (3H, t, J 7.2 Hz, OCH2CH3), 
1.21-1.23 (24H, m, CH3(CH2)12(CH2)2CO), 1.29 (3H, t, J 7.0 Hz, OCH2CH3), 1.58-1.60 (2H, m, 
CH2CH2CO), 2.21 (2H, t, J 7.6 Hz, CH2CO) 3.61-3.69 (1H, m, OCH2CH3), 3.84-3.91 (1H, m, 
OCH2CH3), 4.08-4.13 (2H, m, OCH2CH3), 5.48 (1H, dd, J 9.5, J 21.0 Hz, NHCHP), 6.54 (1H, m, 
br, NH), 7.28 (1H, t, J 7.3 Hz, ArH), 7.32 (2H, t, J 7.5 Hz, ArH),  7.41 (2H, d, J 8.1 Hz, ArH);  13C 
NMR (125 MHz, CDCl3) δ 14.1, 16.1 (d, 3JPC 5.9 Hz), 16.4 (d, 3JPC 5.8 Hz), 22.7, 25.6, 29.2, 29.31, 
29.34, 29.47, 29.58, 29.64, 29.65, 29.68, 31.9, 36.6, 50.0 (d, 1JPC 153 Hz), 62.9 (d, 2JPC 7.0 Hz), 
63.5 (d, 2JPC 7.0 Hz), 128.0 (d, 3JPC 6.1 Hz), 128.1 (d, 4JPC 2.6 Hz), 128.6 (d, 5JPC 1.5 Hz), 135.2, 
172.4 (d, 3JPC 7.8 Hz). 
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Diethyl (octadecanamido(phenyl)methyl)phosphonate (38e) 
 
White solid (0.51 g, 89%), m.p. 79.5-80.3 °C. Rf: 0.61 (80% EtOAc in LP, KMnO4 dip). ESI-MS, 
m/z: 532 [M + Na]+. HRMS calculated for C29H52NNaO4P+ 532.3526, found 532.3522. 1H NMR 
(500 MHz, CDCl3) δ 0.85 (3H, t, J 7.0 Hz, CH3(CH2)16CO), 1.05 (3H, t, J 7.1 Hz, OCH2CH3), 
1.21-1.23 (28H, m, CH3(CH2)14(CH2)2CO), 1.29 (3H, t, J 7.1 Hz, OCH2CH3), 1.58-1.61 (2H, m, 
CH2CH2CO), 2.21 (2H, t, J 7.5 Hz, CH2CO) 3.85-3.88 (1H, m, OCH2CH3), 3.89-3.92 (1H, m, 
OCH2CH3), 4.06-4.15 (2H, m, OCH2CH3), 5.49 (1H, dd, J 9.5, J 21.0 Hz, NHCHP), 6.55 (1H, m, 
br, NH), 7.28 (1H, t, J 7.3 Hz, ArH), 7.32 (2H, t, J 7.0 Hz, ArH),  7.40 (2H, d, J 7.9 Hz, ArH);  13C 
NMR (125 MHz, CDCl3) δ 14.1, 16.1 (d, 3JPC 5.7 Hz), 16.4 (d, 3JPC 5.7 Hz), 22.7, 25.6, 29.2, 29.31, 
29.35, 29.47, 29.58, 29.64, 29.66, 29.69, 31.9, 36.6, 50.0 (d, 1JPC 153 Hz), 62.9 (d, 2JPC 7.1 Hz), 
63.5 (d, 2JPC 6.6 Hz), 128.0 (d, 3JPC 6.0 Hz), 128.1 (d, 4JPC 2.6 Hz), 128.6 (d, 5JPC 1.5 Hz), 135.2, 
172.4 (d, 3JPC 8.1 Hz). 
Diethyl ((2-(octyloxy)acetamido)(phenyl)methyl)phosphonate (38f) 
 
Yellow oil (0.19 g, 48%). Rf: 0.46 (60% EtOAc in LP, KMnO4 dip). ESI-MS, m/z: 436 [M + Na]+. 
HRMS calculated for C21H36NNaO5P+ 436.2229, found 436.2221. 1H NMR (500 MHz, CDCl3) δ 
0.87 (3H, t, J 7.0 Hz, CH3(CH2)7O), 1.11 (3H, t, J 7.0 Hz, OCH2CH3), 1.26-1.31 (10H, m, 
CH3(CH2)5(CH2)2O), 1.27 (3H, t, J 7.3 Hz, OCH2CH3), 1.60-1.63 (2H, m, CH2CH2O), 3.45-3.54 
(2H, m, CH2O) 3.75-3.80 (1H, m, OCH2CH3), 3.90-3.99 (3H, m, OCH2CH3, OCH2CO), 4.05-4.11 
(2H, m, OCH2CH3), 5.48 (1H, dd, J 9.5, J 20.5 Hz, NHCHP), 7.27-7.35 (3H, overlapped t, ArH), 
7.41 (2H, d, J 8.0 Hz, ArH);  13C NMR (125 MHz, CDCl3) δ 14.1, 16.1 (d, 3JPC 5.9 Hz), 16.3 (d, 
3JPC 5.6 Hz), 22.6, 26.0, 29.2, 29.37, 29.46, 31.8, 49.0 (d, 1JPC 153 Hz), 63.0 (d, 2JPC 7.1 Hz), 63.3 
(d, 2JPC 6.6 Hz), 70.1, 72.0, 127.9 (d, 3JPC 6.0 Hz), 128.2 (d, 4JPC 2.5 Hz), 128.6 (d, 5JPC 1.6 Hz), 
134.8, 169.4 (d, 3JPC 7.3 Hz). 
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Diethyl ((2-(hexadecyloxy)acetamido)(phenyl)methyl)phosphonate (38g) 
 
Off-white solid (0.12 g, 37%), m.p. 46.8-47.6 °C. Rf: 0.39 (60% EtOAc in LP, KMnO4 dip). ESI-
MS, m/z: 548 [M + Na]+. HRMS calculated for C29H52NNaO5P+ 548.3481, found 548.3478. 1H 
NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, CH3(CH2)15O), 1.11 (3H, t, J 7.0 Hz, OCH2CH3), 
1.24-1.35 (26H, m, CH3(CH2)13(CH2)2O), 1.27 (3H, t, J 7.3 Hz, OCH2CH3), 1.60-1.64 (2H, m, 
CH2CH2O), 3.46-3.53 (2H, m, CH2O) 3.75-3.80 (1H, m, OCH2CH3), 3.90-3.99 (3H, m, OCH2CH3, 
OCH2CO), 4.06-4.11 (2H, m, OCH2CH3), 5.48 (1H, dd, J 10.0, J 21.0 Hz, NHCHP), 7.2 (1H, t, 
ArH), 7.33 (2H, t, J 7.0 Hz, ArH), 7.41 (2H, d, J 7.0 Hz, ArH);  13C NMR (125 MHz, CDCl3) δ 
14.1, 16.1 (d, 3JPC 5.9 Hz), 16.4 (d, 3JPC 5.9 Hz), 22.7, 26.0, 29.3, 29.43, 29.47, 29.60, 29.61, 29.65, 
29.7, 31.9, 49.0 (d, 1JPC 153 Hz), 63.0 (d, 2JPC 7.1 Hz), 63.3 (d, 2JPC 6.9 Hz), 70.1, 72.1, 127.9 (d, 
3JPC 6.0 Hz), 128.2 (d, 4JPC 2.5 Hz), 128.6 (d, 5JPC 1.6 Hz), 134.8, 169.3 (d, 3JPC 7.4 Hz). 
General procedure for the preparation of phosphonic acids (33a-g, 34g).67 
 
 
The reactions were carried out under anhydrous conditions. To the corresponding diethyl ester 33a-
g or 34g (0.2 mmol, 1 eq) was added dry chloroform (5 mL), and the mixture was stirred. TMSBr 
(1.6 mmol, 8 eq) was then added, and the reaction mixture was stirred for two days under argon 
atmosphere. Excess TMSBr was removed under a stream of nitrogen, and the residue co-evaporated 
with MeOH to further remove TMSBr. The residue was then dissolved in MeOH (15 mL) and the 
resulting mixture was stirred and heated at 50 °C under argon for two hours. MeOH was then 
evaporated and the product was further dried under high vacuum for two days to give the 
corresponding phosphonic acids 33a-g and 34g. 
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(Decanamido(phenyl)methyl)phosphonic acid (33a) 
 
Off-white hygroscopic solid (0.03 g, 91%). ESI-MS, m/z: 340 [M - H]-. HRMS calculated for 
C17H27NO4P- 340.1683, found 340.1681. 1H NMR (500 MHz, CD3OD) δ 0.88 (3H, t, J 6.8 Hz, 
CH3CH2), 1.26-1.28 (12H, m, CH3(CH2)6), 1.60 (2H, m, CH2CH2CO), 2.30 (2H, t, J 7.3 Hz, 
CH2CO),  5.45 (1H, dd, J 9.5, 21.5 Hz, NHCHP), 7.25-7.35 (3H, m, ArH), 7.45 (2H, d, J 8.1 Hz, 
ArH); 13C NMR (125 MHz, CD3OD) δ  14.4, 23.7, 26.9, 30.1, 30.3, 30.4, 30.5, 33.0, 36.8, 52.2 (d, 
1JPC 153 Hz), 128.6 (d, 4JPC 2.5 Hz), 129.2 (d, 3JPC 5.9 Hz), 129.4 (d, 5JPC 1.6 Hz), 137.0, 175.8 (d, 
3JPC 7.6 Hz). 
(Dodecanamido(phenyl)methyl)phosphonic acid (33b) 
 
Light yellow hygroscopic solid (0.04 g, 97%). ESI-MS, m/z: 368 [M - H]-. HRMS calculated for 
C19H31NO4P- 368.1996, found 368.1999. 1H NMR (500 MHz, CD3OD) δ 0.88 (3H, t, J 7.0 Hz, 
CH3CH2), 1.26-1.28 (16H, m, CH3(CH2)8), 1.60 (2H, m, CH2CH2CO), 2.30 (2H, t, J 7.3 Hz, 
CH2CO),  5.47 (1H, dd (br), J 21.5 Hz, NHCHP), 7.26-7.35 (3H, m, ArH), 7.45 (2H, d, ArH); 13C 
NMR (125 MHz, CD3OD) δ  14.5, 23.7, 26.9, 30.1, 30.3, 30.4, 30.5, 30.6, 30.7, 33.0, 36.8, 52.3 (d, 
1JPC 153 Hz), 128.5 (d, 4JPC 2.5 Hz), 129.1 (d, 3JPC 5.9 Hz), 129.5 (d, 5JPC 1.6 Hz), 137.0, 175.8 (d, 
3JPC 7.5 Hz). 
(Phenyl(tetradecanamido)methyl)phosphonic acid (33c) 
 
Light pink solid (0.04 g, 100%) m.p. 95.6-96.7 °C. ESI-MS, m/z: 396 [M - H]-. HRMS calculated 
for C21H36NO4P- 396.2304, found 396.2299. 1H NMR (500 MHz, CD3OD) δ 0.88 (3H, t, J 7.0 Hz, 
CH3CH2), 1.27-1.33 (20H, m, CH3(CH2)10), 1.60 (2H, m, CH2CH2CO), 2.30 (2H, t, J 7.3 Hz, 
CH2CO),  5.42 (1H, d, J 21.0 Hz, NHCHP), 7.26 (1H, t, J 7.3 Hz, ArH), 7.32 (2H, t, J 7.5 Hz, 
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ArH),  7.45 (2H, d, J 7.5 Hz, ArH); 13C NMR (125 MHz, CD3OD) δ 14.4, 23.7, 30.0, 30.1, 30.2, 
30.45, 30.47, 30.62, 30.68, 30.75, 30.77, 33.1, 34.9, 37.0, 52.3 (d, 1JPC 153 Hz), 128.6 (d, 4JPC 2.5 
Hz), 129.2 (d, 3JPC 5.8 Hz), 129.4 (d, 5JPC 1.6 Hz), 137.8, 175.9 (d, 3JPC 7.9 Hz). IR (cm-1): 3261, 
2917, 2851, 1653, 1603, 1534. 
(Hexadecanamido(phenyl)methyl)phosphonic acid (33d) 
 
Light yellow solid (0.04 g, 100%) m.p. 79.7-80.0 °C. ESI-MS, m/z: 424 [M - H]-. HRMS calculated 
for C23H39NO4P- 424.2622, found 424.2619. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 6.9 Hz, 
CH3CH2), 1.27 (24H, m, CH3(CH2)12), 1.60 (2H, m, CH2CH2CO), 2.30 (2H, t, J 7.3 Hz, CH2CO),  
5.42 (1H, dd (br), J 21.4 Hz, NHCHP), 7.24-7.35 (3H, m, ArH), 7.45 (2H, d, J 7.0 Hz, ArH); 13C 
NMR (125 MHz, CD3OD) δ 14.4, 23.7, 27.0, 30.18, 30.21, 30.44, 30.47, 30.63, 30.69, 30.76, 
30.77, 30.79, 33.1, 36.8, 52.2 (d, 1JPC 153 Hz), 128.6 (d, 4JPC 2.5 Hz), 129.3 (d, 3JPC 5.8 Hz), 129.5 
(d, 5JPC 1.6 Hz), 137.8, 175.8 (d, 3JPC 7.6 Hz).   
(Octadecanamido (phenyl)methyl)phosphonic acid (33e) 
 
Off-white solid (0.05 g, 100%) m.p. 114.1-114.3 °C. ESI-MS, m/z: 452 [M - H]-. HRMS calculated 
for C25H43NO4P- 452.2935, found 452.2938. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3CH2), 1.26-1.33 (28H, m, CH3(CH2)16), 1.60 (2H, m, CH2CH2CO), 2.29 (2H, t, J 7.5 Hz, 
CH2CO),  5.42 (1H, d, J 21.5 Hz, NHCHP), 7.24-7.34 (3H, m, ArH), 7.45 (2H, d, J 7.0 Hz, ArH); 
13C NMR (125 MHz, CD3OD) δ 14.4, 23.7, 26.9, 27.0, 30.18, 30.2, 30.43, 30.46, 30.62, 30.68, 
30.8, 33.1, 36.8, 36.9, 52.3 (d, 1JPC 153 Hz), 128.7 (d, 4JPC 2.5 Hz), 129.3 (d, 3JPC 5.9 Hz), 129.4 (d, 
5JPC 1.5 Hz), 137.9, 175.8 (d, 3JPC 7.5 Hz).  
 
P
H
N
HO
OHO (CH2)14Me
O
P
H
N
HO
OHO (CH2)16Me
O
	   80	  
((2-(Octyloxy)acetamido)(phenyl)methyl)phosphonic acid (33f) 
 
Yellow solid (0.04 g, 100%), m.p. 126.0-128.20C. ESI-MS, m/z: 356 [M - H]-. HRMS calculated 
for C17H27NO5P- 356.1632, found 356.1636. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3CH2), 1.30-1.42 (10H, m, CH3(CH2)5), 1.62-1.67 (2H, m, CH2CH2O), 3.50-3.60 (2H, m, 
CH2O), 3.94-4.08 (2H, m, OCH2CO), 5.34 (1H, d, J 21.5 Hz, NHCHP), 7.27-7.35 (3H, m, ArH), 
7.41 (2H, d, J 7.5 ArH); 13C NMR (125 MHz, CD3OD) δ 14.4, 23.7, 27.2, 30.4, 30.54, 30.58, 33.0, 
52.2 (d, 1JPC 150 Hz), 70.8, 73.0, 128.8 (d, 4JPC 2.3 Hz), 128.9 (d, 3JPC 5.5 Hz), 129.5, 137.5, 172.1 
(d, 3JPC 7.5 Hz). 
((2-(Hexadecyloxy)acetamido)(phenyl)methyl)phosphonic acid (33g) 
 
Yellow solid (0.05 g, 99%), m.p. 120.5-122.2 °C. ESI-MS, m/z: 468 [M - H]-. HRMS calculated for 
C25H43NO5P- 468.2884, found 468.2883. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3CH2), 1.28-1.32 (26H, m, CH3(CH2)13), 1.62-1.67 (2H, m, CH2CH2O), 3.49-3.59 (2H, m, 
CH2O), 3.94-4.08 (2H, m, OCH2CO), 5.34 (1H, d, J 21.1 Hz, NHCHP), 7.28 (1H, t, J 6.8 Hz, 
ArH), 7.34 (2H, t, J 7.5 Hz, ArH), 7.43 (2H, d, J 6.9 Hz, ArH); 13C NMR (125 MHz, CD3OD) δ 
14.4, 23.7, 27.2, 30.46, 30.6, 30.70, 30.73, 30.78, 33.1, 52.3 (d, 1JPC 150 Hz), 70.8, 73.0, 128.8 (d, 
4JPC 1.9 Hz), 129.0 (d, 3JPC 5.4 Hz), 129.5, 137.5, 172.1 (d, 3JPC 7.6 Hz). 
((2-(Hexadecyloxy)acetamido)(4-methoxyphenyl)methyl)phosphonic acid (34g) 
 
Yellow solid (0.05 g, 100%), m.p. 70.7-72.6 °C. ESI-MS, m/z: 498 [M - H]-. HRMS calculated for 
C26H45NO6P- 498.2990, found 498.2998. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3(CH2)15O), 1.28-1.32 (26H, m, CH3(CH2)13), 1.61-1.66 (2H, m, CH2CH2O), 3.49-3.57 (2H, m, 
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CH2O), 3.77 (3H, s, ArOCH3) 3.92-4.08 (2H, m, OCH2CO), 5.28 (1H, d, J 20.7 Hz, NHCHP), 6.89 
(2H, d, J 8.7 Hz, ArH), 7.33-7.35 (2H, d, J 8.7 Hz, ArH); 13C NMR (125 MHz, CD3OD) δ 14.4, 
23.7, 27.2, 30.46, 30.6, 30.7, 33.1, 52.0 (d, 1JPC 152 Hz), 55.8, 70.8, 73.0, 114.9 (d, 4JPC 1.3 Hz), 
129.3, 130.1 (d, 3JPC 5.9 Hz), 160.8 (d, 5JPC 2.3 Hz), 172.0 (d, 3JPC 7.5 Hz). IR (cm-1): 3252, 2917, 
2850, 1615, 1556, 1515. 
2.4.2  pPAP extraction and purification 
1. Extraction of PAP from pig allantoic fluid 
2.2 L of allantoic fluid from pigs was obtained from a slaughterhouse and stored at -80 °C until 
analysed. The frozen allantoic fluid was kept at 4 °C until it was fully thawed. The resulting liquid 
was then centrifuged 6 times at 4000 g for 30 minutes each until there was no visible sedimentation. 
The supernatant (2.0 L) was then collected and filtered through a 0.22 µm membrane to ensure that 
there will be no blockage when the sample was loaded onto the column using FPLC. The first 
purification step was to pass the filtered fluid (1.8 L, pH 7.8) at 4 mL/min through a carboxymethyl 
(CM) cellulose column (2.6 x 100 cm, with a bed height of 85 cm), which was first generated, and 
equilibrated with 0.01 M Tris-HCl buffer, pH 8.5; to allow basic proteins to bind to the resin. The 
column was then washed with 0.85 L of 0.1 M NaCl in 0.01 M Tris-HCl, pH 8.5 at 2 mL/min to 
elute out the heme protein. A further 1.5 L of the buffer with increasing gradient of NaCl from 0.1 
M to 1 M was passed through the column to elute out PAP. Figure 32 shows the chromatogram of 
the elution profile. 
Out of 135 fractions collected, 50 fractions (fractions 76-126) with 12 mL per fraction have 
significant absorbance at 280 nm. As there was still some purple protein stuck on the column, a 
further 400 mL of 3 M NaCl in 0.01 M Tris-HCl buffer, pH 8.5 was passed through the column, 
which resulted in another 5 fractions (fractions 15-19) having significant absorbance at 280 nm. All 
55 fractions were checked if they have p-NPP activity, and 42 fractions had p-NPP activity.  
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Figure 32: Chromatogram of the elution profile of the filtered supernatant from the allantoic fluid 
of a pregnant pig from a CM-cellulose column, eluted with 0.1-1 M sodium chloride gradient in 
Tris-HCl, pH 8.5 at 2 mL/min. 
2. SDS-PAGE analysis on fractions collected from ion-exchange chromatography 
To check the purity of the fractions, each fraction was individually concentrated using a Millipore 
Amicon centrifugal concentrator to around 1 mg/mL and 15 µL of each concentrated fraction was 
added 5 µL of gel loading buffer, which contains 40% dithiothreitol (DTT). Each of the mixture 
was then boiled at 100 °C for three minutes to denature the proteins in the mixture. Each sample 
was then loaded into the wells of 12% Mini-PROTEAN TGX Precast Gel from Bio-Rad immersed 
in a gel running buffer. The gel was run at 200 volt for 30 minutes or until the dye has run off. The 
gel was then stained with Bio-Safe Coomassie G-250 stain overnight, and then de-stained with 
distilled water. The SDS-PAGE analysis revealed three bands, for a protein with a molecular weight 
of 35 kDa, and another 2 proteins with higher molecular weight in all of the fractions (see Figure 
22 in Section 2.2.3).  
3. Purification of pPAP using gel filtration chromatography 
The fractions with p-NPP activity were combined and concentrated using a Millipore Amicon 
centrifugal concentrator to 18 mL and dialysed with 0.1 M NaOAc, pH 4.9. 4.5 mL of the dark 
	   83	  
purple sample was then loaded onto a Sephacryl S-200 column on FPLC, which was initially 
equilibrated with 0.1 M NaOAc buffer, pH 4.9. The sample was then eluted out with the same 
buffer. Figure 33 shows the chromatogram of the elution profile. Out of the 80 fractions collected, 
20 fractions with 3 mL per fraction had significant absorbance at 280 nm. Kinetic analysis was 
performed on all 20 fractions for p-NPP activity, of which 5 fractions did (fractions 19-25). 
4. SDS-PAGE analysis on fractions  
Each of the five fractions was then concentrated individually to around 2–5 mg/mL. SDS-PAGE 
analysis was then performed on the five fractions to determine the purity of the fractions according 
to the protocol above. SDS-PAGE analysis revealed a single band for five fractions, which reflected 
samples of high purity (see Figure 23 in Section 2.2.3).  
Steps 3 and 4 were repeated three times for the remaining 13.5 mL of the concentrated fractions 
from the ion-exchange chromatography step.  The fractions that contained a mixture of pPAP and 
other contaminant proteins were then pooled together, and steps 3 and 4 were performed on these 
pooled fractions.  
The resulting highly pure pPAP fractions were then pooled together and concentrated using a 
Milipore Amicon centrifugal concentrator to 32.06 mg/mL in 0.1 M NaOAc, pH 4.9. The 
concentration of pPAP was determined by measuring the absorbance at 280 nm, where an A280 of 
1.41 corresponds to a concentration of 1 mg/mL (28.6 µM). The total amount of pure pPAP 
extracted from 2 L allantoic fluid of a pregnant pig using this method was 306 mg. This pure pPAP 
stock was then divided into 200 µL aliquots and kept at -80 °C for future use. 1 mL was kept aside 
in 0.1 M sodium acetate, pH 4.9 at 4 °C for further use in this project. 
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Figure 33: Chromatogram of the elution profile of the filtered supernatant from the allantoic fluid 
of a pregnant pig from a Sephacryl S-200 column on FPLC, eluted with 0.1 M NaOAc buffer, pH 
4.9 at 1 mL/min. 	  	  	  	  
	   85	  
2.4.3  Kinetic Assays 
Established protocol for reduction of pPAP that was used in our group 
Pig PAP is reduced to convert it into its activated (reduced) form (Fe(III)Fe(II)) by incubating it 
with 0.77 mM BME/ferrous ammonium sulfate (10-fold) for ten minutes at 37 °C to be used in the 
screening and kinetic assays. After reduction, the reducing agent was removed by using Econo-Pac 
10DG column in 0.1 M sodium acetate buffer, pH 4.9. Determination of pPAP concentration was 
done by measuring the absorbance of the solution at 280 nm, where an A280 of 1.41 corresponds to a 
solution with pPAP concentration of 1 mg/mL (28.6 µM). The final enzyme concentration used in 
each well or cuvette for kinetic measurement was 10.2 nM. The specific activity of the fully 
reduced pPAP increased by two- to four-fold compared to the specific activity of the enzyme before 
reduction.  
Optimisation of reduction of pPAP for the freshly extracted and purified enzyme from Section 
2.4.2.  
The new stock of pPAP was reduced according to the established reduction protocol as descrived 
previously. However, results were not as expected, where the specific activity of the fully reduced 
pPAP decreased instead of increased, in multiple reduction preparations. Testing different reduction 
conditions then resulted in the optimised reduction protocol. Table 15 shows the different 
conditions to optimise the reduction protocol for the new stock of pPAP. 
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Table 15: The specific activities of the new stock of pPAP before and after reduction for several 
trials with slight modifications to the reduction procedure. 
Trial Modification 
Specific activity 
(µmol/min/mg of 
protein) before 
reduction 
Specific activity 
(µmol/min/mg of 
protein) after 
reduction 
1 None 235.4 74.9 
2 None 235.4 79.3 
3 None 490.9 185.9 
4 None 490.9 176.4 
5 Used a different bottle of BME 230.2 161.8 
6 Added ferrous ammonium sulfate in excess 200.0 95.1 
7 Added excess ferrous ammonium sulfate (10-fold) 250.4 111.9 
8 Did not go through desalting column 250.4 15.9 
9 None 170.3 97.1 
10 Added excess ferrous ammonium sulfate (10-fold) 170.3 114.2 
11 Reducing agent: 58 mM ferrous ammonium sulfate, 140 mM BME 48.2 190.0 
12 
Reducing agent: 100-fold molar excess 
of ferrous ammonium sulfate, and 200-
fold molar excess of BME, 20 nM final 
pPAP concentration 
48.2 437.2 
Based on the results from Table 15, it was then deduced that the optimum reduction protocol would 
be by using 200-fold and 100-fold molar excess of BME and ferrous ammonium sulfate, 
respectively. Therefore, a small amount (20 – 60 µL) of pPAP stock was diluted to 2.37 mg/mL 
(67.9 µM). 10% v/v (the final volume of the diluted pPAP stock) of 1000-fold and 2000-fold molar 
excess of ferrous ammonium sulphate and BME, respectively (67 mM and 134 mM, respectively) 
was added to the diluted pPAP stock. The pPAP mixture was then incubated for ten minutes at 37 
°C to be used in the screening and kinetic assays. After reduction, the reducing agent was removed 
by using Econo-Pac 10DG column in 0.1 M sodium acetate buffer, pH 4.9. The concentration of 
pPAP was determined by measuring the absorbance of the solution at 280 nm, where an A280 of 
1.41 corresponds to a solution with pPAP concentration of 1 mg/mL (28.6 µM). The specific 
activity of the fully reduced pPAP increased by two- to four-fold compared to the specific activity 
of the enzyme before reduction. 
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Several trials were also then set up to determine the optimum final concentration of the fully 
reduced pPAP to be used in the kinetic assays. Therefore, specific activities of fully reduced pPAP 
using the new reduction protocol were determined for varying final pPAP concentrations, ranging 
from 5 nM – 70 nM assayed against 5 mM p-NPP over several trials as shown in Table 16 
according to the procedure for screening assays which will be described later. 
Table 16: The specific activities of fully reduced pPAP from the new stock of pPAP at varying 
final concentrations. 
Trial Specific activity (µmol/min/mg of protein) Final pPAP concentration (nM) 
1 
437.2 19.4 
240.9 38.9 
244.7 50.5 
110.8 62.2 
79.4 70.0 
2 
75.7 5.0 
113.8 7.6 
164.3 10.2 
131.8 11.6 
112.8 14.7 
125.7 17.8 
133.9 20.1 
129.7 21.8 
122.1 24.9 
3 
124.7 4.8 
112.7 7.8 
105.6 10.1 
95.7 11.7 
94.6 14.8 
87.2 17.9 
86.3 20.2 
59.7 21.8 
95.0 24.9 
Based on the results from Table 16, it was decided that a final concentration of 20 nM of the fully 
reduced pPAP will be used for all kinetic assays. 
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Screening assays 
Screening assays were performed against fully reduced pPAP with a UV/Vis spectrophotometer 
with 96 wells 400µL multi-titre plate to determine the inhibition percentage of the inhibitors for 
pPAP according to the general method described in the literature.56 The substrate that was used is 
para-nitrophenyl phosphate (p-NPP) as PAPs catalyse the hydrolysis of p-NPP to release para-
nitrophenol (p-NP) (Scheme 7), which has an intense yellow colour. The amount of p-NP produced 
(or p-NPP hydrolysed) is then easily measured at 405 nm by using a spectrophotometer.  
	  
Scheme 7: The hydrolysis of p-NPP to yield p-NP by PAP. The intense yellow colour of p-NP 
could be conveniently measured at 405 nm using a spectrophotometer. 
The amount of p-NP formed due to the hydrolysis of p-NPP catalysed by pPAP was measured by 
using a continuous assay. The kinetic measurements were carried out at pH 4.9 (optimum pH for 
pPAP) in 0.1 M acetate buffer in 25% DMSO at 25 °C and λ = 405 nm, with Δε405 = 342.9 L mol-1 
cm-1, with p-NPP concentration of 5 mM; and the data were collected at 132-264 seconds, with 
each measurement carried out in duplicates.  Inhibitor concentrations used were 1, 10 and 100 µM. 
Enzyme concentration used was 20 nM in all screening assays, as was previously optimised.  
Kinetic assays 
Kinetic assays were performed against fully reduced pPAP with a UV/Vis spectrophotometer with 
96 wells 400 µL multi-titre plate to determine the inhibition constants (Ki) of the inhibitors for 
pPAP according to the method described in the literature.56 Kinetic measurements were carried out 
at pH 4.9 (0.1 M sodium acetate buffer in 25% DMSO) at 25 °C and λ = 405 nm using para-
nitrophenyl phosphate (p-NPP) as substrate at different concentrations (ranging from 1 to 17.5 
mM); and the data were collected at 132-264 seconds, with each measurement carried out in 
duplicates. The concentrations for the inhibitors used ranged from 0.1 µM to 100 µM. pPAP 
concentration used was 20 nM in all kinetic assays.  
kcat (s-1) was converted from (Vmax) according to the equation: 
kcat (s-1) = Vmax/60 x molecular weight of enzyme in mg/µmol, 
OP
HO
NO2
O
HO PAP
H2O
OH
NO2
+ H3PO4
p-NPP p-NP
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where: 
Specific activity (Vmax) is the units of activity per mg of protein (U/mg). 
A unit of enzme activity (U) is the release of 1 µmol per product per minute (µmol/min). 
Molecular weight of pPAP is 35000 µmol/mg. 
The data were analysed by using non-linear regression using the general inhibition equation 
(equation 5) performed by WinCurveFit (Kevin Raner software). 
𝑣   =    !!"#[!]! !!   !!!"# !  !! !!   [!]!!"                            (equation 5) 
In equation 5, Kic and Kiuc represent the equilibrium dissociation constants for competitive and 
uncompetitive inhibitor binding, respectively; while Vmax, KM, [S] and [I] represent the maximum 
rate of product formation, Michaelis constant, substrate concentration and inhibitor concentration, 
respectively. The scheme for an inhibited reaction is shown in Scheme 8.58 
	  
Scheme 8: Inhibited reaction scheme. E = enzyme, I = inhibitor, S = substrate, P = product, EI = 
enzyme inhibitor complex, ES = enzyme substrate complex. Kic represents the equilibrium 
dissociation constant for the inhibitor and the free enzyme (competitive binding), and Kiuc 
represents the equilibrium dissociation constant for the inhibitor and the enzyme substrate complex 
(uncompetitive binding). 
  
E   +   I EI
+
S
ES   +   I
+
S
ESI
E
+
P
Kic
Kiuc
kcat
KS KS
	   90	  
2.5  References 
1. Barrett-Connor, E.; Black, D.; Bonjour, J.-P.; Dequeker, J.; Ehrlich, G. E.; Eis, S. R.; 
Genant, H. K.; Gennari, C.; Johnell, O.; Kanis, J.; Liberman, U. A.; Masri, B.; Mautalen, C. 
A.; Meunier, P. J.; Miller, P. D.; Morii, H.; Poor, G.; Reid, I.; Sankaran, B.; Woolf, A. D.; 
Yu, W. Prevention and management of osteoporosis; WHO Technical Report Series - 921; 
World Health Organisation: Geneva, 2003; 1-194. 
2. Osteoporosis overview; National Institute of Arthritis and Musculoskeletal and Skin 
Diseases: Bethesda, Maryland, USA, 2009; 1-10. 
3. Boonen, S., Addressing the age-related needs of osteoporotic patients with strontium 
ranelate. Osteoporosis Int. 2010, 21, 415-423. 
4. Cosman, F.; de Beur, S. J.; LeBoff, M. S.; Lewiecki, E. M.; Tanner, B., Clinician's Guide to 
Prevention and Treatment of Osteoporosis. Osteoporosis Int. 2014, 25, 2359-2381. 
5. Cranney, A.; Wells, G. A.; Yetisir, E.; Adami, S.; Cooper, C., Ibandronate for the 
prevention of nonvertebral fractures: a pooled analysis of individual patient data. 
Osteoporosis Int. 2009, 20, 291-297. 
6. Black, D.; Cummings, S. R.; Karpf, D. B.; Cauley, J. A.; Thompson, D. E., Randomised 
trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. 
Fracture Intervention Trial Research Group. Lancet 1996, 348, 1535-1541. 
7. Black, D. M.; Thompson, D. E.; Bauer, D. C.; Ensrud, K.; Musliner, T., Fracture risk 
reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT 
Research Group. J. Clin. Endocrinol. Metab. 2000, 85, 4118-4124. 
8. Papapoulos, S.; Quandt, S. A.; Liberman, U. A.; Hochberg, M. C.; Thompson, D. E., Meta-
analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal 
women. Osteoporosis Int. 2005, 16, 468-474. 
9. McClung, M. R.; Geusens, P.; Miller, P. D.; Zippel, H.; Bensen, W. G., Effect of risedronate 
on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. 
Engl. J. Med. 2001, 344, 333-340. 
10. Delmas, P.; Recker, R. R.; Chesnut, C. H.; Skag, A.; Stakkestad, J. A., Daily and 
intermittent oral ibandronate normalize bone turnover and provide significant reduction in 
vertebral fracture risk: results from the BONE study. Osteoporosis Int. 2004, 15, 792-798. 
11. Chesnut III, C. H.; Skag, A.; Christiansen, C.; Recker, R.; Stakkestad, J. A., Effects of oral 
ibandronate administered daily or intermittently on fracture risk in postmenopausal 
osteoporosis. J. Bone Miner. Res. 2004, 19, 1241-1249. 
12. Harris, S.; Blumentals, W. A.; Miller, P. D., Ibandronate and the risk of non-vertebral and 
clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of 
phase III studies. Curr. Med. Res. Opin. 2008, 24, 237-245. 
	   91	  
13. Meunier, P. J., Anabolic agents for treating postmenopausal osteoporosis. Joint Bone Spine 
2001, 68, 576-581. 
14. Papapoulos, S. E.; Schimmer, R. C., Changes in bone remodelling and antifracture efficacy 
of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. 
Postgrad. Med. J. 2008, 84, 307-312. 
15. Schwender, C. F.; Beers, S. A.; Malloy, E.; Demarest, K.; Minor, L.; Lau, K. H. W., 1-
Naphthylmethylphosphonic acid derivatives as osteoclastic acid phosphatase inhibitors. 
Bioorg. Med. Chem. Lett. 1995, 5, 1801-1806. 
16. Schenk, G.; Mitic, N.; Hanson, G. R.; Comba, P., Purple acid phosphatase: A journey into 
the function and mechanism of a colorful enzyme. Coord. Chem. Rev. 2013, 257, 473-482. 
17. Odvina, C.; Zerwekh, J. E.; Rao, D. S.; Maalouf, N.; Gottschalk, F. A., Severely suppressed 
bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 
2005, 90, 1294-1301. 
18. Visekruna, M.; Wilson, D.; McKiernan, F. E., Severely suppressed bone turnover and 
atypical skeletal fragility. J. Clin. Endocrinol. Metab. 2008, 93, 2948-2952. 
19. Rozental, T.; Vazquez, M. A.; Chacko, A. T.; Ayogu, N.; Bouxsein, M. L., Comparison of 
radiographic fracture healing in the distal radius for patients on and off bisphosphonate 
therapy. J. Hand Surg. Am. 2009, 34, 595-602. 
20. Hoff, A.; Toth, B. B.; Altundag, K.; Johnson, M. M.; Warneke, C. L., Frequency and risk 
factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous 
bisphosphonates. J. Bone Miner. Res. 2008, 23, 826-836. 
21. Magopoulos, C.; Karakinaris, G.; Telioudis, Z.; Vahtsevanos, K.; Dimitrakopoulos, I., 
Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment 
proposals. Am. J. Otolaryngol. 2007, 28, 158-163. 
22. Black, D. M.; Delmas, P. D.; Eastell, R.; Reid, I. R.; Boonen, S., Once-yearly zoledronic 
acid for treatment of postmenopausal osteoporosis. N. Eng. J. Med. 2007, 356, 1809-1822. 
23. Heckbert, S.; Li, G.; Cummings, S. R.; Smith, N. L.; Psaty, B. M., Use of alendronate and 
risk of incident atrial fibrillation in women. Arch. Intern. Med. 2008, 168, 826-831. 
24. Abrahamsen, B.; Eiken, P.; Eastell, R., Subtrochanteric and diaphyseal femur fractures in 
patients treated with alendronate: a register-based national cohort study. J. Bone Miner. Res. 
2009, 24, 1095-1102. 
25. Somford, M.; Draijer, F. W.; Thomassen, B. J. W.; Chavassieux, P. M.; Boivin, G., Bilateral 
fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment 
with alendronate: clues to the mechanism of increased bone fragility. J. Bone Miner. Res. 
2009, 24, 1736-1740. 
	   92	  
26. Goh, S.; Yang, K. Y.; Koh, J. S. B.; Wong, M. K.; Chua, S. Y., Subtrochanteric 
insufficiency fractures in patients on alendronate therapy: a caution. J. Bone Joint Surg. Brit. 
2007, 89, 349-353. 
27. Kwek, E.; Goh, S. K.; Koh, J. S. B.; Png, M. A.; Sen Howe, T., An emerging pattern of 
subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 
2008, 39, 224-231. 
28. Lenart, B.; Lorich, D. G.; Lane, J. M., Atypical fractures of the femoral diaphysis in 
postmenopausal women taking alendronate. N. Eng. J. Med. 2008, 358, 1304-1306. 
29. Lenart, B.; Neviaser, A. S.; Lyman, S.; Chang, C. C.; Edobor-Osula, F., Association of low-
energy femoral fractures with prolonged bisphosphonate use: a case control study. 
Osteoporosis Int. 2009, 20, 1353-1362. 
30. Angel, N. Z.; Walsh, N.; Forwood, M. R.; Ostrowski, M. C.; Cassady, A. I.; Hume, D. A., 
Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate 
of bone turnover. J. Bone Miner. Res. 2000, 15, 103-110. 
31. Valizadeh, M.; Schenk, G.; Nash, K.; Oddie, G. W.; Guddat, L. W.; Hume, D. A.; de Jersey, 
J.; Burke, T. R.; Hamilton, S., Phosphotyrosyl peptides and analogues as substrates and 
inhibitors of purple acid phosphatases. Arch. Biochem. Biophys. 2004, 424, 154-162. 
32. Andersson, G.; Ek-Rylander, B.; Oellig, C. Use of activated TRAP for screening for specific 
inhibitor of TRAP and method for aiding in the identification of a compound for use in the 
treatment of diseases or degenerative conditions resulting in increased bone resorption. 
WO200031289-A; EP1131463-A; WO200031289-A1; AU200019019-A; NO200102453-A; 
EP1131463-A1; US6451548-B1; JP2002530117-W; AU759597-B; NZ511428-A, 2000. 
33. Oddie, G. W.; Schenk, G.; Angel, N. Z.; Walsh, N.; Guddat, L. W.; de Jersey, J.; Cassady, 
A. I.; Hamilton, S. E.; Hume, D. A., Structure, function, and regulation of tartrate-resistant 
acid phosphatase. Bone 2000, 27, 575-584. 
34. Vella, P.; McGeary, R. P.; Gahan, L. R.; Schenk, G., Tartrate-resistant acid phosphatase: a 
target for anti-osteoporotic therapeutics. Curr. Enzyme Inhib. 2010, 6, 118-129. 
35. Moss, D. W.; Raymond, F. D.; Wile, D. B., Clinical and biological aspects of acid 
phosphatase. Crit. Rev. Clin. Lab. Sci. 1995, 32, 431-467. 
36. Ek-Rylander, B.; Flores, M.; Wendel, M.; Heinegård, D.; Andersson, G., Dephosphorylation 
of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. 
Modulation of osteoclast adhesion in vitro. J. Biol. Chem. 1994, 269, 14853-14856. 
37. Hayman, A. R.; Jones, S. J.; Boyde, A.; Foster, D.; Colledge, W. H. In Tartrate-resistant 
acid phosphatase deficient mice have defective osteoclast function and develop late-onset 
osteopetrosis, Mary Ann Liebert: 1996; 164-164. 
	   93	  
38. Moonga, B. S.; Moss, D. W.; Patchell, A.; Zaidi, M., Intracellular regulation of enzyme 
secretion from rat osteoclasts and evidence for a functional role in bone resorption. J 
Physiol. 1990, 429, 29-45. 
39. Zaidi, M.; Moonga, B.; Moss, D. W.; MacIntyre, I., Inhibition of osteoclastic acid 
phosphatase abolishes bone resorption. Biochem. Biophys. Res. Commun. 1989, 159, 68-71. 
40. Twitchett, M. B.; Sykes, A. G., Structure, properties and reactivity of the Fe(II)Fe(III) and 
Zn(II)Fe(III) purple acid phosphatases. Eur. J. Inorg. Chem. 1999, 2105-2115. 
41. Mitic, N.; Smith, S. J.; Neves, A.; Guddat, L. W.; Gahan, L. R.; Schenk, G., The catalytic 
mechanisms of binuclear metallohydrolases. Chem. Rev. 2006, 106, 3338-3363. 
42. Zenger, S.; Hollberg, K.; Ljusberg, J.; Norgard, M.; Ek-Rylander, B.; Kiviranta, R.; 
Andersson, G., Proteolytic processing and polarized secretion of tartrate-resistant acid 
phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-
deficient mice. Bone 2007, 41, 820-832. 
43. Wang, Y. L.; Andersson, G., Expression and proteolytic processing of mammalian purple 
acid phosphatase in CHO-K1 cells. Arch. Biochem. Biophys. 2007, 461, 85-94. 
44. Lu, X.; Su, N.; Yang, J.; Huang, W.; Li, C.; Zhao, L.; He, Q.; Du, X.; Shen, Y.; Chen, B.; 
Chen, L., Fibroblast growth factor receptor 1 regulates the differentiation and activation of 
osteoclasts through Erk1/2 pathway. Biochem. Biophys. Res. Commun. 2009, 390, 494-499. 
45. Hasegawa, S.; Yonezawa, T.; Ahn, J. Y.; Cha, B. Y.; Teruya, T.; Takami, M.; Yagasaki, K.; 
Nagai, K.; Woo, J. T., Honokiol inhibits osteoclast differentiation and function in vitro. 
Biol. Pharm. Bull. 2010, 33, 487-492. 
46. Adibi, H. The University of Queensland, Australia. Unpublished work, 2012. 
47. Sträter, N.; Jasper, B.; Scholte, M.; Krebs, B.; Duff, A. P.; Langley, D. B.; Han, R.; Averill, 
B. A.; Freeman, H. C.; Guss, J. M., Crystal Structures of Recombinant Human Purple Acid 
Phosphatase With and Without an Inhibitory Conformation of the Repression Loop. J. Mol. 
Biol. 2005, 351, 233-246. 
48. Klabunde, T.; Krebs, B., The dimetal center in purple acid phosphatases. In Struct. Bond., 
Springer-Verlag Berlin: Berlin 33, 1997; Vol. 89, pp 177-198. 
49. Schenk, G.; Mitić, N.; Gahan, L. R.; Ollis, D. L.; McGeary, R. P.; Guddat, L. W., Binuclear 
Metallohydrolases: Complex Mechanistic Strategies for a Simple Chemical Reaction. Acc. 
Chem. Res. 2012, 1593-1603. 
50. Schenk, G.; Guddat, L. T.; Ge, Y.; Carrington, L. E.; Hume, D. A., Identification of 
mammalian-like purple acid phosphatases in a wide range of plants. Gene 2000, 250, 117-
125. 
	   94	  
51. Flanagan, J. U.; Cassady, A. I.; Schenk, G.; Guddat, L. W.; Hume, D. A., Identification and 
molecular modeling of a novel, plant-like, human purple acid phosphatase. Gene 2006, 377, 
12-20. 
52. Guddat, L. W.; McAlpine, A. S.; Hume, D.; Hamilton, S.; de Jersey, J.; Martin, J. L., 
Crystal structure of mammalian purple acid phosphatase. Structure 1999, 7, 757-767. 
53. Protein Data Bank. http://www.rcsb.org/pdb/home/home.do (accessed 13 August 
2011). 
54. Mitic, N.; Valizadeh, M.; Leung, E. W. W.; de Jersey, J.; Hamilton, S.; Hume, D. A.; 
Cassady, A. I.; Schenk, G., Human tartrate-resistant acid phosphatase becomes an effective 
ATPase upon proteolytic activation. Arch. Biochem. Biophys. 2005, 439, 154-164. 
55. Beck, J. L.; Durack, M. C. A.; Hamilton, S. E.; de Jersey, J., Irreversible inactivation of 
purple acid phosphatase by hydrogen peroxide and ascorbate. J. Inorg. Biochem. 1999, 73, 
245-252. 
56. Elliott, T. W.; Mitic, N.; Gahan, L. R.; Guddat, L. W.; Schenk, G., Inhibition studies of 
purple acid phosphatases: Implications for the catalytic mechanism. J. Braz. Chem. Soc. 
2006, 17, 1558-1565. 
57. Schenk, G.; Elliott, T. W.; Leung, E.; Carrington, L. E.; Mitic, N.; Gahan, L. R.; Guddat, L. 
W. Crystal structures of a purple acid phosphatase, representing different steps of this 
enzyme's catalytic cycle. BMC Struct. Biol. [Online], 2008. http://www.biomedcentral.com/content/pdf/1472-­‐6807-­‐8-­‐6.pdf (accessed 27 August 
2011). 
58. McGeary, R. P.; Vella, P.; Mak, J. Y. W.; Guddat, L. W.; Schenk, G., Inhibition of purple 
acid phosphatase with [alpha]-alkoxynaphthylmethylphosphonic acids. Bioorg. Med. Chem. 
Lett. 2009, 19, 163-166. 
59. Molegro virtual docker: user manual. http://www.lightwave-­‐scientific.com/Resources/MVD_Manual.pdf (accessed August 2011). 
60. Khan, M. S.; Akhtar, S.; Al-Sagair, O. A.; Arif, J. M., Protective Effect of Dietary 
Tocotrienols against Infection and Inflammation-induced Hyperlipidemia: An In Vivo and In 
Silico Study Phytother. Res. 2011, 25, 1586-1595. 
61. Frączek, T.; Siwek, A.; Paneth, P., Assessing molecular docking tools for relative biological 
activity prediction: a case study of triazole HIV-1 NNRTIs. J. Chem. Inf. Model. 2013, 53, 
3326-3342. 
62. Ghosh, S.; Rangan, L., Molecular docking and inhibition studies of α-amylase activity by 
labdane diterpenes from Alpinia nigra seeds. Med. Chem. Res. 2014, 23, 4836-4852. 
63. Kumar, V.; Gupta, G. K.; Kaur, K.; Singh, R., 4-Fluorophenylhydrazones as potential COX-
2 inhibitors: a novel, efficient, one pot solid phase synthesis, docking study and 
pharmacological evaluation. Med. Chem. Res. 2013, 22, 5890-5900. 
	   95	  
64. Mohd-Pahmi, S. H.; Hussein, W. M.; Schenk, G.; McGeary, R. P., Synthesis, modelling and 
kinetic assays of potent inhibitors of purple acid phosphatase. Bioorg. Med. Chem. Lett. 
2011, 21, 3092-3094. 
65. Fang, H.; Fang, M.; Liu, X.; Tang, G.; Zhao, Y., Syntheses, characterizations, and crystal 
structures of phosphonopeptides. Heteroat. Chem. 2007, 18, 9 - 15. 
66. Hussein, W. A.; Ross, B. P.; Landsberg, M. J.; Levy, D.; Hankamer, B.; McGeary, R. P., 
Synthesis of nickel-chelating fluorinated lipids for protein monolayer crystallizations. J. 
Org. Chem. 2009, 74, 1473-1479. 
67. Vovk, A. I.; Kalchenko, V. I.; Cherenok, S. A.; Kukhar, V. P.; Muzychkaa, O. V.; 
Lozynsky, M. O., Calix[4]arene methylenebisphosphonic acids as calf intestine alkaline 
phosphatase inhibitors. Org. Biomol. Chem. 2004, 2, 3162-3166. 
68. Kemp, W., Phosphorous-31 NMR Spectra. In NMR in Chemistry: A Multinuclear 
Introduction, Macmillan Education Ltd.: London, 1986; pp 176-181. 
69. Wissner, A.; Kohler, C. A.; Goldstein, B. M., Analogues of platelet activating factor. 3. 
Replacement of the phosphate moiety with a sulfonylbismethylene group. J. Med. Chem. 
1985, 28, 1365-1367. 
70. Hussein, W. The University of Queensland, Australia. Unpublished work, 2012. 
71. Campbell, H. D.; Dionysius, D. A.; Keough, D. T.; Wilson, B. E.; Jersey, J. d.; Zerner, B., 
Iron-containing acid phosphatases: Comparison of the enzymes from beef spleen and pig 
allantoic fluid. Biochem. Biophys. Res. Commun. 1978, 82, 615-620. 
72. Bazer, F.; Chen, T. T.; Knight, J. W.; Schlosnagle, D.; Baldwin, N. J., Presence of a 
progesterone-induced, uterine specific, acid phosphatase in allantoic fluid of gilts. J. Anim. 
Sci. 1975, 41, 1112-1119. 
73. Schlosnagle, D. C.; Bazer, F. W.; Tsibris, J. C. M.; Roberts, R. M., An Iron-Containing 
Phosphatase Induced by Progesterone in the Uterine Fluids of Pigs. J. Biol. Chem. 1974, 
249, 7574-7579. 
74. Kan, M.-W. The Development of New Purple Acid Phosphatase Inhibitors: A Light into 
Anti-osteoporotic Drugs. Ph. D. Thesis, The University of Queensland, Australia, 2011. 
75. Segel, I. H., Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state 
enzyme systems. John Wiley and Sons, Inc: New York, 1993. 
76. Hwang, C. H.; Chong, Y. H.; Song, S. Y.; Kwaka, H. S.; Lee, E., Asymmetric synthesis of 
secondary alcohols from primary alcohols via intramolecular carbenoid C–H insertion 
catalyzed by rhodium(II) 3-phenylcholestane-2-carboxylate. Chem. Commun. 2004, 816-
817. 
	   96	  
77. LLC, Q. Inhibitors of Biofilm Formation of Gram-Positive and Gram-Negative Bacteria. 
WO2009/77844 A2, 2009. 	  
	   97	  
Chapter 3  ACYL DERIVATIVES OF α-((4-
ETHOXYPHENYL)(AMINO)METHYL)PHOSPHONIC ACID  
3.1  Introduction 
It was discussed in previous chapters that this work aimed to develop new anti-osteoporotic drug 
leads that target PAP inhibition. Chapter 2 has discussed the development of new series of novel 
potent PAP inhibitors 33 and 34. The most potent compound developed in the previous chapter was 
compound 33e with Kic value of 168 nM against pig PAP (pPAP). Although this was only a slight 
improvement compared with the most potent pPAP inhibitor previously developed (25g, Kic = 203 
nM),1 it was demonstrated that designing new PAP inhibitors using lead compounds by employing 
the strategy of design, synthesis and testing could yield potent PAP inhibitors with improved 
potencies that could be further developed as anti-osteoporotic drug leads.  
According to the conclusions made based on the modelling and kinetic results obtained, the 
potencies of the compounds on PAP might be improved by targeting one of the pockets proximal to 
the active site. This could possibly be achieved by having a substituent on the phenyl ring that could 
fit and bind to the one of the pockets to increase binding interactions between the inhibitors and the 
enzyme, as it was shown that having a methoxy group at the para-position of the phenyl ring 
resulted in superior inhibition potency on pPAP compared with the compounds without any 
substituent on the phenyl ring (see Section 2.2.4 for details). Therefore, compounds with chemical 
structure 43 (Figure 34) were proposed to comprise the next series of PAP inhibitors in this work.  
 
43 
Figure 34: Chemical structure of α-((4-ethoxyphenyl)(amido)methyl)phosphonic acid (43), where 
R is an alkyl or 2-alkoxymethyl chain with different lengths. 
The docking results obtained in the previous chapter did not correlate well with the inhibition 
results. This might be due to the docking scores were calculated based on energy minimisations. 
This however might not represent or take into account the actual behaviour of the compounds and 
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the enzymes in either the assay conditions in vitro or physiological conditions in vivo. Therefore, it 
was best to not rely solely on the results from the docking simulations, but more on the results 
obtained from the kinetic studies, as they would reflect the inhibition properties of the compounds 
better in terms of the binding affinities and the inhibition modes. Nonetheless, in silico docking 
simulations still provide some guidance when designing PAP inhibitors with improved inhibition 
properties. Thus, this chapter will present and discuss the molecular modelling results, the 
syntheses, and the kinetic properties of the new series of 43 on pPAP. 
3.2  Results and Discussion 
3.2.1  Molecular Modelling 
Similar to the reasons described in Section 2.2.1, docking simulations for the new inhibitors 43 
were performed on both hPAP and pPAP to predict and visualise how they might bind to both 
enzymes. A total of four derivatives, 43c-f were chosen to be synthesised as racemates according to 
the reasons described later in Section 3.2.2. Consequently, both the R and S isomers of all 
derivatives of 43 were docked on both human PAP (hPAP) and pPAP by using Molegro Virtual 
Docker (MVD).2 Table 17 show the structures of R and S isomers of 43c-f, and their respective 
docking scores (presented as MolDock scores) as calculated by MVD based on energy 
minimisations.2  
Table 17: The chemical structure of the compounds 43c-f that were docked in hPAP and pPAP, and 
the docking scores as calculated by MVD. 
 
R-43 
 
S-43 
MolDock Scorea (kcal/mol) 
hPAP pPAP 
Compound R = R isomer S isomer R isomer S isomer 
43c Me(CH2)12- -132 -117 -200 -150 
43d Me(CH2)14- -151 -109 -154 -172 
43e Me(CH2)16- -141 -86 -165 -78 
43f Me(CH2)7OCH2- -149 -151 -203 -148 
aThe binding affinities of the inhibitors to the enzymes are calculated based on energy minimisation and given a 
MolDock Score. Larger negative values indicate higher binding affinities of the inhibitors to the enzymes. 
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Generally, both isomers of 43c-f were calculated to have high binding affinities to both hPAP and 
pPAP, as presented by the large negative MolDock scores (see Table 17). In addition, the 
compounds were also calculated to have quite comparable docking scores across the two enzymes. 
This suggested that the compounds would have similar binding affinities to both hPAP and pPAP, 
and thus the kinetic parameters of compounds 43c-f on pPAP obtained from the kinetic studies 
described in Section 3.2.3 could be extrapolated to hPAP. 
Compounds R-43d and S-43f were calculated to have the highest binding affinities to hPAP, and 
compounds R-43c and R-43f had the highest calculated binding affinities to pPAP. All of the 
predicted binding orientations of both R and S isomers of 43c-e on hPAP and pPAP can be found in 
Appendix D.2. One of the similar features in the predicted binding of all of the compounds on both 
PAPs was that strong binding was achieved through strong electrostatic interactions between the 
phosphoryl oxygen atoms and the two iron ions in the active site. Another similar binding 
orientation that was observed was that none of the long chain of all derivatives of 43 was predicted 
to bind through the groove as was hypothesised. Most of the chains of the derivatives were 
predicted to first go out into the solution and then curl back to make some hydrophobic interactions 
with the backbone of the surface residues of the enzymes. A similar observation was also obtained 
from the docking results for the previous series of PAP inhibitors 33 (see Section 2.2.1 for details). 
Furthermore, the ethoxy group at the para-position of the phenyl ring in 43c-f was not predicted to 
bind to any of the pockets in either enzyme, except for R-43f to pPAP (as shown in Figure 35), as 
was hypothesised. This could indicate that the pocket is not large enough to fit a component that is 
larger than a methoxy group at the para-position of the phenyl ring.  
Compound R-43d was calculated to have the highest binding affinity to hPAP. Figure 36 shows the 
predicted binding orientation of R-43d on hPAP. Like all the other compounds docked, R-43d binds 
to the diiron centre via electrostatic interactions through its phosphoryl oxygen atoms (termed PO1, 
PO2 and PO3). PO1 was predicted to bridge both iron ions at a distance of 2.0 Å. PO2 was 
predicted to ligate Fe(III) (2.0 Å) and also coordinate to Fe(II) through a weaker electrostatic 
interaction at a distance of 4.2 Å. The distances between PO3 and the two iron ions were both 3.3 Å 
apart. In addition, PO3 was also predicted to make hydrogen-bonding interaction with the side 
chain amide proton of Asn89, with a distance of 3.1 Å. Furthermore, the amide proton in R-43d was 
also predicted to make hydrogen bonds with two of the imidazole nitrogens of His221 at distances 
of 3.0 and 3.4 Å, respectively. The long alkyl chain was predicted to make some hydrophobic 
interactions with the backbone of the surface residues on hPAP (His221, Asp245, Glu192, His193). 
The oxygen atom in the 4-ethoxy group was not predicted to make any interaction with hPAP. 
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R-­‐43f	  
	  
Figure 35: Predicted binding orientation of compound R-43f in pPAP. The phosporyl oxygen atoms 
were predicted to bind to the diiron centre (shown as faint yellow spheres) via electrostatic 
interactions. The ethoxy group at the para-position of the phenyl ring was seen to fit into one of the 
small pockets near the active site. The amide group binds to the other pocket by making a hydrogen 
bond between its proton and the imidazole nitrogen in His195 (2.6 Å). The oxygen atom in the 
chain was hydrogen-bonded to the amide proton in Gln151 (3.0 Å). The chain was predicted to 
make some hydrophobic interactions with the surface residue of pPAP (Asn91, His92, Asp146, 
Thr57, Phe56, Asp52 and Tyr55). 	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R-43d 
	  
Figure 36: Predicted binding orientation of compound R-43d in hPAP. The phosphonate moiety 
was predicted to bind to the diiron centre (shown as faint yellow spheres). See text for details of 
other interactions between R-43d and hPAP. 
The predicted binding affinities of compounds 43c-f were quite high, as presented by the large 
negative values of their calculated MolDock scores (see Table 17). However as previously 
discussed, the docking results should not be used as the sole information to determine the inhibition 
potencies of the designed compounds on PAP. Until experimentally determined crystal structures 
are obtained, the actual binding orientation of the compounds on PAPs could not be determined. 
Therefore, all compounds 43c-f were synthesised and then tested on pPAP to determine their 
inhibition parameters on PAP.  	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3.2.2 Syntheses of α-((4-ethoxyphenyl)(amido)methyl)phosphonic acids (43c-f) 
 
Scheme 9: Synthetic route from 4-hydroxybenzaldehyde (44) to α-((4-
ethoxyphenyl)(amido)methyl)phosphonic acid (43). 
Scheme 9 shows the synthetic route for compounds 43 using the same synthetic methods previously 
established for inhibitors 33 as described in Section 2.2.2, except that 4-ethoxybenzaldehyde (45) 
was required to be synthesised first as the starting material from 4-hydroxybenzaldehyde (44), 
according to standard procedure in literature.3 This was achieved by stirring a solution of 44, 
potassium carbonate and iodoethane in acetone under reflux for 19 hours (refer Scheme 9). 
Purification by flash column chromatography afforded 45 in 90% yield. The 1H NMR spectrum of 
45 was consistent with that reported in the literature.3  
The conversion of 4-ethoxybenzaldehyde (45) into diethyl ((4-ethoxy)(amino)methyl)phosphonate 
hydrochloride (46) was achieved in two steps by heating 45 with a mixture of ammonium acetate 
and diethyl phosphite in ethanol according to standard procedure described in the literature;4  
followed by treatment with hydrogen chloride gas to give its corresponding hydrochloride salt in 
21% overall yield (refer Scheme 9).4 The identitiy of 46 was confirmed by nuclear magnetic 
resonance (NMR) spectroscopy, namely one-dimensional NMR spectroscopy such as 1H, 13C, 13C-
DEPT (distortionless enhancement by polarisation transfer), and two-dimensional NMR 
spectroscopy such as correlation spectroscopy (COSY) and heteronuclear single-quantum 
correlation spectroscopy (HSQC) (NMR spectra are not included) and low- and high-resolution 
mass spectrometry (LRMS and HRMS, respectively).  
According to the kinetic results obtained for the inhibition data of compounds 33, significant PAP 
inhibition (Ki values in the nanomolar range) was achieved when the alkyl chain lengths were at 
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least 13 carbons (see Table 13 in Section 2.2.4). Therefore, it was decided that this would be the 
minimum number of carbons in the alkyl chains of all derivatives of subsequent new PAP inhibitors 
to be synthesised and tested in this work. Nonetheless compound 43f was also synthesised, as the 
previously synthesised acid 39f (Figure 37) was available. Furthermore, the promising docking 
results obtained for 43f as described previously (see Section 3.2.1) also made it desirable to 
investigate its inhibition properties on pPAP.  
  
39f 
Figure 37: Chemical structure of 2-(octyloxy)acetic acid (39f). 
Therefore, a total of four derivatives of 43 were synthesised, by first introducing amide bonds to 46 
by reacting 46 with acyl chlorides to yield 47c-f. Acid chlorides (37c-f) were first prepared by 
refluxing carboxylic acids (39c-f) with thionyl chloride (detailed procedure is described in Section 
2.4.1).5-6 The conversion of 46 into its corresponding amides (47c-f) was achieved by reacting 46 
with 37c-f and DIPEA in dichloromethane (see Scheme 9). Purification by flash column 
chromatography gave 47c-f in good yields (see Table 18 for details).  
The identities of 47c-f were confirmed by NMR spectroscopy (1H, 13C, 13C-DEPT, COSY, HSQC) 
(NMR spectra are not included) and mass spectrometry (MS), by both LRMS and HRMS. Similar 
with compounds 38a-g (see Figure 20 in Section 2.2.2 for details), characteristic 1H NMR peaks 
were also observed for compounds 47c-f, which are the doublet of doublets at around 5.5 ppm, 
which was attributable to the coupling of the methine proton at the α-carbon with the phosphorous 
atom and the amide proton, and the complex multiplet signals for the methylene protons in the 
ethoxy groups. Similarly, the characteristic carbon signals were also observed in the 13C NMR 
spectra for all derivatives of 47 (see Figure 21 in Section 2.2.2 for the characteristic carbon 
signals), which are the doublet peak for the α-carbon at around 49 ppm with a coupling constant of 
155 Hz, a typical J value of a one-bond coupling between a carbon and a phosphorous atom,7 and 
the doublet peak at the carbonyl carbon region, which further proved that the introduction of the 
amide bond in 46 was successful.  
The dealkylation of the diester groups of the phosphonates in 47c-f was achieved by stirring 47c-f 
with bromotrimethylsilane in dry chloroform, which was subsequently followed by methanolysis, 
according to the standard procedure described in the literature8 to afford their corresponding 
phosphonic acids 43c-e in quantitative yields and 43f in moderate yield (see Table 18). All spectral 
data acquired for 43c-f (1D and 2D NMR, LRMS and HRMS) were used to characterise and 
HO O (CH2)7Me
O
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confirm the structures of 43c-f. All of the peaks in both the 1H and 13C NMR spectra for all 
derivatives of 43 were consistent with that observed for their corresponding precursors, 47c-f, with 
the disappearance of the ethoxy signals, hence confirming that the cleavage of the diester bonds in 
the phosphonates 47c-f was successfully achieved.  
Table 18: Yields obtained for diethyl α-((4-ethoxyphenyl)(amido)methyl)phosphonates (47c-f) and 
α-((4-ethoxyphenyl)(amido)methyl)phosphonic acids (43c-f). 
R = 
Compound 
 
47 
Yield % 
Compound 
 
43 
Yield % 
Me(CH2)12- 47c 93 43c 99 
Me(CH2)14- 47d 90 43d 99 
Me(CH2)16- 47e 91 43e 99 
Me(CH2)7OCH2- 47f 95 43f 72 
 
3.2.3 Kinetic Assays 
All kinetic assays were performed using the extracted and purified pPAP according to the assay 
protocol as described in Chapter 2. As previously mentioned, screening assays are required to be 
carried out for all synthesised compounds before performing inhibition assays to investigate if they 
have sufficient PAP inhibition potencies to save time, and to assist in choosing the inhibitors’ 
concentrations to be used in the inhibition assays. Therefore, compounds 43a-f were initially 
screened against pPAP using the same assay conditions: (1) concentration of p-NPP = 5 mM, (2) 
0.1 M sodium acetate buffer, pH = 4.9, (3) concentrations of compounds = 1, 10 and 100 µM, and 
(4) 25% DMSO. Despite the desirably high docking scores and favourable binding orientation 
previously obtained for 43f on hPAP and pPAP (see Table 17 and Figure 35 for details), the 
screening assay results suggested otherwise. Compound 43f only inhibited 19% of pPAP activity at 
100 µM, and no inhibition was observed at the lower concentrations of 1 and 10 µM. This result 
indicated that compound 43f was not a potent PAP inhibitor, and its Ki value would be more than 
100 µM. Therefore, the kinetic properties of 43f on PAP was not further investigated through 
inhibition assay. 
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During screening assays, it was observed that compounds 43d and 43e had low solubility at high 
concentration (100 µM) even in the assay conditions with 25% DMSO. This was in contrast to that 
observed for compounds 25, where even the derivative with the longest alkyl chain, 25i (structure is 
shown in Figure 38) did not have solubility problems in the same assay conditions.1 Fortunately, 
compounds 43c-e were quite potent pPAP inhibitor, therefore high concentrations (no more than 10 
µM) of the compounds were not required to be used in the inhibition assays.  
 
25i 
Figure 38: The chemical structure of ((docosyloxy)(naphthalene-1-yl)methyl)phosphonic acid 
(25i). 
Figure 39 to Figure 41 show the steady-state inhibition data for compounds 43c-e on pPAP at pH 
4.9, which also show the concentrations of inhibitors used in the continuous assays.  
 
43c 
	  
Figure 39: Steady-state inhibition of pPAP by compound 43c at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 43c concentrations ranged from 0 to 10 µM (as shown on the right 
of the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-
linear regression using equation 5 (see Section 2.4.3). 
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43d 
	  
Figure 40: Steady-state inhibition of pPAP by compound 43d at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 43d concentrations ranged from 0 to 1 µM (as shown on the right of 
the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-linear 
regression using equation 5 (see Section 2.4.3). 
	  
43e 
	  
Figure 41: Steady-state inhibition of pPAP by compound 43e at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 43e concentrations ranged from 0 to 10 µM (as shown on the right 
of the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-
linear regression using equation 5 (see Section 2.2.4). 
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Table 19 summarises the kinetic parameters of compounds 43c-e on pPAP. There was no 
observable trend among the derivatives of 43 in terms of increasing chain length and PAP inhibition 
potencies. However this might be due to the derivatives with shorter or longer chain length of this 
series were not synthesised and tested on pPAP.  
All three compounds 43c-e exhibited only competitive inhibition on pPAP with Kic values in the 
low and sub micromolar range (see Table 19), and the Kiuc values found were too large (high mM 
range) to be relevant. The competitive inhibition modes of all three compounds were also reflected 
by the increase in the KM values,9 as the true KM value for pPAP with p-NPP as the substrate was 
determined to be 3.7 mM at pH 4.9.10 Additionally, these results also correlate well with the 
docking results obtained as described in Section 3.2.1, where all three compounds bind to the active 
site of pPAP through strong electrostatic interactions between their phosphonate moieties and both 
the diiron ions, making them competitive inhibitors.  
The most potent pPAP inhibitor in this series was compound 43d with a Kic value of 606 nM. The 
derivatives 43c and 43e with shorter and longer alkyl chains respectively, showed comparable Kic 
values. This could bring us to the conclusion that the maximum inhibition potency for this series of 
compounds 43 on pPAP would be reached when the number of carbons in the alkyl chain was 15. 
However, this was not conclusive as the derivatives with longer alkyl chains than that of compound 
43e were not synthesised and tested. Nonetheless, a similar result was observed for the series of 25 
(see Table 7 in Section 1.3.1 for details), where maximum inhibition potency was reached when the 
number of carbons in the alkyl chain was 18 and 14 on pPAP and rkbPAP, respectively. The 
derivatives of 25 with longer alkyl chains showed marked decrease in inhibition potencies.1 
Therefore, it was still plausible that compound 43d would be the most potent compound in the 
series. 
Furthermore, as mentioned before, low solubility of compound 43e was observed in the assay 
conditions. Therefore, compounds with longer alkyl chains would have lower solubilities than that 
of compound 43e in the assay conditions. If these compounds have lower inhibition potencies on 
pPAP due to the longer alkyl chains, such as that observed when comparing the Kic values of 43d 
and 43e, higher concentrations of the derivatives with the longer alkyl chains would be required to 
be used in the assays. Due to the low solubilities of these compounds, especially at high 
concentrations, the inhibition properties obtained for these compounds would be less accurate. 
Therefore, it was decided that derivatives with longer alkyl chains for this series 43 would not be 
synthesised and tested. 
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Table 19: Inhibition properties of inhibitors 43c-e obtained from kinetic assays performed on pPAP 
at pH 4.9. 
 
43 
kcat (s-1)a KM (mM)b Kic (µM)c Kiuc (µM)c,d 
Inhibitor R = 
43c Me(CH2)12- 290 ± 37 7 ± 2 3.4 ± 2.2 - 
43d Me(CH2)14- 316 ± 39 7 ± 2 0.606 ± 0.227 - 
43e Me(CH2)16- 493 ± 59 10 ± 3 5.7 ± 2.0 - 
akcat represents the maximum rate. 
bKM represents the Michaelis constant. 
cKic and Kiuc represent competitive and uncompetitive inhibition constants, respectively. 
dNo value indicates that the value found is too large (more than ten-fold of Kic values), thus is irrelevant, hence 
neglected. 
3.3  Conclusion 
In this chapter, new series of compounds 43 were designed based on the results gathered in Chapter 
2. It was hypothesised that compounds 43 might have improved inhibition potencies on PAP with a 
longer alkyloxy group substituted at the para-position of the phenyl ring, as an extra carbon would 
have an extra hydrophobic interaction with the enzyme, particularly at the target pocket near the 
active site of PAP.  
A total of four derivatives were designed, synthesised and tested in this new series 43. Modelling 
results showed that the hypothesis might not be correct, as the ethoxy group might be too large to fit 
into the target pocket, compared with a methoxy group. Nonetheless, high docking scores were 
achieved for all four derivatives of 43 for both pPAP and hPAP. Therefore, these four compounds 
were synthesised and tested for PAP inhibition activity, where three derivatives exhibited quite high 
inhibition potencies on pPAP. Compound 43f had the highest calculated binding affinity for both 
hPAP and pPAP, but did not show good inhibition potency when screened on pPAP. This indicates 
that the docking scores are not accurate representation for the binding affinities and thus the 
inhibition potencies of the designed inhibitors. Hence, kinetic parameters of the designed inhibitors 
should always be experimentally determined through kinetic assays.  
The most potent compound in this series was compound 43d with a Kic value of 606 nM. Although 
it was in the nanomolar range, an improvement in the inhibition potency of the new series was not 
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achieved, as it was almost four times less potent than the most potent compound in the previous 
series described in Chapter 2 (33g, Kic = 168 nM on pPAP). As this work aimed to develop potent 
PAP inhibitors to be developed as anti-osteoporotic drug leads, therefore improvement on the 
inhibition potencies of the designed inhibitors is desirable. Hence, efforts were then put into testing 
another hypothesis made based on the results from Chapter 2 in order to design more PAP 
inhibitors with improved potencies, which would be discussed in Chapter 4. 
3.4  Experimental 
3.4.1  Syntheses 
All chemical reagents are of analytical grade unless stated otherwise. Chloroform was dried by 
distillation from phosphorous pentoxide. Light petroleum (LP, b.p. 40-60 °C) was distilled before 
use. Flash column chromatography was carried out with Merck Kieselgel 60 as described in the 
literature.11 NMR experiments were recorded on a 500 MHz spectrometer (Bruker, Rheinstetten, 
Germany). Chemical shifts are reported in parts per million (ppm) on a δ scale, relative to the 
solvent peak (CDCl3 δH 7.24, δC 77.0; CD3OD δH 3.30, δC 49.0). Coupling constants (J) are 
reported in hertz and peak multiplicities described as singlet (s), doublet (d), doublet of doublet 
(dd), triplet (t), quartet (q), pentet (p), multiplet (m), or broad (br). High-resolution electrospray 
ionization (EI) accurate mass measurements were recorded in positive and negative modes on a 
quadrupole – time of flight instrument (Bruker) with an ESI source. Accurate mass measurements 
were carried out with external calibration using sodium formate as reference calibrant and/or 
Agilent tune mix (mw > 500). Low and high-resolution electron impact ionization mass 
measurements were recorded using perfluorokerosene-H as reference calibrant. Melting points were 
determined with DigiMelt MPA161 (Stanford Research Systems). 
4-Ethoxybenzaldehyde (45)3 
 
The reaction was carried out as described in the literature.3 A solution of 4-hydroxybenzaldehyde 
(44) (9.77 g, 0.08 mol) and potassium carbonate (14.37 g, 0.10 mol) in acetone (160 mL) was added 
iodoethane (9.7 mL, 0.12 mol), and the mixture was stirred under reflux. TLC monitoring showed 
that the reaction has completed after 19 hours. The reaction mixture was then filtered through celite, 
O H
OEt
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and acetone was evaporated in vacuo. Purification by flash column chromatography (10% EtOAc in 
LP) afforded 45 as yellow semi-solid (10.81 g, 90%). Rf: 0.76 (30% EtOAc in LP, UV, KMnO4 
dip). 1H NMR (500 MHz, CDCl3) δ 1.40 (3H, t, J 7.0 Hz, OCH2CH3), 4.06 (2H, q, J 7.0 Hz, 
OCH2CH3), 6.93 (2 H, d, J 8.8 Hz, ArH), 7.77 (2H, d, J 8.8 Hz, ArH), 9.83 (1H, s, CHO), 
consistent with literature.3 
Diethyl (amino(4-ethoxyphenyl)methyl)phosphonate hydrochloride (46) 
 
This compound was synthesised based on the standard procedure described in the literature.4 The 
reaction was carried out under anhydrous conditions. Anhydrous ammonium acetate (4.1 g, 53 
mmol) was added to activated molecular sieves (2.0 g, 4 Å), and was further dried under high 
vacuum. Introduction of argon was followed by the addition of ethanol (15 mL) along with 45 (8.0 
g, 53 mmol) and diethyl phosphite (6.8 mL, 53 mmol) to the reaction mixture, which was then 
stirred at 60 °C under argon atmosphere. After 45 hours, monitoring with TLC showed that the 
reaction had gone to completion. The liquid was then decanted, carefully leaving the molecular 
sieves and quantitatively transferred with ethanol. The pH was adjusted to pH 1 using conc. HCl, 
and the resulting mixture was washed with diethyl ether (50 mL) to remove neutral materials. The 
aqueous layer was collected, and further extracted with water (20 mL). The combined aqueous 
layers were treated with NaOH (1 M) to change the pH to 11, and the product was extracted with 
CH2Cl2 (5 x 50 mL), dried with Na2SO4, and the solvent was evaporated in vacuo. The crude 
product dissolved in Et2O (20 mL) was then treated with HCl gas (reaction from conc. H2SO4 and 
NH4Cl). Vacuum filtration afforded the product as off-white solid (3.56 g, 21%), m.p. 156.6-
156.8oC. ESI-MS, m/z: 310 [M + Na]+. HRMS calculated for C13H22NNaO4P 310.1184, found 
310.1182. 1H NMR (500 MHz, CDCl3) δ 1.14 (3H, t, J 7.0 Hz, POCH2CH3), 1.24 (3H, t, J 7.0 Hz, 
POCH2CH3), 1.38 (3H, t, J 7.0 Hz, ArOCH2CH3), 3.89-3.95 (1H, m, POCH2CH3), 3.96-4.04 (3H, 
m, P(OCH2CH3)2), 4.03-4.10 (2H, q, J 7.1 Hz, ArOCH2CH3), 4.68 (1H, d, JPH 15.9 Hz, PCHNH2), 
6.84 (2H, d, J 8.6 Hz, ArH), 7.49 (2H, d, J 7.2 Hz, ArH), 9.26 (2H, s (br), NH2); 13C NMR (125 
MHz, CDCl3) δ 14.8, 16.2 (d, 3JPC 5.4 Hz), 16.3 (d, 3JPC 5.4 Hz), 51.0 (d, 1JPC 155 Hz), 63.4, 64.2 
(d, 2JPC 6.8 Hz), 64.5 (d, 2JPC 7.1 Hz), 114.8, 121.5, 130.1 (d, 3JPC 5.8 Hz), 159.6. IR (cm-1): 2986, 
2901, 2036, 1519, 1256. 
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General procedure for the preparation of diethyl phosphonates (47c-f).  
 
The reaction was carried out under anhydrous conditions. To the acid chlorides 37c-f (2 mmol), a 
solution of DIPEA (1.7 mL, 10 mmol) and the hydrochloride salt 46 (0.28 g, 1.00 mmol) in CH2Cl2 
(5 mL) was added dropwise to the acid chlorides 37c-f and the reaction mixture was stirred under 
argon atmosphere at room temperature for 18 h. The reaction was stopped and concentrated in 
vacuo. The solid was then dissolved in minimum amount of 10% EtOAc in LP and gravity filtered 
to get rid of the salt of DIPEA. The crude filtrate was then purified using silica flash column 
chromatography (10-70% EtOAc in LP) to give 47c-f as solid products. 
Diethyl ((4-ethoxyphenyl)(tetradecanamido)methyl)phosphonate (47c) 
 
Off-white solid (0.47 g, 93%), m.p. 72.2-73.6 °C. ESI-MS, m/z: 520 [M + Na]+. HRMS calculated 
for C27H48NNaO5P 520.3168, found 520.3173. 1H NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, 
CH3(CH2)12CO),  1.07 (3H, t, J 7.0 Hz, POCH2CH3), 1.17-1.26 (20H, m, CH3(CH2)10(CH2)2CO), 
1.29 (3H, t, J 7.0 Hz, POCH2CH3), 1.38 (3H, t, J 7.0 Hz, ArOCH2CH3), 1.57-1.59 (2H, m, 
CH2CH2CO), 2.20 (2H, t, J 7.5 Hz, CH2CO), 3.64-3.72 (2H, m, POCH2CH3),  3.86-3.91 (1H, m, 
POCH2CH3), 3.95-4.01 (1H, m, POCH2CH3), 4.07-4.12 (2H, q, J 7.5 Hz, ArOCH2CH3), 5.43 (1H, 
dd, J 9.5, J 20.5 Hz, NHCHP), 6.59 (1H, br, NH), 6.83 (2H, d, J 8.5 Hz, ArH), 7.31 (2H, d, J 7.0 
Hz, ArH); 13C NMR (125 MHz, CDCl3) δ 14.1, 14.7, 16.1 (d, 3JPC 5.5 Hz), 16.4 (d, 3JPC 5.9 Hz), 
22.6, 25.6, 29.32, 29.38, 29.48, 29.54, 29.58, 29.61, 29.62, 29.63, 31.9, 36.4, 49.0 (d, 1JPC 155 Hz), 
63.0 (d, 2JPC 7.1 Hz), 63.4, 63.45 (d, 2JPC 6.6 Hz), 114.5 (d, 4JPC 1.2 Hz), 127.0, 129.4 (d, 3JPC 6.2 
Hz), 158.7 (d, 5JPC 2.4 Hz), 172.6 (d, 3JPC 7.4 Hz).  IR (cm-1): 3225, 2918, 2851, 1630, 1545, 1515, 
1246. 
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Diethyl ((4-ethoxyphenyl)(palmitamido)methyl)phosphonate (47d) 
 
Off-white solid (0.49 g, 90%), m.p. 77.2-78.9 °C. ESI-MS, m/z: 548 [M + Na]+. HRMS calculated 
for C29H52NNaO5P 520.3481, found 548.3490. 1H NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, 
CH3(CH2)14CO),  1.07 (3H, t, J 7.1 Hz, POCH2CH3), 1.19-1.26 (24H, m, CH3(CH2)12(CH2)2CO), 
1.29 (3H, t, J 7.1 Hz, POCH2CH3), 1.38 (3H, t, J 7.0 Hz, ArOCH2CH3), 1.57-1.60 (2H, m, 
CH2CH2CO), 2.20 (2H, t, J 7.6 Hz, CH2CO), 3.67-3.72 (2H, m, POCH2CH3),  3.86-3.91 (1H, m, 
POCH2CH3), 3.95-4.01 (1H, m, POCH2CH3), 4.07-4.12 (2H, q, J 7.2 Hz, ArOCH2CH3),  5.42 (1H, 
dd, J 9.5, J 20.7 Hz, NHCHP), 6.50 (1H, dd, J 4.1, 9.3 Hz, NH), 6.83 (2H, d, J 8.6 Hz, ArH), 7.31 
(2H, d, J 7.0 Hz, ArH); 13C NMR (125 MHz, CDCl3) δ 14.1, 14.8, 16.1 (d, 3JPC 5.6 Hz), 16.4 (d, 
3JPC 5.8 Hz), 18.4, 22.7, 25.6, 25.7, 29.12, 29.16, 29.32, 29.34, 29.37, 29.48, 29.57, 29.59, 29.64, 
29.68, 29.74, 31.9, 36.6, 49.0 (d, 1JPC 155 Hz), 62.9 (d, 2JPC 7.2 Hz), 63.4, 63.5 (d, 2JPC 6.5 Hz), 
114.6 (d, 4JPC 1.2 Hz), 127.0, 129.3 (d, 3JPC 6.2 Hz), 158.8 (d, 5JPC 2.2 Hz), 172.4 (d, 3JPC 7.7 Hz). 
Diethyl ((4-ethoxyphenyl)(stearamido)methyl)phosphonate (47e) 
 
Off-white solid (0.55 g, 91%), m.p. 83.2-83.4 °C. ESI-MS, m/z: 576 [M + Na]+. HRMS calculated 
for C31H56NNaO5P 576.3794, found 576.3800. 1H NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, 
CH3(CH2)16CO),  1.07 (3H, t, J 7.1 Hz, POCH2CH3), 1.21-1.26 (28H, m, CH3(CH2)14(CH2)2CO), 
1.29 (3H, t, J 7.1 Hz, POCH2CH3), 1.38 (3H, t, J 7.0 Hz, ArOCH2CH3), 1.57-1.62 (2H, m, 
CH2CH2CO), 2.19 (2H, t, J 7.6 Hz, CH2CO), 3.64-3.69 (1H, m, POCH2CH3),  3.86-3.91 (1H, m, 
POCH2CH3), 3.99 (2H, q, J 7.0 Hz, ArOCH2CH3), 4.07-4.13 (2H, m, POCH2CH3),  5.42 (1H, dd, J 
9.6, J 20.7 Hz, NHCHP), 6.46 (1H, dd, J 4.3, 9.5 Hz, NH), 6.83 (2H, d, J 8.6 Hz, ArH), 7.32 (2H, 
d, J 8.7 Hz, ArH); 13C NMR (125 MHz, CDCl3) δ 14.1, 14.8, 16.1 (d, 3JPC 5.5 Hz), 16.4 (d, 3JPC 5.7 
Hz), 22.7, 25.6, 29.2, 29.32, 29.35, 29.49, 29.59, 29.64, 29.66, 29.68, 31.9, 36.6, 49.7 (d, 1JPC 154 
Hz), 62.8 (d, 2JPC 7.1 Hz), 63.3 (d, 2JPC 7.8 Hz), 63.4, 114.6, 127.0, 129.3 (d, 3JPC 6.3 Hz), 158.8, 
172.3 (d, 3JPC 7.7 Hz). 
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Diethyl ((4-ethoxyphenyl)(2-(octyloxy)acetamido)methyl)phosphonate (47f) 
 
Light yellow oil (0.43 g, 95%), ESI-MS, m/z: 480 [M + Na]+. HRMS calculated for C23H40NNaO6P 
480.2485, found 480.2478. 1H NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, CH3(CH2)7O),  
1.12 (3H, t, J 7.0 Hz, POCH2CH3), 1.23-1.31 (10H, m, CH3(CH2)5(CH2)2O), 1.27 (3H, t, J 7.3 Hz, 
POCH2CH3), 1.37 (3H, t, J 8.0 Hz, ArOCH2CH3), 1.57-1.62 (2H, p, J 7.0 Hz, CH2CH2CO), 3.43-
3.52 (2H, m, CH2CH2O), 3.75-3.89 (1H, m, POCH2CH3),  3.86-3.91 (1H, m, POCH2CH3), 3.90-
3.99 (5H, m, OCH2CH3, OCH2CO, ArOCH2CH3), 4.03-4.12 (2H, m, POCH2CH3),  5.42 (1H, dd, J 
9.9, J 20.4 Hz, NHCHP), 6.83 (2H, d, J 8.5 Hz, ArH), 7.32 (2H, d, J 8.5 Hz, ArH); 13C NMR (125 
MHz, CDCl3) δ 14.1, 14.8, 16.1 (d, 3JPC 5.8 Hz), 16.4 (d, 3JPC 5.6 Hz), 22.6, 26.0, 29.2, 29.35, 
29.43, 31.8, 49.0 (d, 1JPC 155 Hz), 62.8 (d, 2JPC 7.2 Hz), 63.2 (d, 2JPC 6.7 Hz), 63.4, 70.1, 72.0, 
114.6, 126.7, 129.1 (d, 3JPC 6.1 Hz), 158.9, 179.2 (d, 3JPC 7.5 Hz). 
General procedure for the preparation of phosphonic acids (43c-f).8 
 
 
The reactions were carried out under anhydrous conditions. To the corresponding diethyl ester 47c-f 
(0.2 mmol, 1 eq) was added dry chloroform (5 mL), and the mixture was stirred. TMSBr (1.6 mmol, 
8 eq) was then added, and the reaction mixture was stirred for two days under argon atmosphere. 
Excess TMSBr was removed under a stream of nitrogen, and the residue co-evaporated with MeOH 
to further remove TMSBr. The residue was then dissolved in MeOH (15 mL) and the resulting 
mixture was stirred and refluxed at 50oC under argon for two hours. MeOH was then evaporated 
and the product was further dried under high vacuum for two days to give the corresponding 
phosphonic acids 43c-f. 
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((4-Ethoxyphenyl)(tetradecanamido)methyl)phosphonic acid (43c) 
 
Orange solid (0.11 g, 99%). m.p. 118.8-119.3 °C. ESI-MS, m/z: 440 [M - H]-. HRMS calculated for 
C23H39NO5P- 440.2571, found 440.2561. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3(CH2)12CO), 1.25-1.27 (20H, m, CH3(CH2)10(CH2)2CO), 1.35 (3H, t, J 7.0 Hz, ArOCH2CH3), 
1.57-1.60 (2H, m, CH2CH2CO), 2.28 (2H, t, J 7.5 Hz, CH2CO), 4.00 (2H, q, J 7.0 H, 
ArOCH2CH3), 5.32 (1H, d, J 21.0 Hz, NHCHP), 6.85 (2H, d, J 8.6 Hz, ArH), 7.36 (2H, d, J 7.0 Hz, 
ArH); 13C NMR (125 MHz, CD3OD) δ 14.5, 15.2, 23.6, 27.0, 30.2, 30.4, 30.62, 30.68, 30.75, 
30.76, 33.1, 36.8, 52.0 (d, 1JPC 151 Hz), 64.5, 115.3, 129.4, 130.4 (d, 3JPC 5.9 Hz), 159.9, 175.8 (d, 
3JPC 7.5 Hz). IR (cm-1): 3322, 2917, 2850, 1653, 1533, 1514. 
((4-Ethoxyphenyl)(hexadecanamido)methyl)phosphonic acid (43d) 
 
Orange solid (0.09 g, 99%). m.p. 121.6-122.7 °C. ESI-MS, m/z: 468 [M - H]-. HRMS calculated for 
C25H43NO5P- 468.2884, found 468.2883. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3(CH2)14CO),  1.25-1.33 (24H, m, CH3(CH2)12(CH2)2CO), 1.36 (3H, t, J 7.0 Hz, ArOCH2CH3), 
1.58-1.60 (2H, m, CH2CH2CO), 2.28 (2H, t, J 7.5 Hz, CH2CO), 4.00 (2H, q, J 7.0 Hz, 
ArOCH2CH3),  5.32 (1H, d, J 21.1 Hz, NHCHP), 6.85 (2H, d, J 8.7 Hz, ArH), 7.35 (2H, d, J 6.8 
Hz, ArH); 13C NMR (125 MHz, CD3OD) δ 14.5, 15.2, 23.6, 27.0, 27.5, 30.2, 30.4, 30.5, 30.62, 
30.68, 30.75, 30.76, 33.1, 36.8, 52.0 (d, 1JPC 151 Hz), 64.5, 115.3, 129.4, 130.4 (d, 3JPC 5.9 Hz), 
159.9, 175.8 (d, 3JPC 7.5 Hz).   
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 ((4-Ethoxyphenyl)(octadecanamido)methyl)phosphonic acid (43e) 
 
Off-white solid (0.05 g, 99%). m.p. 121.7-122.8 °C. ESI-MS, m/z: 496 [M - H]-. HRMS calculated 
for C27H47NO5P- 496.3197, found 496.3210. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 6.9 Hz, 
CH3(CH2)16CO),  1.28-1.31 (28H, m, CH3(CH2)14(CH2)2CO), 1.36 (3H, t, J 7.0 Hz, ArOCH2CH3), 
1.58-1.61 (2H, m, CH2CH2CO), 2.28 (2H, t, J 7.4 Hz, CH2CO), 4.00 (2H, q, J 7.0 Hz, 
ArOCH2CH3),  5.32 (1H, d, J 21.0 Hz, NHCHP), 6.86 (2H, d, J 8.6 Hz, ArH), 7.35 (2H, d, J 6.9 
Hz, ArH); 13C NMR (125 MHz, CD3OD) δ 14.4, 15.2, 23.7, 27.0, 30.2, 30.46, 30.47, 30.6, 30.70, 
30.76, 30.79, 33.1, 36.9, 52.0 (d, 1JPC 152 Hz), 64.5, 115.4, 129.6, 130.5 (d, 3JPC 5.8 Hz), 160.0 (d, 
5JPC 2.1 Hz), 175.7 (d, 3JPC 7.4 Hz).   
((4-Ethoxyphenyl)(stearamido)methyl)phosphonic acid (43e) 
 
Brown solid (0.07 g, 72%). m.p. 105.3-106.5 °C. ESI-MS, m/z: 400 [M - H]-. HRMS calculated for 
C19H31NO6P- 400.1889, found 400.1893. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3(CH2)7O),  1.28-1.40 (10H, m, CH3(CH2)5(CH2)2O), 1.36 (3H, t, J 7.0 Hz, ArOCH2CH3), 1.60-
1.66 (2H, p, J 7.0 Hz, CH2CH2O), 3.48-3.58 (2H, m, CH2O), 3.93-4.07 (4H, m, ArOCH2CH3, 
OCH2CO),  5.29 (1H, d, J 20.7 Hz, NHCHP), 6.87 (2H, d, J 8.6 Hz, ArH), 7.32 (2H, d, J 8.7 Hz, 
ArH); 13C NMR (125 MHz, CD3OD) δ 14.4, 15.1, 23.7, 27.2, 30.4, 30.54, 30.58, 33.0, 51.5 (d, 1JPC 
152 Hz), 64.5, 70.8, 73.0, 115.5, 129.2, 130.2 (d, 3JPC 5.8 Hz), 160.1 (d, 5JPC 2.4 Hz), 172.0 (d, 3JPC 
7.6 Hz).   
 
3.4.2 Kinetic Assays 
All kinetic assays were conducted based on the procedure previously described in Section 2.4.3. 
pPAP was reduced before use in all steady-state assays using 67 mM ferrous ammonium sulfate and 
134 mM BME as the reducing agent. Continuous assays were conducted using p-NPP as the 
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substrate, in 0.1 M sodium acetate buffer with 25% DMSO, pH 4.9 (optimum pH for pPAP), at 25 
°C. Kinetic measurements was measured with a UV/Vis spectrophotometer at λ = 405 nm, with 
Δε405 = 342.9 L mol-1 cm-1, and the data were collected at 132-264 seconds, with each measurement 
carried out in duplicates. Fully reduced pPAP concentration was 20 nM in all assays. 
In screening assays, p-NPP concentration was 5 mM, and inhibitor concentrations used were 1, 10 
and 100 µM. Screening results were calculated as inhibition %. In inhibition assays, p-NPP 
concentrations used were 1, 3, 5, 7.5, 10, 12.5, 15 and 17.5 mM; and inhibitors’ concentrations used 
ranged between 0 to 10 µM (see Figure 39 to Figure 41 for the concentrations used for 43c-e). 
Data were analysed using non-linear regression performed by WinCurveFit (Kevin Raner software). 
kcat (s-1) was converted from (Vmax) according to the equation: 
kcat (s-1) = Vmax/60 x molecular weight of enzyme in mg/µmol, 
where: 
Specific activity (Vmax) is the units of activity per mg of protein (U/mg). 
A unit of enzme activity (U) is the release of 1 µmol per product per minute (µmol/min). 
Molecular weight of pPAP is 35000 µmol/mg. 	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Chapter 4  ACYL DERIVATIVES OF α-(AMINO(FURAN-2-
YL)METHYL)PHOSPHONIC ACID  
4.1  Introduction 
As gathered from previous chapters, it was demonstrated that both molecular modelling and kinetic 
studies results provide valuable information in designing new PAP inhibitors with improved 
potencies. Based on the results and the conclusions made from Chapter 2, it was hypothesised that 
improvements could be made in the design of new PAP inhibitors if (1) the compound could bind to 
either one or both pockets that are situated near the active site, and (2) the size of the aromatic 
component in the inhibitor was reduced (as shown by reducing the size of the aromatic ring from a 
naphthalene to a phenyl) (see Section 2.3 for details). 
Based on this information, compounds with a general chemical structure 48 (see Figure 42) were 
developed as the new series of PAP inhibitors. Compounds 48 were hypothesised to have improved 
inhibition potencies than compounds 33 by having the aromatic component with one carbon smaller 
than the phenyl ring in 33; a furan ring. This furan ring was also hypothesised to bind to one of the 
pockets to have higher binding affinities to PAP. Therefore this chapter will present and discuss the 
results obtained from docking studies, the syntheses of the compounds, and the kinetic studies of 
the compounds in this series performed on pig PAP (pPAP) as a human PAP (hPAP) model.  
 
48 
Figure 42: Chemical structure of α-(amido(furan-2-yl)methyl)phosphonic acid (48), where R is an 
alkyl chain with different lengths. 
4.2  Results and Discussion 
4.2.1 Molecular Modelling 
Docking simulations using Molegro Virtual Docker (MVD)1 were used to dock and then visualise 
the predicted binding orientations of the compounds to both hPAP and pPAP. Although it was 
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shown and emphasised in the previous chapters that the docking results especially in terms of the 
docking scores do not reflect the actual trends in the potencies of the compounds, docking 
simulations were useful in providing insights on how the compounds were predicted to bind to the 
enzymes. However it is important to note that the results from these computer simulations are only 
predictions, and until the crystal structures of the enzyme-inhibitor complex are obtained, the actual 
binding modes of the inhibitors to the enzymes cannot be determined.  
Table 20 shows the compounds that were docked in the crystal structure coordinates of both hPAP 
and pPAP. The inhibitors in this series were designed to have the chemical structure such as 48 (see 
Figure 42). However, due to the difficulties in synthesising compounds 48 which will be described 
later in Section 4.2.2, the kinetic studies could only be performed on pPAP to investigate the 
inhibition potencies of the available compounds 49c-e and 50c-d. Therefore, in silico docking 
simulations were also carried out for compounds 49c-e and 50c-d to predict and visualise how they 
might bind to the enzymes and thus contributed to the inhibition potencies that they exhibit towards 
pPAP (see Section 4.2.3 later for details).  
All of the new PAP inhibitors developed in this work used the strategy of using a substrate mimic. 
Therefore, the phosphonic acid moieties in all of the new inhibitors were postulated to bind to the 
dimetal centre in PAP by making strong electrostatic interactions. This requires the phosphonates to 
be negatively charged at pH 4.9, the optimum pH for animal PAPs. The docking studies were 
performed with the compounds ionised, as they would be at pH 4.9 (as described in Section 2.2.1). 
As can be observed, the phosphonate diesters in compounds 50c-d (see Table 20) do not have a 
free phosphonic acid that can be deprotonated at pH 4.9, to bind to the metals in the active site of 
PAP. Therefore, it was intriguing to investigate the possible binding interactions of 50c-d to PAPs 
that would result in them having inhibition activities on PAP. 
Table 20 summarise the docking scores obtained from the in silico docking simulations for both 
isomers of compounds 48c-e, 49c-e and 50c-d performed on both hPAP and pPAP. Generally, all of 
the compounds docked were calculated to have quite good binding affinities on both PAPs, except 
S-49e, which was calculated to have quite small negative MolDock Score on hPAP. In addition, 
almost all compounds were also calculated to have comparable binding affinities to both enzymes. 
This might indicate that the inhibition properties obtained for the compounds from kinetic studies 
performed on pPAP could be extrapolated to hPAP. Furthermore, as discussed in previous chapters, 
similar inhibition constants were found for different inhibitors against both PAPs in the literature,2-6 
which was likely due to the highly conserved seven invariant metal-ligating residues in the active 
sites and the same catalytic mechanism,2,4,7-9 thus further substantiate our hypothesis that the kinetic 
results obtained in this work could be extrapolated to hPAP. 
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Table 20: The chemical structure of the compounds 48c-e, 49c-e and 50c-d that were docked in 
hPAP and pPAP using MVD, and the calculated docking scores calculated by MVD. 
Compound R = 
MolDock Scorea (kcal/mol) 
hPAP pPAP 
 
R-48 
 
S-48 
R isomer S isomer R isomer S isomer 
48c Me(CH2)12- -140 -113 -131 -176 
48d Me(CH2)14- -140 -129 -80 -130 
48e Me(CH2)16- -113 -101 -131 -81 
 
R-49 
 
S-49 
R isomer S isomer R isomer S isomer 
49d Me(CH2)14- -78 -69 -80 -121 
49e Me(CH2)16- -118 -35 -132 -147 
 
R-50 
 
S-50 
R isomer S isomer R isomer S isomer 
50c Me(CH2)12- -97 -30 -146 -113 
50d Me(CH2)14- -57 -82 -117 -104 
From the docking results as summarised in Table 20, the diethyl phosphonate esters 50c-d were 
predicted to have lower binding affinities to hPAP than to pPAP. Compounds R-48c and R-48d, and 
compound R-49e had the highest calculated binding affinities to hPAP among compounds 48, and 
among compounds 49 respectively. Compound R-50c was calculated to have the highest binding 
affinity to pPAP among the derivatives of 50. 
All of the predicted binding conformations for all compounds that were docked in this series to 
hPAP and pPAP can be found in Appendix D.3. As predicted, all compounds 48 make strong 
electrostatic interactions with the diiron metals in the active site of both PAPs. The furan rings were 
also predicted to bind to one of the pockets near the active sites of both enzymes, as was 
hypothesised. The alkyl chains of all derivatives of 48 for both isomers were predicted to make 
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hydrophobic interactions with the surface residues on hPAP, while on pPAP, the alkyl chains of 
compounds 48 were predicted to bind to the groove that was initially targeted in the design of all of 
the new PAP inhibitors developed in this work. Figure 43 shows the predicted binding orientation 
of R-48c to hPAP. Similar to all compounds 48 docked, R-48c binds to the diiron centre via 
electrostatic interactions through its phosphoryl oxygen atoms (termed PO1, PO2 and PO3). PO1 
coordinates to Fe(II) and Fe(III) with distances of 2.0 and 3.3 Å, respectively. In addition, PO1 was 
also predicted to be hydrogen bonded to the hydroxyl group of Asp50 (3.1 Å) and to the amide 
proton of Asn89 (3.0 Å). PO2 was predicted to ligate Fe(II) with a distance of 2.0 Å, and weakly 
coordinates to Fe(III) with a distance of 3.6 Å. Furthermore, PO2 was also predicted to make 
hydrogen bonding with the phenol of Tyr53 with a distance of 3.4 Å. PO3 was predicted to make 
weak electrostatic interactions with both Fe(II) and Fe(III) with distances of 3.8 and 4.1 Å, 
respectively. It can be seen from Figure 43 that the furan ring fits into one of the pockets next the 
active site in hPAP. Additionally, the long alkyl chain of R-48c was predicted to make hydrophobic 
interactions with the surface residues of hPAP. 
 
R-48c 
 
Figure 43: Predicted binding orientation of compound R-48c in hPAP. The phosphonate moiety 
was observed to bind to the diiron centre (shown as faint yellow spheres). The furan ring can be 
seen to slot nicely into the pocket proximal to the active site. The alkyl chain makes hydrophobic 
interactions with the backbone of the surface residues in hPAP. 
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There were variations in the predicted binding orientations of both isomers of monoesters 49 to both 
hPAP and pPAP. Figure 44 shows the predicted binding orientation of compound R-49e to hPAP, 
which was calculated to have the highest binding affinity on hPAP among monoesters 49. Again, 
the furan ring was also predicted to fit into one of the pockets next to the active site of hPAP. The 
phosphoryl oxygen atoms (termed PO1 and PO2) were predicted to make electrostatic interactions 
with both iron ions, in addition to making hydrogen bonds with other amino acid residues. PO1 
binds to Fe(II) and Fe(III) with distances of 2.9 and 3.6 Å, respectively. In addition, PO1 was also 
predicted to make hydrogen bonds with the hydroxyl group of Asp50 (3.6 Å) and with the amine 
group of Asn89 (2.9 Å). PO2 was predicted to bind to Fe(II) and Fe(III) with distances of 3.6 and 
2.0 Å, respectively. PO2 was also hydrogen-bonded to the phenol of Tyr53 with a distance of 3.4 Å. 
The alkyl chain of R-49e was seen to curl, covering the cavity of the active site. A similar behaviour 
of the carbon tail was also predicted for all of the derivatives of 33 (see Section 2.2.1 for details) on 
both hPAP and pPAP. As compounds 33 were very potent pPAP inhibitors (see Section 2.2.4 for 
details), it was postulated that compounds 49 would also be potent PAP inhibitors. 
 
R-49e 
 
Figure 44: Predicted binding orientation of compound R-49e in hPAP. The phosphonate moiety 
was observed to bind to the diiron centre (shown as faint yellow spheres). 
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As previously mentioned, the phosphonate diesters 50 were also docked on both hPAP and pPAP to 
visualise how they would be predicted to bind to the enzymes as they were found to have inhibition 
activity against pPAP (see Section 4.2.3 later for details). Figure 45 shows the predicted binding of 
R-50c to pPAP. There was no predicted interaction between the diester of the phosphonate groups 
and the diiron centre. However, it can be observed that the furan ring fits nicely into one of the 
pockets proximal to the active site of pPAP. The long alkyl chain of R-50c was predicted to bind to 
the groove next to the active site. Similar binding orientation was predicted for both isomers of 50c-
d on pPAP. This binding orientation might be the contributing factor for the inhibition potencies of 
50c-d on pPAP. Although compounds 50c-d do not have the phosphonic acid moieties that can bind 
directly to the dimetal centre, but both the docking results and kinetic results obtained for these 
compounds described in this chapter show that if PAP inhibitors are designed to bind both to the 
groove and the pockets near to the active site, improved inhibition potencies could be achieved.  
 
R-50c 
 
Figure 45: Predicted binding orientation of compound R-50c in pPAP. The phosphonate moiety 
was observed to bind to the diiron centre (shown as faint yellow spheres). The furan ring is seen to 
fit nicely into one of the pockets, and the long chain binds to the groove, both of which are adjacent 
to the active site of PAP. 
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4.2.2 Syntheses of ethyl hydrogen (furan-2-yl(alkylamido)methyl)phosphonate (49d-e) and 
diethyl α-alkylamido(furan-2-yl)methylphosphonates (50c-e) 
 
Scheme 10: Proposed synthetic route to yield α-amido(furan-2-yl)methylphosphonic acid (48), 
where R is an alkyl or 2-alkoxymethyl chain with different lengths. 
Scheme 10 shows the proposed synthetic route to yield all derivatives of 48 according to the similar 
synthetic methods established for the previous series 33 and 43 (Chapters 2 and 3) as described in 
the literature.9-12 However, the first step to yield the hydrochloride salt of diethyl (amino(furan-2-
yl)methyl)phosphonate (52) from furfural (51) according to Scheme 11 was unsuccessful. When the 
crude diethyl (amino(furan-2-yl)methyl)phosphonate was treated with hydrogen chloride gas in 
ethanol, only black tar was produced, presumably due to 52 being acid-sensitive. 
 
Scheme 11: Unsuccessful attempt to synthesise 52 from 51. 
Another procedure was then sought in the literature. Wu et al.13 have described an efficient one-pot 
synthesis of aromatic α-aminophosphonates on silica in solvent-free conditions. Using the method 
described, the first step in the synthetic route of 48 was successfully achieved by heating a mixture 
of furfural (51), diethyl phosphite and ammonium acetate in the presence of chromatography silica 
gel support; at 60 °C for 90 minutes, to yield diethyl (amino(furan-2-yl)methyl)phosphonate (53) in 
17% yield (see Scheme 12).13 
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Scheme 12: Synthesis of diethyl (amino(furan-2-yl)methyl)phosphonate (53). 
The next step was to convert the free amine in 53 into amides by reacting it with acid chlorides as 
previously described (Chapters 2 and 3). Similar to the decision made in synthesising the previous 
series 43 (see Section 3.2.2 for details), only the derivatives with a minimum of 13 carbons in the 
chain would be synthesised for this new series of compounds 48. However, a slight modification in 
the method was employed, where a base (DIPEA (N,N-diisopropylethylamine)) was not used, as it 
was not available at the time of reaction. Compound 53 with the free amine was unstable, therefore 
it was decided that the reaction should proceed without DIPEA. The reaction was carried out 
according to the steps shown in Scheme 13; where acid chlorides (37c-e) were first prepared by 
refluxing carboxylic acids (39c-e) with thionyl chloride.14 The conversion of 53 into its 
corresponding amides (50c-e) was achieved by reacting compound 53 with acid chlorides 37c-e in 
dichloromethane. Purification by flash column chromatography gave 50c-e in moderate yields 
(Table 21). Only moderate yields were achieved due to the absence of a base in the reaction, 
however the amounts of 50c-e obtained were enough to be used in the next step; therefore the 
reactions were not repeated to yield more 50c-e. 
 
Scheme 13: Synthesis route of diethyl (alkylamido(furan-2-yl)methyl)phosphonates (50c-e). 
Table 21: Diethyl α-alkylamido(furan-2-yl)methylphosphonates (50c-e). 
Compound number R Yield % 
50c Me(CH2)12- 49 
50d Me(CH2)14- 47 
50e Me(CH2)16- 21 
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The final step to produce the new series of PAP inhibitor 48 required the cleavage of the diester 
bonds of the phosphonates in 50c-e to give their corresponding phosphonic acids 48c-e.  However, 
the established hydrolysis method for this step that have been used for the previous series of PAP 
inhibitors in this work using trimethylsilyl bromide and subsequent methanolysis was not successful 
to yield the desired phosphonic acids 48 (Scheme 14). It was proposed that this was due to the furan 
ring being acid-sensitive,13 thus was opened when 50 underwent hydrolysis in acidic conditions. 
The lack of signals in the aromatic region in the 1H NMR spectra of the products from the reactions 
shown in Scheme 14 further supported the hypothesis that the furan ring was opened. 
 
Scheme 14: Unsuccessful attempts to yield 48c-e. 
Another attempt to dealkylate the phosphonate esters in 50 was performed, where base hydrolysis 
using 2 M sodium hydroxide solution was carried out to yield the desired compounds 48. However, 
as expected from a base hydrolysis of phosphonate diesters, the monoesters15 49 were formed 
(Scheme 15). At this point, only compounds 50d-e were available to be used in this step, as the 
reaction shown in Scheme 14 were repeated several times for compound 50c, making it unavailable 
to undergo hydrolysis in basic conditions. A later attempt to synthesise more 50c according to the 
reaction shown in Scheme 13 using the synthesised 53 was unsuccessful. This was because as 
mentioned before, compound 53 was not stable, and its NMR and LRMS spectra did not show the 
peaks of those of 53. Another attempt to yield more of compound 53 by repeating the reaction 
shown in Scheme 12 was also unsuccessful. Nonetheless, monoesters 49d-e were synthesised in 
quite high yield (see Table 22). The mechanism for base hydrolysis of 50d-e to yield monoesters 
49d-e is shown in Scheme 16. The hydrolysis of phosphonate diesters in basic conditions only 
produced monoesters, as the negatively charged hydroxide ion could not attack the negatively 
charged 49d-e formed during the reaction.  
 
Scheme 15: Base hydrolysis of 50d-e yielded the monoesters 49d-e. 
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Table 22: Ethyl hydrogen (furan-2-yl(alkylamido)methyl)phosphonate (49d-e). 
Compound number R Yield % 
49d Me(CH2)14- 90 
49e Me(CH2)16- 91 
 
 
Scheme 16: The mechanism of base hydrolysis of 50 to 49. 
Compounds 49d-e were found to be quite potent pPAP inhibitor, which will be discussed later in 
Section 4.2.3. As even the monoesters 49d-e had quite high inhibition potencies on pPAP, it was 
intriguing to investigate the inhibition properties of the desired phosphonic acids 48 on PAP. 
Therefore, more efforts were then put into synthesising 48. 
Another method was proposed to yield the desired compound 48, according to the synthetic route in 
the scheme below (Scheme 17). This route was chosen, as the last step of this route would not 
require hydrolysis in acidic environment, which will cause the furan ring to be opened, or in basic 
hydrolysis, which will only yield the monoacids 49. Theoretically, debenzylation of 55 by 
hydrogenation using Pd/C catalyst would yield the desired phosphonic acids 48. 
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Scheme 17: Proposed synthetic route from furfural (51) to α-alkylamido(furan-2-
yl)methylphosphonic acids (48). 
The first step was carried out according to the standard procedure in literature13 for a similar 
reaction, but dibenzyl phosphite was used instead of diethyl phosphite as shown in Scheme 18. The 
reaction was stopped when it had gone to completion, as shown by thin layer chromatography 
(TLC), with the spot for 51 disappeared and a new spot appearing. However, immediately before 
applying the crude product to the silica to purify it using flash column chromatography, the spots 
for 51 and dibenzyl phosphite appeared again, as indicated by TLC. Nonetheless, purification of the 
crude product was still attempted to isolate the pure product 54. However, this purification step was 
proven to be difficult, as all of the fractions collected contained at least two compounds, as shown 
by TLC. The 1H NMR spectra for the some of the fractions collected also showed a peak typical of 
that of an aldehyde proton, indicating the existence of furfural (51) in the crude product. This might 
mean that the product 54 was highly unstable, and therefore the reaction might be reversible. 
 
Scheme 18: Synthesis of dibenzyl (amino(furan-2-yl)methyl) phosphonate (54). 
As the pure product 54 could not be isolated, the impure product was then used in the second step, 
as it was thought that the pure 55 would be easier to be isolated. This second step was carried out 
according to Scheme 19. Attempt to purify 55 from the crude product by flash column 
chromatography yielded only 0.02 g of product. The 1H NMR spectrum of the product showed that 
it was contaminated with the acid chloride 37e. 
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Scheme 19: Synthesis of dibenzyl (furan-2-yl(stearamido)methyl) phosphonate (55e). 
Due to the much difficulties faced in the efforts to synthesise the desired phosphonic acids 48, it   
was decided that compounds 48 would not be pursued anymore. Efforts were then put into 
developing another novel series of PAP inhibitor, which will be described later in Chapter 5. 
4.2.3 Kinetic Assays 
To test the inhibitory activities of the compounds synthesised against pPAP, screening assays were 
first carried out to ascertain whether they have inhibition activity against pPAP. From this series, 
only the monoesters 49d-e were successfully synthesised. Since the phosphonate diesters 50c-e 
were also available, they were also screened to probe whether they would have any inhibition effect 
on pPAP. Surprisingly, 50c-d had moderate pPAP inhibition even at 10 µM. Compound 50e 
showed very low potency, with only 14% pPAP inhibition at 100 µM. Consequently, kinetic 
parameters were determined for a total of four compounds in this series, namely 49d-e and 50c-d.  
Figure 46 to Figure 49 show the steady-state inhibition data for compounds 49d-e and 50c-d on 
pPAP at pH 4.9. 
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49d 
 
Figure 46: Steady-state inhibition of pPAP by compound 49d at pH 4.9. p-NPP concentrations 
ranged from 1 to 17.5 mM, and 49d concentrations ranged from 0 to 0.5 µM (as shown on the right 
of the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-
linear regression using equation 5 (see Section 2.4.3). 
 
49e 
 
Figure 47: Steady-state inhibition of pPAP by compound 49e at pH 4.9. p-NPP concentrations 
ranged from 1 to 17.5 mM, and 49e concentrations ranged from 0 to 5 µM (as shown on the right of 
the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-linear 
regression using equation 5 (see Section 2.4.3). 
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50c 
 
Figure 48: Steady-state inhibition of pPAP by compound 50c at pH 4.9. p-NPP concentrations 
ranged from 1 to 17.5 mM, and 50c concentrations ranged from 0 to 50 µM (as shown on the right 
of the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-
linear regression using equation 5 (see Section 2.4.3). 
 
50d 
 
Figure 49: Steady-state inhibition of pPAP by compound 50d at pH 4.9. p-NPP concentrations 
ranged from 1 to 17.5 mM, and 50d concentrations ranged from 0 to 70 µM (as shown on the right 
of the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-
linear regression using equation 5 (see Section 2.4.3). 
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Table 23: Inhibition properties of inhibitors 49d-e and 50c-d obtained from kinetic assays 
performed on pPAP at pH 4.9. 
Inhibitor R = kcat (s-1)a KM (mM)b Kic (µM)c Kiuc (µM)c,d 
 
49 
49d Me(CH2)14- 406 ± 120 5.4 ± 0.5 1.1 ± 0.2 - 
49e Me(CH2)16- 612 ± 42 10.3 ± 1.5 1.4 ± 0.4 - 
 
50 
50c Me(CH2)12- 473 ± 40 10.2 ± 1.8 18 ± 4 - 
50d Me(CH2)14- 308 ± 20 3.1 ± 0.6 28 ± 9 - 
akcat represents the maximum rate. 
bKM represents the Michaelis constant. 
cKic and Kiuc represent competitive and uncompetitive inhibition constants, respectively. 
dNo value indicates that the value found is too large (more than ten-fold of Kic values), thus is irrelevant, hence 
neglected. 
Table 23 summarises the kinetic parameters of compounds 49d-e and 50c-d on pPAP. All 
compounds were determined to be inhibiting pPAP activity in solely competitive modes with Kic 
values in the low micromolar range, as the Kiuc values found were too large (high mM range) to be 
relevant. The competitive inhibition modes of all three compounds were also reflected by the 
increase in the KM values,16 as the true KM value for pPAP with p-NPP as the substrate was 
determined to be 3.7 mM at pH 4.9 in previous studies.6 The predicted binding orientations of these 
compounds on both pPAP and hPAP from the docking results obtained for these compounds 
described previously in Section 4.2.1 also correlated well with these kinetic results. Based on the 
docking results, the compounds were predicted to bind to the active site by making electrostatic 
interactions between their phosphoryl oxygen atoms and the metal ions (compounds 49d-e), or by 
binding to the groove and the pocket adjacent to the active site, thus covering the cavity of the 
active site (compounds 50c-d), making them competitive inhibitors. 
Although these compounds exhibited good inhibition potency against pPAP, improved inhibition 
potencies were still not achieved in this work. However, this was to be expected for compounds 
49d-e and 50c-d, as they do not have the phosphonic diacid moiety, which would bind strongly to 
the dimetal centre. Based on the docking results described previously in Section 4.2.1, the initially 
designed inhibitors for this series, compounds 48 (Figure 50) were predicted to have favourable 
binding orientations on both hPAP and pPAP compared to compounds 49d-e and 50c-d. Therefore, 
based on the inhibition parameters determined for compounds 49d-e and 50c-d (see Table 23), it 
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can be postulated that derivatives of 48 would have improved inhibition potencies. Unfortunately, 
as discussed previously in Section 4.2.2, the desired compounds 48 could not be synthesised. It 
would be very interesting to determine PAP inhibition properties of compounds with a chemical 
structure such that as 48. Efforts towards achieving this will be discussed in Chapter 5. 
 
48 
Figure 50: Chemical structure of α-(amido(furan-2-yl)methyl)phosphonic acid (48), where R is 
alkyl chain with different lengths. 
Based on the results from Table 13, the diethyl phosphonate esters 50 displayed very surprising 
results, with Kic values in the mid-micromolar range. It was therefore fascinating to investigate if 
similar results would be found for the other diethyl phosphonate esters synthesised throughout this 
work, compounds 38a-g (from Chapter 2) and compounds 47c-f (from Chapter 3). Screening assays 
were then performed for all these compounds on pPAP, and they were found to have no inhibition 
at all on pPAP activity even at 100 µM inhibitor concentration. These three compounds (38, 47 and 
50) only differed in the sizes of their aromatic rings, where compounds 50 have the smallest 
aromatic ring, with only one carbon less compared with the phenyl ring in compounds 38. Docking 
studies suggested that the small furan ring in 50 fits nicely into one of the pockets near the active 
site of PAP. This therefore could bring us to the conclusion that our hypothesis that having a 
smaller aromatic component, and targeting one or both of the small pockets adjacent to the active 
site of PAP could result in improved inhibition potencies in PAP inhibitors. 
4.3  Conclusion 
This chapter described the design, synthesis and testing of new PAP inhibitors based on the 
hypothesis that a smaller aromatic component in the compound and having a component in the 
compound that is targeted to bind into one or both of the small pockets near the active site of PAP 
could result in more potent PAP inhibitors. Therefore, compounds 48 were designed to test this 
hypothesis and to yield more potent PAP inhibitors towards developing osteoporosis 
chemotherapeutics.  
The attempts to synthesise compounds 48 according to the synthetic procedure established for the 
previous series of PAP inhibitors described in this work (Chapters 2 and 3) were unsuccessful. 
Attempts to synthesise compounds 48 using modified methods were also unsuccessful. This was 
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mostly due to the furan ring in 48 being acid-sensitive, thus the ring could be opened when 
reactions were carried out in acidic conditions. Base hydrolysis of the phosphonate diesters 50 only 
yielded monoesters 49, as expected.  
The docking simulations performed for all of the compounds docked in hPAP and pPAP in this 
chapter predicted that all of them have favourable binding orientations that could yield high PAP 
inhibition potencies. In addition, the docking results also showed that the furan ring in the 
compounds might bind into the target pocket, which could improve the inhibition potencies of the 
new PAP inhibitors.  
The kinetic studies yielded surprising results, as even the phosphonate diesters 50 exhibited 
moderate inhibition potencies on pPAP. The potencies improved at least ten-fold when even only 
one of the ethyl phosphonate diesters was cleaved, as exhibited by the lower Kic values determined 
for the monoesters 49 compared with the Kic values of the diesters 50. In silico docking simulations 
predicted that the desired phosphonic acids 48 would have high binding potencies on PAP, as they 
were predicted to bind to PAP via strong electrostatic interactions between the phosphoryl oxygen 
atoms and both of the iron ions in the active site. It would therefore be very exciting to investigate if 
compounds with a chemical structure such as 48 would have improved inhibition potencies on PAP. 
Efforts towards this investigation will be discussed in Chapter 5. 
4.4  Experimental 
4.4.1  Syntheses 
All chemical reagents are of analytical grade unless stated otherwise. Chloroform was dried by 
distillation from phosphorous pentoxide. Furfural was distilled over sodium carbonate (7% w/w) 
under reduced pressure (2 mm Hg) before use.  Light petroleum (LP, b.p. 40-60 °C) was distilled 
before use. Flash column chromatography was carried out with Merck Kieselgel 60 as described in 
the literature.5 NMR experiments were recorded on a 500 MHz spectrometer (Bruker, Rheinstetten, 
Germany). Chemical shifts are reported in parts per million (ppm) on a δ scale, relative to the 
solvent peak (CDCl3 δH 7.24, δC 77.0; CD3OD δH 3.30, δC 49.0; D2O δH 2.49). Coupling 
constants (J) are reported in hertz and peak multiplicities described as singlet (s), doublet (d), 
doublet of doublets (dd), triplet (t), quartet (q), pentet (p), multiplet (m), or broad (br). High-
resolution electrospray ionisation accurate mass measurements were recorded in positive and 
negative modes on a quadrupole – time of flight instrument (Bruker) with an ESI source. Accurate 
mass measurements were carried out with external calibration using sodium formate as reference 
	   135	  
calibrant and/or Agilent tune mix (mw > 500). Low and high-resolution electron impact ionization 
mass measurements were recorded using perfluorokerosene-H as reference calibrant. Melting points 
were determined with DigiMelt MPA161 (Stanford Research Systems). 
Diethyl (amino(furan-2-yl)methyl)phosphonate (53)  
 
This compound was prepared according to the procedure described in the literature.13 The reaction 
was carried out under anhydrous conditions. Chromatography silica gel (0.8 g) was added to 
anhydrous ammonium acetate (11.6 g, 0.15 mol), after which furfural (51) (8.3 mL, 0.1 mol), 
followed by diethyl phosphite (13 mL, 0.1 mol) were added to the mixture and stirred vigorously. 
The reaction mixture was then smoothly heated to 60 °C for 90 minutes. TLC monitoring confirmed 
the reaction had gone to completion. The mixture was then allowed to cool to room temperature. 
The silica was filtered, and the resulting mixture was washed with NaCl (50 mL) and extracted with 
CH2Cl2 (3 x 20 mL). Water (50 mL) was then added and the aqueous phase was acidified to pH 1 
using conc. HCl. The mixture was then washed with EtOAc (2 x 50 mL). The aqueous phase was 
then changed to pH 11 using 6 M NaOH, and the compound was extracted with EtOAc (2 x 75 
mL). The combined organic layers were dried with Na2SO4, and the solvent evaporated. 
Purification by flash column chromatography (10%-90% EtOAc in LP) afforded the product as dark 
brown oil (3.88 g, 17%). Rf: 0.10 (80% EtOAc in LP, KMnO4 dip). ESI-MS, m/z: 256 [M +Na]+. 
1H NMR (500 MHz, CD3OD) δ 1.24 (3H, t, J 7.1 Hz, POCH2CH3), 1.31 (3H, t, J 7.1 Hz, 
POCH2CH3), 3.99-4.16 (4H, m, P(OCH2CH3)2), 4.47 (1H, d, JPH 18.1 Hz, PCHNH2), 6.35 (1H, t, J 
2.6 Hz, furfuryl), 6.49 (1H, s, furfuryl), 7.39 (1H, d, J 4.2 Hz, furfuryl), consistent with literature.13 
General procedure for the preparation of acid chloride (37a-g). All acid chlorides were prepared 
according to the procedure described by Hussein et al.14 Reactions were carried out under 
anhydrous conditions. Carboxylic acids 39a-g (2 eq., 4 mmol) were refluxed in thionyl chloride (3 
mL) for three hours. Excess thionyl chloride was evaporated using an aspirator. Co-evaporation of 
the resulting reaction mixture with toluene (3 x 5 mL) until dryness gave the corresponding acid 
chlorides 37a-g.  
NH2P
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General procedure for the preparation of diethyl (alkylamido(furan-2-yl)methyl)phosphonates 
(50c-e). 
The reaction was carried out under anhydrous condition. To the acid chlorides 37c-e, a solution of 
53 (0.23 g, 1.00 mmol) in CH2Cl2 (5 mL) was added dropwise to the acid chloride 37c-e and the 
reaction mixture was stirred under argon atmosphere for 18 hours. CH2Cl2 was then evaporated in 
vacuo, and the crude product was purified using silica flash column chromatography (10-50% 
EtOAc in LP) to give 50c-e as solid products. 
Diethyl (furan-2-yl(tetradecanamido)methyl)phosphonate (50c) 
 
White solid (0.22 g, 49%), m.p. 49.1-50.8 °C. ESI-MS, m/z: 466 [M + Na]+. HRMS calculated for 
C23H42NNaO5P 466.2698, found 466.2695. 1H NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, 
CH3(CH2)12CO),  1.18 (3H, t, J 7.2 Hz, POCH2CH3), 1.22-1.26 (20H, m, CH3(CH2)10(CH2)2CO), 
1.30 (3H, t, J 7.0 Hz, POCH2CH3), 1.58-1.64 (2H, m, CH2CH2CO), 2.21 (2H, t, J 7.6 Hz, CH2CO), 
3.85-3.93 (1H, m, POCH2CH3), 4.00-4.07 (1H, m, POCH2CH3), 4.08-4.18 (2H, m, POCH2CH3), 
5.67 (1H, dd, J 9.6, J 21.0 Hz, NHCHP), 6.24 (1H, d, J 8.2 Hz, NH), 6.33 (1H, t, J 2.4 Hz, 
furfuryl), 6.38 (1H, d, J 6.0 Hz, furfuryl), 7.37 (1H, d, J 2.0 Hz, furfuryl); 13C NMR (125 MHz, 
CDCl3) δ 14.1, 16.2 (d, 3JPC 5.9 Hz), 16.4 (d, 3JPC 5.6 Hz), 22.7, 25.5, 29.1, 29.29, 29.33, 29.5, 
29.57, 29.62, 29.64, 31.9, 36.5, 44.0 (d, 1JPC 160 Hz), 63.2 (d, 2JPC 7.0 Hz), 63.4 (d, 3JPC 6.8 Hz), 
108.9 (d, 3JPC 6.9 Hz), 110.7, 142.7 (d, 5JPC 2.4 Hz), 148.0, 172.2 (d, 3JPC 6.1 Hz).  
Diethyl (furan-2-yl(hexadecanamido)methyl)phosphonate (50d) 
 
Off-white solid (0.22 g, 47%), m.p. 56.3-57.7 °C. ESI-MS, m/z: 494 [M + Na]+. HRMS calculated 
for C25H46NNaO5P 494.3006, found 494.3009. 1H NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, 
CH3(CH2)14CO),  1.18 (3H, t, J 7.1 Hz, POCH2CH3), 1.22-1.25 (24H, m, CH3(CH2)12(CH2)2CO), 
1.30 (3H, t, J 7.1 Hz, POCH2CH3), 1.58-1.62 (2H, m, CH2CH2CO), 2.21 (2H, t, J 7.6 Hz, CH2CO), 
3.85-3.93 (1H, m, POCH2CH3), 4.00-4.06 (1H, m, POCH2CH3), 4.07-4.18 (2H, m, POCH2CH3), 
5.67 (1H, dd, J 9.7, J 21.1 Hz, NHCHP), 6.26 (1H, d, J 7.9 Hz, NH), 6.33 (1H, t, J 2.5 Hz, 
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furfuryl), 6.38 (1H, d, J 6.1 Hz, furfuryl), 7.37 (1H, d, J 2.0 Hz, furfuryl); 13C NMR (125 MHz, 
CDCl3) δ 14.1, 16.2 (d, 3JPC 5.6 Hz), 16.4 (d, 3JPC 5.9 Hz), 22.7, 25.6, 29.3, 29.4, 29.59, 29.64, 
29.68, 31.9, 36.4, 43.9 (d, 1JPC 160 Hz), 63.3 (d, 2JPC 7.2 Hz), 63.5 (d, 2JPC 6.8 Hz), 109.0 (d, 3JPC 
7.0 Hz), 110.7 (d, 4JPC 1.7 Hz), 142.7 (d, 5JPC 2.5 Hz), 148.0, 172.3 (d, 3JPC 6.4 Hz). IR (cm-1): 
3547, 3246, 2918, 2851, 1653, 1542, 1252. 
Diethyl (furan-2-yl(octadecanamido)methyl)phosphonate (50e) 
 
Off-white solid (0.10 g, 21%), m.p. 59.3-59.5 °C. ESI-MS, m/z: 522 [M + Na]+. HRMS calculated 
for C27H50NNaO5P 522.3319, found 522.3316. 1H NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, 
CH3(CH2)16CO),  1.18 (3H, t, J 7.2 Hz, POCH2CH3), 1.22-1.26 (28H, m, CH3(CH2)14(CH2)2CO), 
1.30 (3H, t, J 7.1 Hz, POCH2CH3), 1.58-1.63 (2H, p, J 7.3 Hz, CH2CH2CO), 2.21 (2H, t, J 7.6 Hz, 
CH2CO), 3.85-3.93 (1H, m, POCH2CH3), 4.00-4.08 (1H, m, POCH2CH3), 4.09-4.18 (2H, m, 
POCH2CH3), 5.67 (1H, dd, J 9.6, J 21.1 Hz, NHCHP), 6.28 (1H, d, J 8.1 Hz, NH), 6.33 (1H, t, J 
2.5 Hz, furfuryl), 6.38 (1H, t, J 3.0 Hz, furfuryl), 7.37 (1H, t, J 2.0 Hz, furfuryl); 13C NMR (125 
MHz, CDCl3) δ 14.1, 16.2 (d, 3JPC 5.6 Hz), 16.4 (d, 3JPC 5.9 Hz), 22.7, 25.5, 29.1, 29.30, 29.35, 
29.4, 29.58, 29.64, 29.68, 31.9, 36.5, 43.5 (d, 1JPC 160 Hz), 63.2 (d, 2JPC 7.0 Hz), 63.4 (d, 2JPC 6.4 
Hz), 108.9 (d, 3JPC 6.6 Hz), 110.7 (d, 4JPC 1.5 Hz), 142.7 (d, 5JPC 2.5 Hz), 148.0, 172.1 (d, 3JPC 6.0 
Hz). 
General procedure for the preparation of ethyl hydrogen (furan-2-
yl(alkylamido)methyl)phosphonate (49d-e). 
50d-e (0.15 mmol) was stirred with both MeOH (5 mL) and 2 M NaOH solution (1.5 mL) at room 
temperature for four days. The reaction mixture was then concentrated in vacuo and the residue was 
then acidified with citric acid to around pH 2, and extracted with EtOAc (5 x 25 mL). The 
combined organic layer was then washed with brine (2 x 60 mL), followed by water (50 mL), and 
the organic layer was then dried with Na2SO4 and EtOAc evaporated to yield the monoesters 49d-e. 
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Ethyl hydrogen (furan-2-yl(palmitamido)methyl)phosphonate (49d) 
 
Orange solid (0.05 g, 73%), m.p. 87.3-88.5 °C. ESI-MS, m/z: 442 [M - H]-. HRMS calculated for 
C23H41NO5P 442.2722, found 442.2724. 1H NMR (500 MHz, D2O) δ 0.86 (3H, t, J 7.0 Hz, 
CH3(CH2)14CO),  1.18 (3H, t, J 7.2 Hz, POCH2CH3), 1.22-1.26 (24H, m, CH3(CH2)12(CH2)2CO), 
1.59-1.62 (2H, m, CH2CH2CO), 2.23 (2H, t, J 7.5 Hz, CH2CO), 3.83-3.91 (2H, m, POCH2CH3), 
5.35 (1H, dd, J 7.4, J 19.7 Hz, NHCHP), 6.30 (1H, d, J 5.1 Hz, furfuryl), 6.36 (1H, t, J 2.7 Hz, 
furfuryl), 7.37 (1H, d, J 1.8 Hz, furfuryl); 13C NMR (125 MHz, CDCl3) δ 14.1, 16.2 (d, 3JPC 5.6 
Hz), 22.7, 25.6, 29.3, 29.4, 29.59, 29.64, 29.68, 31.9, 36.4, 43.9 (d, 1JPC 160 Hz), 63.3 (d, 2JPC 7.2 
Hz), 109.0 (d, 3JPC 7.0 Hz), 110.7 (d, 4JPC 1.7 Hz), 142.7 (d, 5JPC 2.5 Hz), 148.0, 172.3 (d, 3JPC 6.4 
Hz). IR (cm-1): 3297, 2917, 2850, 1648, 1535. 
Ethyl hydrogen (furan-2-yl(stearamido)methyl)phosphonate (49e) 
 
Brown solid (0.05 g, 83%), m.p. 89.7-90.9 °C. ESI-MS, m/z: 470 [M - H]-. HRMS calculated for 
C25H45NO5P 470.3035, found 470.3031. 1H NMR (500 MHz, MeOD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3(CH2)16CO),  1.25 (3H, t, J 7.1 Hz, POCH2CH3), 1.28-1.31 (28H, m, CH3(CH2)14(CH2)2CO), 
1.59-1.62 (2H, p, J 7.1 Hz, CH2CH2CO), 2.23 (2H, t, J 7.5 Hz, CH2CO), 4.02-4.05 (2H, m, 
POCH2CH3), 5.58 (1H, d, J 21.0 Hz, NHCHP), 6.38 (1H, d, J 5.1 Hz, furfuryl), 6.44 (1H, t, J 2.8 
Hz, furfuryl), 7.46 (1H, d, J 1.7 Hz, furfuryl); 13C NMR (125 MHz, CDCl3) δ 14.1, 16.4 (d, 3JPC 5.9 
Hz), 22.7, 25.5, 29.1, 29.30, 29.35, 29.4, 29.58, 29.64, 29.68, 31.9, 36.5, 43.5 (d, 1JPC 160 Hz), 63.4 
(d, 2JPC 7.1 Hz), 108.9 (d, 3JPC 6.6 Hz), 110.7 (d, 4JPC 1.5 Hz), 142.7 (d, 5JPC 2.5 Hz), 148.0, 172.1 
(d, 3JPC 6.0 Hz). 
Unsuccessful synthetic attempts  
As discussed in Section 4.2.2, the desired α-(alkylamido(furan-2-yl)methyl)phosphonic acids (48) 
could not be synthesised. Therefore, another method was proposed to yield the desired compound 
48, according to the synthetic route in the scheme below (Scheme 20).  
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Scheme 20: Proposed synthetic route from furfural (51) to α-(alkylamido(furan-2-
yl)methyl)phosphonic acids (48). 
The first step was carried out according to the standard procedure in literature13 for a similar 
reaction, but dibenzyl phosphite was used instead of diethyl phosphite as shown in Scheme 21; 
furfural (51) was distilled from Na2CO3 (7% w/w) at room temperature under reduced pressure (2 
mm Hg), and the reaction was carried out under anhydrous conditions. Chromatography silica gel 
(0.08 g) was added to anhydrous ammonium acetate (1.16 g, 0.015 mol), after which furfural (51) 
(0.83 mL, 0.01 mol), followed by dibenzyl phosphite (2.2 mL, 0.01 mol) were added to the mixture 
and stirred vigorously at room temperature. The reaction mixture was then smoothly heated to 60 
°C for 90 minutes. The reaction was monitored by TLC. When all the starting material was 
consumed, the reaction was stopped and the reaction mixture was allowed to cool to room 
temperature. The resulting mixture was diluted with CH2Cl2 (60 mL), and filtered. The filtrate was 
evaporated and the resulting crude product was then purified by flash column chromatography 
(30% - 100% EtOAc in LP).  
	  
Scheme 21: Synthesis of dibenzyl (amino(furan-2-yl)methyl) phosphonate (54). 
However, the pure product could not be isolated (at least 2 spots on TLC for the fractions that 
contained the product). In addition, before running the column, TLC showed that the spots for 
furfural (51) and dibenzyl phosphite appeared again in the crude product. The peak for the aldehyde 
proton in furfural also appeared again in the NMR spectra in the earlier fractions collected. 
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As the pure product could not be isolated, the impure product was then used in the second step, as it 
was thought that it would be easier to isolate the pure 54. The second step was carried out by first 
preparing the acid chloride 37e; where stearic acid (39e) (0.57 g, 2 mmol) was refluxed in thionyl 
chloride (1.5 mL). The impure 54 (0.22 g, 0.61 mmol) in DCM (5 mL) and DIPEA (0.8 mL, 5 
mmol) was then added dropwise to 37e, and stirred under argon atmosphere overnight (Scheme 
22). The resulting mixture was then washed with sodium bicarbonate (20 mL), followed with brine 
(2 x 20 mL), extracted with DCM, dried with Na2SO4, and concentrated in vacuo. Purification of 
the crude product (0.62 g) by flash column chromatography (30% - 100% EtOAc in LP) was 
attempted. The fractions with only one spot on TLC yielded only 0.02 g of product. NMR showed 
that it was the correct product, however it was still contaminated with the acid chloride 39e. 
Therefore, it was decided that this synthetic route (Scheme 20) to yield the desired phosphonic 
acids 48 would not be pursued anymore. 
 
Scheme 22: Synthesis of dibenzyl (furan-2-yl(stearamido)methyl) phosphonate (55e). 
4.4.2  Kinetic Assays 
All kinetic assays were conducted based on the procedure previously described in Section 2.4.3. 
pPAP was reduced before use in all steady-state assays using 67 mM ferrous ammonium sulfate and 
134 mM BME as the reducing agent. Continuous assays were conducted using p-NPP as the 
substrate, in 0.1 M sodium acetate buffer with 25% DMSO, pH 4.9 (optimum pH for pPAP), at 25 
°C. Kinetic measurements was measured with a UV/Vis spectrophotometer at λ = 405 nm, with 
Δε405 = 342.9 L mol-1 cm-1, and the data were collected at 132-264 seconds, with each measurement 
carried out in duplicates. Fully reduced pPAP concentration was 20 nM in all assays. 
In screening assays, p-NPP concentration was 5 mM, and inhibitor concentrations used were 1, 10 
and 100 µM. Screening results were calculated as inhibition %. In inhibition assays, p-NPP 
concentrations used were 1, 3, 5, 7.5, 10, 12.5, 15 and 17.5 mM; and inhibitors’ concentrations used 
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ranged between 0 to 10 µM (see Figure 46 to Figure 49 for the concentrations used for 49d-e and 
50c-d). Data were analysed using non-linear regression performed by WinCurveFit (Kevin Raner 
software). 
kcat (s-1) was converted from (Vmax) according to the equation: 
kcat (s-1) = Vmax/60 x molecular weight of enzyme in mg/µmol, 
where: 
Specific activity (Vmax) is the units of activity per mg of protein (U/mg). 
A unit of enzme activity (U) is the release of 1 µmol per product per minute (µmol/min). 
Molecular weight of pPAP is 35000 µmol/mg. 
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Chapter 5  ACYL DERIVATIVES OF α-(AMINO(THIOPHEN-
2-YL)METHYL)PHOSPHONIC ACID  
5.1  Introduction 
As discussed in the preceding chapters, this work aimed to develop new potent PAP inhibitors as 
anti-osteoporotic drug leads. Throughout this work, new series of PAP inhibitors were developed 
through the approach of design, synthesis and testing. This chapter will present and discuss yet 
another series of PAP inhibitors that was developed through the same approach. As discussed in 
Chapter 4, compounds 48 (Figure 51) were designed based on the conclusions made from the 
docking and kinetic studies results of compounds 33 (see Chapter 2 for details), where the 
phosphonic acids moiety was postulated to bind to the dimetal centre of pPAP via strong 
electrostatic interactions, the small furan ring was designed to fit nicely into one of the pockets near 
the active site of PAP, and longer alkyl chains to have increased hydrophobic interactions with the 
enzyme; all of which were hypothesised to improve PAP inhibition potencies. 
 
48 
Figure 51: Chemical structure of α-(amido(furan-2-yl)methyl)phosphonic acid (48), where R is an 
alkyl or alkoxymethyl chain with different lengths. 
As discussed in the previous chapter, efforts to synthesise compounds 48 were unsuccessful (see 
Section 4.2.2 for details) due to the furan ring being acid sensitive. Therefore, only the precursors of 
48, the diethyl phosphonate esters 50, and the product of base hydrolysis of 50, the monoesters 49 
were available to be tested for their PAP inhibition potencies. Interestingly, the monoesters 49 were 
quite potent competitive pPAP inhibitors, with Kic values in the low micromolar range. What was 
more interesting was that even the precursors, phosphonate diesters 50 were found to competitively 
inhibit pPAP, with Kic values in the mid micromolar range (see Section 4.2.3 for details). Since the 
docking results of compounds 48, 49, and 50 suggested that compounds 48 would have higher 
binding affinities to PAPs, thus higher inhibition potencies compared with compounds 49 and 50, it 
is thus very interesting to determine the inhibition parameters of compounds 48, or at least, 
compounds with a similar chemical structure to that of 48. 
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Hence, compounds with a general chemical structure 56 (Figure 52) were designed to be the next 
series of PAP inhibitors in this work. Compounds 56 were hypothesised to have similar binding 
affinities and inhibition potencies against PAPs with that of 48 due to their similar chemical 
structures. The thiophene ring was assumed to be less acid sensitive than the furan ring; therefore 
the synthesis of 56 would be possible. Furthermore, it would be interesting to investigate whether 
the monoesters 57 (Figure 53), synthetic intermediates en route to 56, would have comparable 
pPAP inhibition potencies with that found for monoesters 49 (see Section 4.2.3 for details). Thus, 
this chapter will discuss the results from the in silico docking studies, the syntheses, and the kinetic 
studies of compounds 56 and 57. 
 
56 
Figure 52: Chemical structure of α-(amido(thiophene-2-yl)methyl)phosphonic acid (56), where R is 
an alkyl or alkoxymethyl chain with different lengths. 
 
57 
Figure 53: Chemical structure of ethyl hydrogen (amido(thiophen-2-yl)methyl)phosphonic acids 
(57), where R is an alkyl or alkoxymethyl chain with different lengths. 
5.2  Results and Discussion 
5.2.1 Molecular Modelling 
In silico docking simulations using Molegro Virtual Docker (MVD) were employed throughout this 
work to dock and then visualise the predicted binding orientations of the designed new PAP 
inhibitors to provide some insights into how the compounds might bind to PAPs, which would 
therefore be used to design more potent PAP inhibitors. As discussed in the preceding chapters, 
some of the docking results do not correlate well with the results obtained from the kinetic studies 
performed on pPAP as a hPAP model. Therefore, it must be emphasised that the docking results 
only provide the predicted binding orientations of the compounds on the enzymes based on energy 
minimisations, and do not reflect the compounds actual inhibition potencies. Thus, docking 
simulations must always be accompanied with experimentally determined inhibition parameters, in 
order to investigate a compound’s potential as a PAP inhibitor. 
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As previously discussed, all of the kinetic studies in this work could only be performed on pPAP as 
a hPAP model, due to the difficulties in obtaining the clinically relevant hPAP, as the current 
method for hPAP expression using baculoviral expression system only produces recombinant hPAP 
in small quantities.1 Although there might be variations in the predicted binding orientations of the 
compounds between hPAP and pPAP, due to the high conservation of the seven invariant metal-
ligating residues in the active sites, the same catalytic mechanism,2-6 and the similar inhibition 
constants for different inhibitors against both hPAP and pPAP,3-4,7-9 the results from both the 
docking and kinetic studies performed on pPAP in this work could therefore be extrapolated to 
hPAP. 
Thus, all of the compounds 56 and 57 were docked into the active sites of both hPAP and pPAP to 
compare and contrast the predicted binding orientations of the inhibitors on each enzyme. 
Furthermore, as both compounds 56 and 57 have a chiral centre, both isomers of all compounds 
were docked on PAPs to predict if either isomer would have higher binding affinity than their 
counterpart. Table 24 summarises the compounds docked on hPAP and pPAP, and their respective 
docking scores calculated by Molegro Virtual Docker (MVD10).  
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Table 24: The chemical structure of the compounds 56c-h and 57c-h that were docked in hPAP and 
pPAP, and the docking scores as calculated by MVD. 
 
R-56 
 
S-56 
MolDock Scorea (kcal/mol) 
hPAP pPAP 
 
R-57 
 
S-57 
Compound R = R isomer S isomer R isomer S isomer 
56c Me(CH2)12- -48 -59 -191 -159 
56d Me(CH2)14- -95 -73 -176 -200 
56e Me(CH2)16- -105 -93 -181 -149 
56f Me(CH2)7OCH2- -161 -6 -175 -207 
56g Me(CH2)15OCH2- -68 -80 -164 -166 
56h Me(CH2)17OCH2- -103 -128 -166 -185 
57c Me(CH2)12- -57 -104 -141 -107 
57d Me(CH2)14- -49 -65 -116 -126 
57e Me(CH2)16- -34 -76 -133 -142 
57f Me(CH2)7OCH2- -31 -20 -128 -142 
57g Me(CH2)15OCH2- -34 -25 -132 -104 
57h Me(CH2)17OCH2- -24 -35 -139 -154 
aThe binding affinities of the inhibitors to the enzymes are calculated based on energy minimisation and given a 
MolDock Score. Larger negative values indicate higher binding affinities of the inhibitors to the enzymes. 
Generally, both isomers of the compounds were calculated to have comparable binding affinities 
between each other. This might be due to each isomer being predicted to bind to either enzyme in a 
similar manner with their counterpart (see Appendix D.4 for the predicted binding orientations for 
all compounds in this chapter). However, all compounds were predicted to have higher binding 
affinities to pPAP compared with hPAP, as suggested by the larger negative values of the calculated 
MolDock scores (see Table 24 for details). Most of the compounds were not predicted to bind to 
the diiron centre in hPAP by making electrostatic interactions through their phosphonate moieties, 
but the phosphonate moieties were predicted to either go into the pocket, or just pointed outwards 
H
NP
S
O
HO
HO
O
R
H
NP
S
O
HO
HO
O
R
H
NP
S
O
HO
EtO
O
R
H
NP
S
O
HO
EtO
O
R
	   148	  
without making any interaction with the enzyme, which resulted in the low docking scores 
obtained. This was a surprising result as compounds 56 and 57 were set to have negatively charged 
phosphoryl oxygen atoms in the docking simulations, as they would have at pH 4.9 (the optimum 
pH for mammalian PAPs, and the pH for the assay conditions performed in this work), thus they 
were expected to make electrostatic interactions with the dimetal centre. Furthermore, the predicted 
binding orientations for 56 and 57 in hPAP also did not correlate with the predicted binding 
orientations of their furan counterpart (see Appendix D.3 and D.4) This was in contrast to the 
predicted binding orientations for all compounds on pPAP, where all of them were predicted to 
make strong electrostatic interactions with the dimetal centre through their phosphonate moieties, 
which contributed to the good docking scores obtained for all compounds on pPAP. The reason 
why the compounds were not predicted to bind to the dimetal centre in hPAP compared with pPAP 
was not fully understood. Nonetheless, as was demonstrated in the previous chapters, the docking 
results could not be solely relied on to determine the inhibition potencies of the compounds, but the 
actual inhibition potencies of the compounds could be determined by experimentally determined 
kinetic parameters obtained from inhibition studies. In addition, previous studies have shown that 
different inhibitors have similar inhibition constants against both hPAP and pPAP,3-4,7-9 therefore 
the docking results obtained for compounds 56 and 57 might not reflect the actual inhibition 
potencies of these compounds against PAPs. 
As mentioned, most of the compounds were not predicted to bind to the dimetal centre in hPAP. 
However, some of compounds 56 that were calculated to have good docking scores (R-56e, S-56c, 
S-56f and S-56h) bind in a similar manner to that predicted for compound R-56f (the compound that 
was calculated to have the highest binding affinity to hPAP), where it was predicted to bind to 
hPAP to the diiron centre in the active site through the phosphonate moiety via strong electrostatic 
interactions (see Figure 54). Furthermore, similar to that observed for the furan ring discussed in 
Section 4.2.1, the thiophene ring was also predicted to fit nicely into one of the pockets adjacent to 
the active site, and the alkyl chain was predicted to curl, covering the cavity of the active site. 
Figure 54 shows the predicted binding orientation of compound R-56f to hPAP, where it was 
predicted to bind to the diiron centre via electrostatic interactions through its phosphoryl oxygen 
atoms (termed PO1, PO2 and PO3). PO1 was predicted to bridge Fe(II) and Fe(III) both at a 
distance of 2.0 Å, and made a hydrogen bond with the hydroxyl group of the side chain of Asp50 
(2.5 Å). PO2 was predicted to make a strong electrostatic interaction with Fe(III) with a distance of 
2.0 Å, and a weaker electrostatic interaction with Fe(II) with a distance of 4.3 Å. PO3 was predicted 
to make weak electrostatic interactions with both Fe(II) and Fe(III) with distances of 3.3 and 3.4 Å, 
respectively. In addition, PO3 was also predicted to make a hydrogen bond with the amine group of 
the side chain of Asn89 (3.0 Å). Furthermore, the NH in the amide group of R-56f was also 
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predicted to be hydrogen-bonded to two of the imidazole nitrogens in the side chain of His221 with 
distances of 2.9 and 3.2 Å. 
 
R-56f 
 
Figure 54: Predicted binding orientation of compound R-56f in hPAP. The phosphonate moiety 
was observed to bind to the diiron centre (shown as faint yellow spheres). The thiophene ring can 
be seen to slot nicely into the pocket proximal to the active site. The alkyl chain was predicted to 
curl, covering the cavity of the active site in hPAP. 
As mentioned, all compounds 56 and most of compounds 57 (R-57c, R-57f, R-57g, R-57h, S-57d, 
S-57e, S-57f and S-57h) were predicted to bind to the diiron centre in the active site of pPAP, which 
resulted in the high calculated binding affinities of the compounds to pPAP. The thiophene ring of 
compounds 56 were mostly predicted to fit to one of the pockets near the active site of pPAP. 
Similar to that observed in the modelling results for most of the compounds in the previous 
chapters, the alkyl chains of 56 were not predicted to bind to the hydrophobic groove adjacent to the 
active site, but they either make hydrophobic interactions with the backbone of the surface residues 
of the enzymes, or first going outwards and then curling, covering the cavity of the active site. 
Figure 55 shows the predicted binding orientation of S-56f (the compound that was calculated to 
have the highest binding affinity among compounds 56) to pPAP. The compound was predicted to 
make electrostatic interactions with the dimetal centre through its phosphoryl oxygen atoms (termed 
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PO1, PO2 and PO3). PO1 was predicted to bridge both iron ions with a distance of 2.0 Å, and also 
make weaker electrostatic interactions with the nitrogen atoms in the imidazole side chains of 
His92, His195, His221 and His223 with distances of 4.1, 4.4, 3.7 and 3.3 Å, respectively. PO2 was 
predicted to make weak electrostatic interactions with Fe(II) and Fe(III) with distances of 3.9 and 
3.2 Å, respectively, while PO3 was predicted to make a strong electrostatic interaction with Fe(III) 
with a distance of 2.0 Å, and a weaker electrostatic interaction with Fe(II) with a distance of 4.6 Å. 
In addition, PO3 was also predicted to make electrostatic interactions with one of the imidazole 
nitrogens of His92 (4.1 Å), and another two imidazole nitrogens of His223 (2.0 and 3.3 Å), while 
also predicted to be hydrogen-bonded to the phenol group of Tyr55 with a distance of 2.5 Å. Due to 
this good docking results obtained for compound 56f, it was therefore predicted to have high 
inhibition potency against pPAP. The kinetic studies performed against pPAP will be discussed 
later in Section 5.2.3. 
 
S-56f 
 
Figure 55: Predicted binding orientation of compound S-56f in pPAP. The phosphonate moiety was 
observed to bind to the diiron centre (shown as faint yellow spheres). The thiophene ring can be 
seen to slot nicely into the pocket proximal to the active site. The alkyl chain was predicted to curl, 
covering the cavity of the active site in pPAP. 
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None of the compounds 57 were predicted to have good binding affinities to hPAP. Although they 
were predicted to bind at the area around the active site, all of the compounds were not predicted to 
bind to hPAP through the phosphonate moieties, except compound S-57f, where it was predicted to 
bind to the dimetal centre of hPAP through its phosphoryl oxygens, and the ethoxy group was 
predicted to bind to the pocket near the active site. The phosphonate moieties and the thiophene 
rings of all compounds 57 (except S-57f) were not predicted to make any interaction with hPAP, but 
pointing outwards. Only the alkyl chains of compounds 57 were predicted to make hydrophobic 
interactions with the backbone of the surface residues of hPAP, curling and covering the cavity of 
the active site of hPAP (see Figure 56 for example). Therefore, the docking scores calculated for all 
compounds 57 docked to hPAP were very low (refer Table 24) due to these small amounts of 
interactions predicted between compounds 57 and hPAP. 
	  
Figure 56: Predicted binding orientation of S-57c in hPAP.  
In contrast to the docking results obtained for compounds 57 on hPAP, compounds 57 were 
predicted to have good binding affinities to pPAP (refer Table 24 for details). The docking scores 
obtained were however lower than the docking scores obtained for compounds 56 to pPAP. This 
might be due to reduced amount of electrostatic interactions predicted between compounds 57 and 
pPAP, as compounds 57 only have one negative charge delocalised over two phosphoryl oxygen 
atoms (instead of two negative charges delocalised over three phosphoryl oxygen atoms in 
compounds 56). Most of compounds 57 were predicted to bind to the diiron centre of pPAP via 
strong electrostatic interactions through their phosphoryl oxygen atoms. The thiophene rings were 
mostly predicted to fit into one of the pockets near the active site of pPAP, and the phosphonoester 
groups were predicted to either make hydrophobic interactions with the backbone of the surface 
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residues of pPAP, or pointing towards one of the pockets adjacent to the active site of pPAP. The 
alkyl chains were predicted to either make hydrophobic interactions with the backbone of the 
surface residues of pPAP, or curl into the solution, covering the cavity of the active site of pPAP. 
Figure 57 shows the predicted binding orientation of R-57h (the compound with the highest 
calculated binding affinity) to hPAP. Compound R-57h was predicted to have strong binding 
affinity to pPAP by making electrostatic interactions with the diiron centre through its phosphoryl 
oxygen atoms (termed PO1 and PO2). PO1 was predicted to make several electrostatic interactions, 
with both Fe(II) and Fe(III) with distances of 2.0 and 3.3 Å, respectively, and with the imidazole 
nitrogens of His92, His195 and His221 with distances of 3.7, 3.8 and 4.4 Å, respectively. In 
addition, PO1 was also predicted to make hydrogen bonds with the amine group of the side chain of 
Asn90 (3.1 Å), and with the NH of the side chain imidazole of His221 (3.3 Å). PO2 was predicted 
to make several electrostatic interactions as well, with both Fe(II) and Fe(III) (3.6, 2.0 Å, 
respectively), with an imidazole nitrogen of His92 (3.9 Å), and with two of the side chain imidazole 
nitrogens of His223 (3.8 and 2.4 Å). Additionally, PO2 was also predicted to be hydrogen-bonded 
to the side chain phenol of Tyr55 with a distance of 3.1 Å. Furthermore, the oxygen in the alkyl 
chain of compound R-57h was predicted to make a hydrogen bond with the NH of the side chain 
imidazole of His223, with a distance of 3.5 Å. From Figure 57, it can be observed that the 
thiophene ring was predicted to fit nicely into one of the adjacent pockets, and the alkyl chain made 
hydrophobic interactions with the backbone of the surface residues of pPAP (Asp246, Ser248, 
Glu194, His196, Gln151 and Ser145), curling and covering the cavity of the active site of pPAP. 
These interactions were predicted to contribute to high binding affinity of compound 57h to pPAP, 
and thus high pPAP inhibition potency. The sulfur atom in the thiophene ring was not observed to 
make any interaction with the enzyme, which was a similar observation with that predicted for the 
oxygen atom in the furan ring for the previous series described in Chapter 4 (see Section 4.2.1 for 
details). Therefore, it was hypothesised that compounds 57 would have similar pPAP inhibition 
potencies with that determined for their furan counterpart, compounds 49. This will be discussed 
later in Section 5.2.3. 
Overall, based on the docking results obtained for compounds 56 and 57, it was hypothesised that 
these series of compounds would have high pPAP inhibition potencies, but low inhibition potencies 
against hPAP (see Table 24 for details). However, as was consistently found and demonstrated 
throughout this work, the docking results do not always correlate well with the results obtained 
from the kinetic studies. Therefore, the docking results should not be the point of reference when 
determining the inhibition potencies of the new compounds, but the experimentally determined 
kinetic parameters for the compounds through inhibition studies would provide more reliable results 
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in terms of the inhibition potencies of the compounds. However, in silico molecular modelling is a 
useful tool to be employed to visualise and to provide some insights on the predicted binding 
orientations of the compounds on the enzymes. It could therefore aid in the design of the future 
generation of PAP inhibitors.  
 
R-57h 
 
Figure 57: Predicted binding orientation of compound R-57h in pPAP. The phosphonate moiety 
was observed to bind to the diiron centre (shown as faint yellow spheres). The thiophene ring can 
be seen to slot nicely into the pocket proximal to the active site. The alkyl chain was predicted to 
curl, making some hydrophobic interactions with the backbone of the surface residues, and covering 
the cavity of the active site in pPAP. 
5.2.2 Syntheses of α-(amido(thiophen-2-yl)methyl)phosphonic acids (56c-h) and ethyl 
hydrogen (amido(thiophen-2-yl)methyl)phosphonic acids (57c-h) 
Scheme 23 shows the whole synthetic route of α-(amido(thiophen-2-yl)methyl)phosphonic acids 
(56) from thiophen-2-carbaldehyde (58) using the previously established procedure for the previous 
series 33 (see Section 2.2.2 for details), and to ethyl hydrogen (amido(thiophen-2-
yl)methyl)phosphonic acids (57) from the phosphonate diesters 60 using base hydrolysis as was 
established in the previous Chapter 4 (see Section 4.2.2 for details).  
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The conversion of thiophene-2-carbaldehyde (58) to the hydrochloride salt of diethyl 
(amino(thiophen-2-yl)methyl)phosphonate (59) was achieved without incident in two steps by 
heating 58 with a mixture of ammonium acetate and diethyl phosphite in ethanol, followed by 
treatment with hydrogen chloride gas in diethyl ether to give 59 in 18% yield (refer Scheme 23). 
The 1H NMR spectrum of 59 was consistent with that found in the literature.11 
 
Scheme 23: Synthetic route from thiophen-2-carbaldehyde (58) to α-(amido(thiophen-2-
yl)methyl)phosphonic acids (56) and to ethyl hydrogen (amido(thiophen-2-yl)methyl)phosphonic 
acids (57), where R is alkyl or alkoxymethyl chain with different lengths. 
The introduction of amide bonds to 59 was achieved by reacting 59 with acyl chlorides 37c-h 
(which were first prepared by refluxing carboxylic acids 39c-h in thionyl chloride) in DIPEA and 
DCM (refer Scheme 23). Purification of the crude products by flash column chromatography gave 
60c-h in good yields (see Table 25 for details). The identities of 60c-h were confirmed by nuclear 
magnetic resonance (NMR) spectroscopy, namely one-dimensional NMR spectroscopy such as 1H, 
13C, 13C-DEPT (distortionless enhancement by polarisation transfer), and two-dimensional NMR 
spectroscopy such as correlation spectroscopy (COSY) and heteronuclear single-quantum 
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correlation spectroscopy (HSQC) (NMR spectra are not included) and low- and high-resolution 
mass spectrometry (LRMS and HRMS, respectively). Similar to all the compounds described in 
previous chapters (Chapters 2, 3 and 4), the characteristic doublet of doublet peak of the methine 
proton at around 5.8 ppm was evident in all 1H NMR spectra for all compounds 60c-h. The methine 
proton was coupled to both the phosphorous atom and the amide proton, giving rise to the doublet 
of doublet peak. The appearance of a doublet peak at the carbonyl region in all of the 13C NMR 
spectra for compounds 60c-h further confirmed that the introduction of the amide bonds were 
successful. The doublet signal for the carbonyl carbon in compounds 60 was due to the three-bond 
coupling between the carbonyl carbon and the phosphorous atom. 
Table 25: Yields obtained for diethyl α-(amido(thiophen-2-yl)methyl)phosphonate (60c-h). 
Compound 
 
60 
R = Yield % 
60c Me(CH2)12- 85 
60d Me(CH2)14- 79 
60e Me(CH2)16- 87 
60f Me(CH2)7OCH2- 84 
60g Me(CH2)15OCH2- 99 
60h Me(CH2)17OCH2- 72 
 
Carboxylic acids 39a-e are commercially available. 2-(alkyloxy)acetic acid 39f was synthesised 
previously as described in Section 2.2.2. Based on the high inhibition potencies obtained for 
compounds 33g and 34g against pPAP (see Section 2.2.3 for details), it was of interest to 
investigate if 56g and 57g would also have high pPAP inhibition potency. Furthermore, it would 
also be interesting to probe if a longer alkoxymethyl chain would improve the inhibition activity of 
the compounds. Since all of the acid 39g that was previously synthesised by Dr Waleed Hussein 
was used to synthesise 33g and 34g (see Section 2.2.2 for details), more was required to be 
synthesised. Therefore, acids 39g-h were synthesised from alcohols 40g-h according to Scheme 24, 
where the alcohols (40) were stirred with sodium hydride and bromoacetic acid (41) in dry THF. 
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Scheme 24: Synthesis of 2-(alkyloxy)acetic acids (39g-h), where R = (CH2)15Me (39g, 11%), 
(CH2)17Me (39h, 8%). 
The final step of the cleavage of the diethyl esters in 60 was successfully achieved by stirring 60 in 
TMSBr in dry chloroform, followed by methanolysis to give the phosphonic acids 56 (refer Scheme 
23) in good to quantitative yields (see Table 26). All of the peaks in both the 1H and 13C NMR 
spectra of 56 were consistent with those found for their corresponding phosphonate diesters 60, 
with the disappearance of the ethoxy signals confirming that the cleavage was successful. 
Monoester cleavage of 60 using base hydrolysis yielded monoesters 57 in quantitative yields (see 
Table 26). All spectral data acquired confirmed the identities of 57e-h. 
Table 26: Yields obtained for α-(amido(thiophen-2-yl)methyl)phosphonic acids (56c-h) and ethyl 
hydrogen (amido(thiophen-2-yl)methyl)phosphonic acids (57c-h). 
R = 
Compound 
 
56 
Yield % 
Compound 
 
57 
Yield % 
Me(CH2)12- 56c 100 57c 100 
Me(CH2)14- 56d 91 57d 99 
Me(CH2)16- 56e 100 57e 99 
Me(CH2)7OCH2- 56f 100 57f 99 
Me(CH2)15OCH2- 56g 100 57g 100 
Me(CH2)17OCH2- 56h 100 57h 99 
5.2.3  Kinetic Assays 
All of the compounds 56c-h and 57c-h were first screened against pPAP to determine whether they 
have inhibitory activities against pPAP, before further inhibition assays were carried out to 
determine the inhibition parameters for all of the compounds. The screening results obtained were 
in contrast with the docking results found for compounds 56f and 57f, where they were calculated 
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to have very high binding affinities to pPAP. From the screening assays, both compounds 56f and 
57f were found to have no inhibition against pPAP even at 100 µM (screening results data not 
shown). These conflicting results between the docking studies and the kinetic studies were 
consistently found throughout this work. In addition to compounds 56f and 57f, compounds 56c, 
56d, and 57c were also found to have weak inhibition against pPAP, where they exhibited less than 
50% inhibition at 100 µM, which indicated that their Ki values against pPAP would be more than 
100 µM. Since this work aimed to develop PAP inhibitors with improved inhibition potencies, the 
kinetic properties of these five compounds were not further investigated through inhibition assays. 
The other seven compounds synthesised in these series 56 and 57 were found to have quite potent 
inhibition against pPAP from the screening assays. Therefore, inhibition assays were carried out for 
these seven compounds to determine their inhibition parameters against pPAP. 
Figure 58 to Figure 64 show the steady-state inhibition data for compounds 56e,g,h and 57d,e,g,h 
on pPAP at pH 4.9. 
 
56e 
 
Figure 58: Steady-state inhibition of pPAP by compound 56e at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 56e concentrations ranged from 0 to 70 µM (as shown on the right 
of the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-
linear regression using equation 5 (see Section 2.4.3). 	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56g 
 
Figure 59: Steady-state inhibition of pPAP by compound 56g at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 56g concentrations ranged from 0 to 1 µM (as shown on the right of 
the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-linear 
regression using equation 5 (see Section 2.4.3). 
 
56h 
 
Figure 60: Steady-state inhibition of pPAP by compound 56h at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 56h concentrations ranged from 0 to 3 µM (as shown on the right of 
the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-linear 
regression using equation 5 (see Section 2.4.3). 
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57d 
 
Figure 61: Steady-state inhibition of pPAP by compound 57d at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 57d concentrations ranged from 0 to 50 µM (as shown on the right 
of the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-
linear regression using equation 5 (see Section 2.4.3). 
 
57e 
 
Figure 62: Steady-state inhibition of pPAP by compound 57e at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 57e concentrations ranged from 0 to 5 µM (as shown on the right of 
the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-linear 
regression using equation 5 (see Section 2.4.3). 
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57g 
 
Figure 63: Steady-state inhibition of pPAP by compound 57g at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 57g concentrations ranged from 0 to 3 µM (as shown on the right of 
the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-linear 
regression using equation 5 (see Section 2.4.3). 
 
57h 
 
Figure 64: Steady-state inhibition of pPAP by compound 57h at pH 4.9. p-NPP concentrations 
ranged from 1 to 12.5 mM, and 57h concentrations ranged from 0 to 1 µM (as shown on the right of 
the curves). Values are mean of duplicate measurements ± SEM. Data was analysed by non-linear 
regression using equation 5 (see Section 2.4.3). 
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Table 27 summarises the kinetic parameters of compounds 56e,g,h and 57d,e,g,h on pPAP. These 
compounds exhibited an expected trend of improved inhibition potencies with increasing alkyl 
chain lengths. All compounds 56e,g,h exhibited competitive inhibition against pPAP, and among 
the phosphonic acid series 56, compound 56h was the most potent pPAP inhibitor, with Kic value of 
864 nM. Although this compound has the longest chain among all the inhibitors developed in this 
work, unfortunately this compound was still at least five times less potent than the most potent 
pPAP inhibitor developed previously in this work, which was compound 33e, with Kic value of 168 
nM (see Chapter 2 for details).  
From Table 27, the monoesters 57 were observed to have a different trend than the previously 
obtained for all the previous series of PAP inhibitors developed, where the compound 57d with a 
shorter alkyl chain exhibited competitive inhibition towards pPAP, while the derivatives with the 
longer chains (57e,g,h) were found to inhibit pPAP in a mixed-competitive mode (Kic similar to 
Kiuc12), which means that they bind to both the free enzyme and also to the enzyme-substrate 
complex. The docking results of these compounds showed that they bind directly to the diiron ions, 
which could only indicate competitive inhibition, thus the binding of these compounds to the 
enzyme-substrate complex was not observed from the docking results as the compounds were not 
predicted to bind elsewhere, other than to the dimetal centre via their phosphonate moieties. 
Table 27: Inhibition properties of inhibitors 56e,g,h and 57d,e,g,h obtained from kinetic assays 
performed on pPAP at pH 4.9. 
Inhibitor R = kcat (s-1)a KM (mM)b Kic (µM)c Kiuc (µM)c,d 
 
56 
56e Me(CH2)16- 244 ± 29 9 ± 2 23 ± 7 - 
56g Me(CH2)15OCH2- 262 ± 24 10 ± 2 3.5 ± 1.9 - 
56h Me(CH2)17OCH2- 318 ± 29 11 ± 2 0.864 ± 0.176 - 
 
57 
57d Me(CH2)14- 303 ± 7 11 ± 4 65 ± 40 - 
57e Me(CH2)16- 250 ± 24 7 ± 1 1.7 ± 0.7 6.4 ± 6.4 
57g Me(CH2)15OCH2- 282 ± 27 9 ± 2 0.674 ± 0.192 6.0 ± 5.5 
57h Me(CH2)17OCH2- 265 ± 55 9 ± 4 0.293 ± 0.229 7.8 ± 6.8 
akcat represents the maximum rate. 
bKM represents the Michaelis constant. 
cKic and Kiuc represent competitive and uncompetitive inhibition constants, respectively. 
dNo value indicates that the value found is too large (more than ten-fold of Kic values), thus is irrelevant, hence 
neglected. 
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Among compounds 57 that were tested for their kinetic parameters against pPAP through inhibition 
assays, the most potent compound was compound 57h, with Kic value of 293 nM. Interestingly, 
direct comparison between the phosphonic acids 56 and the monoesters 57 showed that the 
monoesters 57 had higher inhibition potencies against pPAP, although they were found to inhibit 
pPAP in a mixed-mode fashion, compared with compounds 56 that were inhibiting pPAP in a 
solely competitive mode (see Table 27). This was a surprising result, as the phosphonic acids 56 
were expected to bind more strongly to pPAP through strong electrostatic interactions with the 
dimetal centre in the active site as these compounds 56 have two negative charges delocalised over 
three phosphoryl oxygen atoms, compared with only one negative charge delocalised over two 
phosphoryl oxygen atoms in the monoesters 57. These results were also not predicted from the 
docking results obtained, where phosphonic acids 56 generally had higher docking scores to pPAP, 
compared with the docking scores of that found for compounds 57.  
Comparing the inhibition potencies for compounds 57e and 57g, compound 57g with an extra 
carbon in the alkyl chain was more than two times more potent than compound 57e. However, 
compound 57g also had an oxygen atom in the chain, therefore it could not be determined if the 
improved inhibition potency was due to the longer chain, or due to the oxygen atom. The docking 
results obtained for compound 57h showed that the oxygen atom was predicted to make a hydrogen 
bond with the NH of the side chain imidazole of His223 (see Section 5.2.1 for details), however as 
been demonstrated throughout this work, the docking results obtained might not be as reliable as we 
would have hoped. 
Another interesting result that was found, was that when comparing the inhibition properties of the 
monoester 57e (see Table 27) with the monoester 49e (see Table 23 in Section 4.2.3 for details) 
with the furan ring described in the previous Chapter 4, both compounds exhibited similar Kic 
values with 1.7 µM and 1.4 µM, respectively. However, compound 57e was found to inhibit pPAP 
in a mixed-competitive mode, while compound 49e was found to inhibit pPAP in a solely 
competitive mode. This was a strange result, as the only difference between the two compounds 
was either a sulfur atom in 57e or an oxygen atom in 49e in the aromatic component of the 
compounds. The docking results obtained for both compounds predicted that both the thiophene 
ring and the furan ring of compounds 57e and 49e, respectively would bind to one of the pockets 
near the active site, however did not show that either the sulfur or the oxygen atom played any role 
in the interactions between the inhibitors and the enzyme. Therefore, the difference in the inhibition 
modes obtained for these two compounds were not fully understood. 
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5.3  Conclusion 
In this chapter, twelve new compounds were synthesised to be tested for their inhibition potencies 
against pPAP. Seven out of the twelve compounds showed considerable pPAP inhibition potencies, 
particularly the derivatives with the longer alkyl or alkoxymethyl chains. This was a consistent 
result found throughout this work, where increasing chain length resulted in improved pPAP 
inhibition potencies.  
All twelve compounds were synthesised without incident compared to their furan counterpart, as 
described previously in Chapter 4. This was most likely due to the thiophene ring being more acid 
tolerant than the furan ring.  
The docking results obtained for all twelve compounds, 56c-h and 57c-h did not correlate well to 
the results obtained from the kinetic studies. This result was consistently found throughout this 
work. This suggests that the results obtained from docking simulations should not be solely relied 
on when investigating the inhibition activities of the designed PAP inhibitors.  
The most potent compound developed among the phosphonic acid series 56 was compound 56h 
with Kic value of 864 nM, and the most potent compound developed among the monoester series 57 
was compound 57h with Kic value of 293 nM, however compound 57h exhibited a mixed-mode 
inhibition. Overall, none of the compound developed in this series was more potent than the most 
potent compound 33e described in Chapter 2, with Kic value of 168 nM, thus new PAP inhibitor 
with improved inhibition potency was not achieved from these series 56 and 57. 
5.4  Experimental 
5.4.1 Syntheses 
All chemical reagents are of analytical grade unless stated otherwise. Chloroform was dried by 
distillation from phosphorous pentoxide. Light petroleum (LP, b.p. 40-60 °C) was distilled before 
use. Flash column chromatography was carried out with Merck Kieselgel 60 as described in the 
literature.8 NMR experiments were recorded on a 500 MHz spectrometer (Bruker, Rheinstetten, 
Germany). Chemical shifts are reported in parts per million (ppm) on a δ scale, relative to the 
solvent peak (CDCl3 δH 7.24, δC 77.0; CD3OD δH 3.30, δC 49.0). Coupling constants (J) are 
reported in hertz and peak multiplicities described as singlet (s), doublet (d), doublet of doublets 
(dd), doublet of triplets (dt), triplet (t), quartet (q), pentet (p), multiplet (m), or broad (br). High-
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resolution electrospray ionisation accurate mass measurements were recorded in positive and 
negative modes on a quadrupole – time of flight instrument (Bruker) with an ESI source. Accurate 
mass measurements were carried out with external calibration using sodium formate as reference 
calibrant and/or Agilent tune mix (mw > 500). Low and high-resolution electron impact ionization 
mass measurements were recorded using perfluorokerosene-H as reference calibrant. Melting points 
were determined with DigiMelt MPA161 (Stanford Research Systems). 
Diethyl (amino(thiophen-2-yl)methyl)phosphonate hydrochloride (59)13  
 
This compound was prepared according to the general procedure described in the literature.13 The 
reaction was carried out under anhydrous conditions. Ammonium acetate (9.98 g, 0.13 mol) was 
added to EtOH (15 mL) in a round-bottomed flask containing activated molecular sieves (4 Å) (2.0 
g), followed by the addition of thiophene-2-carbaldehyde (58) (14.52 g, 0.13 mol) and diethyl 
phosphite (16.7 mL, 0.13 mol). The reaction mixture was stirred at 60 °C under nitrogen 
atmosphere for 46 hours. Once it has cooled to room temperature, ethanol was evaporated in vacuo, 
and water was added, followed by the addition of conc. HCl to the resulting mixture to acidify it to 
pH 1. Neutral materials were then removed by washing with Et2O (2 x 50 mL), and then extracted 
with water (100 mL).  Addition of 6 M NaOH to the aqueous layer changed the pH to 11, and the 
product was extracted with CH2Cl2 (3 x 100 mL) to give the resulting diethyl (amino(thiophen-2-
yl)methyl)phosphonate. The product was then treated with HCl gas in Et2O (10 mL) and the solid 
was vacuum filtered to obtain the hydrochloride salt of diethyl (amino(thiophen-2-
yl)methyl)phosphonate 59 as light yellow solid (18%). 1H NMR (500MHz, CDCl3) δ 1.20 (3H, t, J 
7.1 Hz, OCH2CH3), 1.28 (3H, t, J 7.0 Hz, OCH2CH3), 3.98-4.21 (4H, m, OCH2CH3), 5.10 (1H, d, J 
17.7 Hz, NHCHP), 6.99 (1H, t, J 4.4 Hz, ArH), 7.30 (1H, d, J 5.1 Hz, ArH), 7.53 (1H, s, ArH), 
9.36 (2H, br s, NH2) (in agreement with that described in the literature).11 IR (cm-1): 3067, 2805, 
2036, 1608, 1515, 1234. 
The general procedure for the preparation of acid chlorides 37a-h was as described in Section 2.4.1.  
General procedure for the preparation of 2-(alkyloxy)acetic acids (39g-h).  
The reaction was carried out according to the general procedure described in the literature.14 The 
reaction was carried out under anhydrous conditions. To NaH (4 eq., 120 mmol, 60% suspension in 
NH2.HClP
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mineral oil) in dry THF (100 mL) was added alcohol (40g-h) (1.3 eq., 40 mmol) dissolved in dry 
THF (100 mL) dropwise under stirring at 25 oC in argon atmosphere and the reaction mixture was 
stirred and monitored using a bubbler until there was no more production of H2 gas. The bubbling 
stopped after three hours, and the reaction was stopped. Bromoacetic acid (41) (1 eq., 30 mmol) in 
dry THF (20 mL) was then carefully added dropwise over a period of 20 minutes at 25 oC under 
stirring and argon atmosphere, during which effervescence was observed. The reaction mixture was 
further stirred for 2 days at 30 °C. The reaction mixture was quenched with water, THF evaporated, 
and the aqueous phase was acidified to between pH 1 and 2 using conc. HCl. The resulting mixture 
was then extracted with Et2O (3 x 100 mL), and the combined Et2O phases were then dried with 
Na2SO4, and evaporated in vacuo. Purification by flash column chromatography (5%-100% EtOAc 
in LP) afforded the products as white solids. 
2-(Hexadecyloxy)acetic acid (39g)14 
 
White solid (1.32 g, 11%). 1H NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, CH3CH2), 1.23-
1.33 (26H, m, CH3(CH2)13(CH2)2CO), 1.60 (2H, p, CH2CH2O), 3.53 (2H, t, J 6.7 Hz, CH2O), 4.09 
(2H, s, OCH2O), consistent with literature;14 13C NMR (125 MHz, CDCl3) δ 14.1, 22.7, 25.9, 29.35, 
29.37, 29.4, 29.53, 29.57, 29.64, 29.65, 29.68, 31.9, 67.7, 72.2, 174.5.  
2-(Octadecyloxy)acetic acid (39h) 
 
White solid (1.23 g, 8%). 1H NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 6.9 Hz, CH3CH2), 1.23-1.33 
(30H, m, CH3(CH2)15(CH2)2CO), 1.61 (2H, p, CH2CH2O), 3.54 (2H, t, J 6.7 Hz, CH2O), 4.08 (2H, 
s, OCH2O); 13C NMR (125 MHz, CDCl3) δ 14.1, 22.7, 25.9, 29.36, 29.4, 29.53, 29.58, 29.66, 
29.69, 29.68, 31.9, 67.7, 72.2, 172.7. Consistent with literature.15 
The general procedure for the preparation of diethyl phosphonates (60c-h) was as described in 
Section 2.4.1.  
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Diethyl (tetradecanamido(thiophen-2-yl)methyl)phosphonate (60c) 
 
Off-white solid (0.78 g, 85%), m.p. 50.1-51.7 °C. Rf: 0.47 (60% EtOAc in LP, KMnO4 dip). ESI-
MS, m/z: 482 [M + Na]+. HRMS calculated for C23H42NNaO4PS+ 482.2464, found 482.2463. 1H 
NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, CH3(CH2)12CO), 1.14 (3H, t, J 6.9 Hz, 
OCH2CH3), 1.22-1.26 (20H, m, CH3(CH2)10(CH2)2CO), 1.30 (3H, t, J 7.0 Hz, OCH2CH3), 1.56-
1.60 (2H, p, J 7.7 Hz, CH2CH2CO), 2.21 (2H, t, J 7.6 Hz, CH2CO) 3.83-3.91 (1H, m, OCH2CH3), 
3.99-4.06 (1H, m, OCH2CH3), 4.08-4.18 (2H, m, OCH2CH3), 5.80 (1H, dd, J 9.5, J 20.9 Hz, 
NHCHP), 6.45 (1H, dd, J 2.7, J 9.5 Hz, NH), 6.95 (1H, t, J 4.4 Hz, ArH), 7.31 (1H, s, ArH),  7.19 
(1H, d, J 5.1 Hz, ArH);  13C NMR (125 MHz, CDCl3) δ 14.1, 16.2 (d, 3JPC 5.8 Hz), 16.4 (d, 3JPC 5.9 
Hz), 22.7, 25.6, 29.17, 29.31, 29.34, 29.4, 29.5, 29.63, 29.66, 31.9, 36.4, 44.9 (d, 1JPC 159 Hz), 63.3 
(d, 2JPC 7.1 Hz), 63.6 (d, 2JPC 6.8 Hz), 125.5 (d, 4JPC  2.6 Hz), 127.0 (d, 3JPC 6.7 Hz), 127.1 (d, 4JPC  
1.9 Hz), 137.5, 172.2 (d, 3JPC  6.6 Hz). IR (cm-1): 3243, 2964, 2918, 2852, 1650, 1548, 1249. 
Diethyl (hexadecanamido(thiophen-2-yl)methyl)phosphonate (60d) 
 
White solid (0.79 g, 79%), m.p. 60.0-68.3 °C. Rf: 0.48 (60% EtOAc in LP, KMnO4 dip). ESI-MS, 
m/z: 510 [M + Na]+. HRMS calculated for C25H46NNaO4PS+ 510.2777, found 510.2781. 1H NMR 
(500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, CH3(CH2)14CO), 1.16 (3H, t, J 7.1 Hz, OCH2CH3), 
1.22-1.28 (24H, m, CH3(CH2)12(CH2)2CO), 1.30 (3H, t, J 7.1 Hz, OCH2CH3), 1.58-1.63 (2H, p, J 
7.7 Hz, CH2CH2CO), 2.21 (2H, t, J 7.6 Hz, CH2CO) 3.83-3.91 (1H, m, OCH2CH3), 3.99-4.05 (1H, 
m, OCH2CH3), 4.06-4.18 (2H, m, OCH2CH3), 5.80 (1H, dd, J 9.6, J 20.9 Hz, NHCHP), 6.48 (1H, 
dd, J 3.1, J 9.5 Hz, NH), 6.95 (1H, t, J 4.4 Hz, ArH), 7.18 (1H, s, ArH),  7.23 (1H, d, J 5.1 Hz, 
ArH);  13C NMR (125 MHz, CDCl3) δ 14.1, 16.2 (d, 3JPC 5.7 Hz), 16.4 (d, 3JPC 5.9 Hz), 22.7, 25.6, 
29.16, 29.30, 29.34, 29.4, 29.5, 29.63, 29.66, 29.67, 31.9, 36.5, 44.7 (d, 1JPC 160 Hz), 63.3 (d, 2JPC 
7.2 Hz), 63.6 (d, 2JPC 6.7 Hz), 125.5 (d, 4JPC  2.6 Hz), 126.9 (d, 3JPC 7.0 Hz), 127.1 (d, 4JPC  1.7 Hz), 
137.5, 172.2 (d, 3JPC  6.4 Hz).  
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Diethyl (octadecanamido(thiophen-2-yl)methyl)phosphonate (60e) 
 
White solid (1.11 g, 87%), m.p. 67.4-68.3 °C. Rf: 0.35 (60% EtOAc in LP, KMnO4 dip). ESI-MS, 
m/z: 538 [M + Na]+. HRMS calculated for C27H50NNaO4PS+ 538.3090, found 538.3098. 1H NMR 
(500 MHz, CDCl3) δ 0.85 (3H, t, J 7.0 Hz, CH3(CH2)16CO), 1.15 (3H, t, J 7.1 Hz, OCH2CH3), 
1.21-1.28 (28H, m, CH3(CH2)14(CH2)2CO), 1.30 (3H, t, J 7.1 Hz, OCH2CH3), 1.57-1.63 (2H, p, J 
7.6 Hz, CH2CH2CO), 2.21 (2H, t, J 7.6 Hz, CH2CO) 3.83-3.89 (1H, m, OCH2CH3), 4.00-4.04 (1H, 
m, OCH2CH3), 4.07-4.17 (2H, m, OCH2CH3), 5.80 (1H, dd, J 9.7, J 20.8 Hz, NHCHP), 6.56 (1H, 
dd, J 3.1, J 9.5 Hz, NH), 6.95 (1H, t, J 4.3 Hz, ArH), 7.18 (1H, s, ArH),  7.22 (1H, d, J 5.1 Hz, 
ArH);  13C NMR (125 MHz, CDCl3) δ 14.2, 16.3 (d, 3JPC 5.8 Hz), 16.5 (d, 3JPC 5.8 Hz), 22.8, 25.7, 
29.30, 29.43, 29.4, 29.6, 29.71, 29.76, 29.79, 29.8, 32.0, 36.6, 45.6 (d, 1JPC 160 Hz), 63.4 (d, 2JPC 
7.2 Hz), 63.7 (d, 2JPC 6.9 Hz), 125.6 (d, 4JPC 2.6 Hz), 127.1 (d, 3JPC 6.9 Hz), 127.1 (d, 4JPC 1.7 Hz), 
137.6, 172.4 (d, 3JPC 6.5 Hz). 
Diethyl ((2-octyloxy)acetamido)(thiophen-2-yl)methyl)phosphonate (60f) 
 
Light yellow oil (0.35 g, 84%). Rf: 0.54 (60% EtOAc in LP, KMnO4 dip). ESI-MS, m/z: 442 [M + 
Na]+. HRMS calculated for C19H34NNaO5PS+ 442.1788, found 442.1786. 1H NMR (500 MHz, 
CDCl3) δ 0.85 (3H, t, J 7.0 Hz, CH3(CH2)7O), 1.18 (3H, t, J 7.2 Hz, OCH2CH3), 1.23-1.33 (10H, 
m, CH3(CH2)5(CH2)2O), 1.27 (3H, t, J 7.1 Hz, OCH2CH3), 1.55-1.60 (2H, p, J 7.0 Hz, CH2CH2O), 
3.42-3.50 (2H, m, CH2O), 3.89-3.98 (3H, m, OCH2CH3, OCH2CO), 4.01-4.10 (3H, m, OCH2CH3), 
5.80 (1H, dd, J 9.9, J 20.6 Hz, NHCHP), 6.95 (1H, t, J 4.3 Hz, ArH), 7.17 (1H, s, ArH),  7.22 (1H, 
d, J 5.2 Hz, ArH);  13C NMR (125 MHz, CDCl3) δ 14.0, 16.2 (d, 3JPC 5.9 Hz), 16.3 (d, 3JPC 5.9 Hz), 
22.6, 25.9, 29.1, 29.3, 29.4, 31.7, 44.8 (d, 1JPC 159 Hz), 63.2 (d, 2JPC 7.1 Hz), 63.4 (d, 2JPC 6.7 Hz), 
69.9, 72.0, 125.6 (d, 4JPC 2.8 Hz), 126.9 (d, 3JPC 7.0 Hz), 127.0 (d, 4JPC 1.8 Hz), 137.0, 169.1 (d, 
3JPC 6.5 Hz). 
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Diethyl ((2-hexadecyloxy)acetamido)(thiophen-2-yl)methyl)phosphonate (60g) 
 
Off-white solid (0.41 g, 99%), m.p. 38.3-39.4 °C. Rf: 0.45 (60% EtOAc in LP, KMnO4 dip). ESI-
MS, m/z: 554 [M + Na]+. HRMS calculated for C27H50NNaO5PS+ 554.3045, found 554.3055. 1H 
NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, CH3(CH2)15O), 1.20 (3H, t, J 7.1 Hz, OCH2CH3), 
1.24-1.35 (26H, m, CH3(CH2)13(CH2)2O), 1.29 (3H, t, J 7.1 Hz, OCH2CH3), 1.56-1.62 (2H, p, J 7.0 
Hz, CH2CH2O), 3.44-3.52 (2H, m, CH2O), 3.91-4.00 (3H, m, OCH2CH3, OCH2CO), 4.03-4.10 
(3H, m, OCH2CH3), 5.78 (1H, dd, J 9.8, J 20.7 Hz, NHCHP), 6.96 (1H, t, J 4.4 Hz, ArH), 7.19 
(1H, s, ArH),  7.23 (1H, d, J 5.9 Hz, ArH);  13C NMR (125 MHz, CDCl3) δ 14.2, 16.3 (d, 3JPC 5.9 
Hz), 16.5 (d, 3JPC 5.7 Hz), 22.8, 26.1, 29.4, 29.54, 29.56, 29.6, 29.72, 29.77, 29.79, 29.8, 32.0, 44.9 
(d, 1JPC 160 Hz), 63.4 (d, 2JPC 7.1 Hz), 63.6 (d, 2JPC 6.7 Hz), 70.1, 72.2, 125.7 (d, 4JPC 2.6 Hz), 
127.1 (d, 3JPC 7.0 Hz), 127.2 (d, 4JPC 1.8 Hz), 137.2, 169.3 (d, 3JPC  6.2 Hz). 
Diethyl ((2-octadecyloxy)acetamido)(thiophen-2-yl)methyl)phosphonate (60h) 
 
Off-white solid (0.30 g, 72%), m.p. 44.1-45.9 °C. Rf: 0.48 (60% EtOAc in LP, KMnO4 dip). ESI-
MS, m/z: 582 [M + Na]+. HRMS calculated for C29H54NNaO5PS+ 582.3353, found 582.3368. 1H 
NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J 7.0 Hz, CH3(CH2)17O), 1.20 (3H, t, J 7.1 Hz, OCH2CH3), 
1.23-1.37 (30H, m, CH3(CH2)15(CH2)2O), 1.29 (3H, t, J 7.0 Hz, OCH2CH3), 1.56-1.62 (2H, p, J 7.2 
Hz, CH2CH2O), 3.44-3.52 (2H, m, CH2O), 3.91-4.00 (3H, m, OCH2CH3, OCH2CO), 4.03-4.12 
(3H, m, OCH2CH3), 5.78 (1H, dd, J 9.9, J 20.6 Hz, NHCHP), 6.97 (1H, t, J 4.3 Hz, ArH), 7.19 
(1H, s, ArH),  7.23 (1H, d, J 5.9 Hz, ArH);  13C NMR (125 MHz, CDCl3) δ 14.1, 16.2 (d, 3JPC 5.6 
Hz), 16.4 (d, 3JPC 5.8 Hz), 22.7, 26.0, 29.3, 29.42, 29.44, 29.5, 29.60, 29.64, 29.69, 31.9, 44.7 (d, 
1JPC 160 Hz), 63.3 (d, 2JPC 7.1 Hz), 63.5 (d, 2JPC 6.9 Hz), 70.0, 72.1, 125.7 (d, 4JPC 2.6 Hz), 127.0 
(d, 3JPC 6.9 Hz), 127.1 (d, 4JPC 1.8 Hz), 137.1, 169.2 (d, 3JPC  6.2 Hz). 
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The general procedure for the preparation of phosphonic acids (56c-h) was as described in Section 
2.4.1.  
 
 (Tetradecanamido(thiophen-2-yl)methyl)phosphonic acid (56c) 
 
Off-white solid (0.14 g, 100%). m.p. 117.9-120.2 °C. ESI-MS, m/z: 402 [M - H]-. HRMS calculated 
for C19H33NO4PS- 402.1873, found 402.1872. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3CH2), 1.27-1.31 (20H, m, CH3(CH2)10), 1.60 (2H, p, J 6.3 Hz, CH2CH2CO), 2.27 (2H, t, J 7.4 
Hz, CH2CO),  5.45 (1H, d, J 21.3 Hz, NHCHP), 6.98 (1H, t, J 4.4 Hz, ArH), 7.21 (1H, s, ArH),  
7.31 (1H, d, J 5.0 Hz, ArH); 13C NMR (125 MHz, CD3OD) δ  14.4, 23.7, 26.0, 26.5, 26.9, 30.2, 
30.4, 30.7, 32.1, 33.1, 34.2, 34.8, 36.7, 46.9 (d, 1JPC 160 Hz), 126.5 (d, 4JPC  2.6 Hz), 127.6 (d, 3JPC 
6.7 Hz), 127.9 (d, 4JPC  1.9 Hz), 139.9, 175.6 (d, 3JPC  6.3 Hz). IR (cm-1): 3243, 2916, 2849, 1643, 
1542. 
(Hexadecanamido(thiophen-2-yl)methyl)phosphonic acid (56d) 
 
White solid (0.09 g, 91%). m.p. 122.4-123.1 °C. ESI-MS, m/z: 430 [M - H]-. HRMS calculated for 
C21H37NO4PS- 430.2186, found 430.2186. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 6.9 Hz, 
CH3CH2), 1.27-1.31 (24H, m, CH3(CH2)12), 1.60 (2H, p, J 6.5 Hz, CH2CH2CO), 2.27 (2H, t, J 7.3 
Hz, CH2CO),  5.66 (1H, d, J 21.1 Hz, NHCHP), 6.96 (1H, t, J 4.3 Hz, ArH), 7.21 (1H, s, ArH),  
7.30 (1H, d, J 5.0 Hz, ArH); 13C NMR (125 MHz, CD3OD) δ  14.4, 23.7, 26.9, 30.1, 30.2, 30.3, 
30.4, 30.73, 30.75, 30.8, 32.9, 36.6, 46.8 (d, 1JPC 155 Hz), 126.2 (d, 4JPC  1.9 Hz), 127.7 (d, 3JPC 6.2 
Hz), 127.8 (d, 4JPC  1.5 Hz), 139.9, 175.2 (d, 3JPC  6.5 Hz). 
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(Octadecanamido(thiophen-2-yl)methyl)phosphonic acid (56e) 
 
Off-white solid (0.13 g, 100%). m.p. 123.6-125.1 °C. ESI-MS, m/z: 458 [M - H]-. HRMS calculated 
for C23H41NO4PS- 458.2499, found 458.2512. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3CH2), 1.28-1.33 (28H, m, CH3(CH2)14), 1.60 (2H, p, J 6.8 Hz, CH2CH2CO), 2.27 (2H, t, J 7.5 
Hz, CH2CO),  5.65 (1H, d, J 21.4 Hz, NHCHP), 6.96 (1H, t, J 4.3 Hz, ArH), 7.21 (1H, s, ArH),  
7.33 (1H, d, J 4.5 Hz, ArH); 13C NMR (125 MHz, CD3OD) δ  14.5, 23.7, 26.93, 26.96, 30.1, 30.2, 
30.4, 30.5, 30.6, 30.71, 30.76, 30.8, 33.0, 36.7, 46.9 (d, 1JPC 158 Hz), 126.0 (d, 4JPC  2.1 Hz), 127.6 
(d, 3JPC 6.3 Hz), 127.8 (d, 4JPC  1.5 Hz), 139.9, 175.6 (d, 3JPC  6.4 Hz). 
((2-(Octyloxy)acetamido)(thiophen-2-yl)methyl)phosphonic acid (56f) 
 
Off-white solid (0.10 g, 100%). m.p. 126.9-127.8 °C. ESI-MS, m/z: 362 [M - H]-. HRMS calculated 
for C15H25NO5PS- 362.1197, found 362.1204. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3(CH2)7O), 1.29-1.39 (10H, m, CH3(CH2)5(CH2)2O), 1.60-1.65 (2H, p, J 7.0 Hz, CH2CH2O), 
3.49-3.57 (2H, m, CH2O), 3.97 (1H, d, J 38.0 Hz, OCH2CO), 4.00 (1H, d, J 32.0 Hz, OCH2CO), 
5.62 (1H, d, J 20.9 Hz, NHCHP), 6.98 (1H, t, J 4.3 Hz, ArH), 7.19 (1H, s, ArH),  7.33 (1H, d, J 5.1 
Hz, ArH); 13C NMR (125 MHz, CD3OD) δ  14.5, 23.7, 27.1, 30.4, 30.51, 30.54, 33.0, 47.8 (d, 1JPC 
155 Hz), 70.7, 73.0, 126.2 (d, 4JPC  1.7 Hz), 127.6 (d, 3JPC 6.3 Hz), 127.9 (d, 4JPC  1.9 Hz), 139.7, 
171.9 (d, 3JPC  6.3 Hz). 
((2-(Hexadecyloxy)acetamido)(thiophen-2-yl)methyl)phosphonic acid (56g) 
 
Off-white solid (0.12 g, 100%). m.p. 109.3-111.4 °C. ESI-MS, m/z: 474 [M - H]-. HRMS calculated 
for C23H41NO5PS- 474.2449, found 474.2453. 1H NMR (500 MHz, CD3OD) δ 0.85 (3H, t, J 7.0 Hz, 
CH3(CH2)15O), 1.27-1.35 (26H, m, CH3(CH2)13(CH2)2O), 1.60-1.66 (2H, p, J 7.0 Hz, CH2CH2O), 
3.49-3.59 (2H, m, CH2O), 4.01 (1H, d, J 38.0 Hz, OCH2CO), 4.06 (1H, d, J 38.0 Hz, OCH2CO), 
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5.61 (1H, d, J 20.9 Hz, NHCHP), 6.96 (1H, t, J 4.5 Hz, ArH), 7.20 (1H, s, ArH),  7.33 (1H, d, J 5.2 
Hz, ArH); 13C NMR (125 MHz, CD3OD) δ  14.5, 23.7, 27.2, 30.4, 30.5, 30.74, 30.76, 30.8, 33.1, 
47.7 (d, 1JPC 155 Hz), 70.7, 72.9, 126.4 (d, 4JPC  1.9 Hz), 127.7 (d, 3JPC 6.1 Hz), 128.0 (d, 4JPC  1.7 
Hz), 139.7, 172.2 (d, 3JPC  6.5 Hz). 
((2-(Octadecyloxy)acetamido)(thiophen-2-yl)methyl)phosphonic acid (56h) 
 
Off-white solid (0.13 g, 100%). m.p. 120.6-121.9 °C. ESI-MS, m/z: 502 [M - H]-. HRMS calculated 
for C25H45NO5PS- 502.2762, found 502.2774. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3(CH2)17O), 1.28-1.39 (30H, m, CH3(CH2)15(CH2)2O), 1.59-1.65 (2H, p, J 7.0 Hz, CH2CH2O), 
3.48-3.57 (2H, m, CH2O), 4.00 (1H, d, J 38.0 Hz, OCH2CO), 4.04 (1H, d, J 38.0 Hz, OCH2CO), 
5.63 (1H, d, J 20.9 Hz, NHCHP), 6.98 (1H, t, J 4.3 Hz, ArH), 7.19 (1H, s, ArH),  7.32 (1H, d, J 5.1 
Hz, ArH); 13C NMR (125 MHz, CD3OD) δ  14.5, 23.7, 27.2, 30.4, 30.5, 30.74, 30.75, 30.76, 30.8, 
33.1, 47.8 (d, 1JPC 156 Hz), 70.8, 73.0, 126.3 (d, 4JPC  2.1 Hz), 127.7 (d, 3JPC 6.3 Hz), 127.9 (d, 4JPC  
1.9 Hz), 139.7, 172.0 (d, 3JPC  6.3 Hz). 
General procedure for the preparation of ethyl hydrogen (thiophen-2-
yl(alkylamido)methyl)phosphonate (57c-h). 
 
60c-h (0.15 mmol) was stirred with both MeOH (5 mL) and 2 M NaOH solution (1.5 mL) at room 
temperature for four days. The reaction mixture was then concentrated in vacuo and the residue was 
then acidified with 2 M HCl to around pH 2, and extracted with EtOAc (2 x 15 mL). The combined 
organic layer was then washed with water (2 x 15 mL), followed by brine (2 x 15 mL), and the 
organic layer was then dried with Na2SO4 and EtOAc evaporated, followed by co-evaporation with 
chloroform in vacuo to yield the monoesters 57c-h. 
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Ethyl hydrogen (tetradecanamido(thiophen-2-yl)methyl)phosphonate (57c) 
 
Off-white solid (0.09 g, 100%), m.p. 67.7-69.4 °C. ESI-MS, m/z: 430 [M - H]-. HRMS calculated 
for C21H37NO4PS- 430.2186, found 430.2174. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3(CH2)12CO), 1.18 (3H, t, J 7.1 Hz, POCH2CH3), 1.24-1.33 (20H, m, CH3(CH2)10(CH2)2CO), 
1.59-1.62 (2H, p, J 7.1 Hz, CH2CH2CO), 2.26 (2H, t, J 7.5 Hz, CH2CO), 3.85-3.92 (2H, m, 
POCH2CH3), 5.48 (1H, d, J 19.8 Hz, NHCHP), 6.91 (1H, t, J 4.4 Hz, ArH), 7.17 (1H, s, ArH),  
7.20 (1H, d, J 5.1 Hz, ArH); 13C NMR (125 MHz, CD3OD) δ 13.2, 15.9 (d, 3JPC 6.3 Hz), 22.4, 25.7, 
28.9, 29.0, 29.39, 29.4, 29.52, 29.53, 31.8, 35.9, 45.2 (d, 1JPC 162 Hz), 60.9 (d, 2JPC 6.0 Hz), 123.7 
(d, 4JPC 1.6 Hz), 125.5 (d, 3JPC 5.9 Hz), 125.6 (d, 4JPC 2.8 Hz), 136.7, 173.8 (d, 3JPC  6.6 Hz). IR 
(cm-1): 3262, 2957, 2917, 2851, 1645, 1525. 
Ethyl hydrogen (hexadecanamido(thiophen-2-yl)methyl)phosphonate (57d) 
 
Off-white solid (0.11 g, 99%), m.p. 116.0-118.6 °C. ESI-MS, m/z: 458 [M - H]-. HRMS calculated 
for C23H41NO4PS- 458.2499, found 458.2498. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3(CH2)14CO), 1.18 (3H, t, J 7.1 Hz, POCH2CH3), 1.25-1.31 (24H, m, CH3(CH2)12(CH2)2CO), 
1.59-1.62 (2H, p, J 7.1 Hz, CH2CH2CO), 2.23 (2H, t, J 7.5 Hz, CH2CO), 3.86-3.90 (2H, m, 
POCH2CH3), 5.35 (1H, d, J 19.8 Hz, NHCHP), 6.91 (1H, t, J 4.3 Hz, ArH), 7.20 (1H, s, ArH),  
7.22 (1H, d, J 5.1 Hz, ArH); 13C NMR (125 MHz, CD3OD) δ 13.2, 15.9 (d, 3JPC 6.4 Hz), 22.4, 25.7, 
28.8, 28.9, 29.16, 29.19, 29.3, 29.41, 29.49, 29.5, 31.8, 35.3, 44.7 (d, 1JPC 162 Hz), 60.9 (d, 2JPC 5.4 
Hz), 123.7 (d, 4JPC 2.6 Hz), 125.5 (d, 3JPC 5.9 Hz), 125.6 (d, 4JPC 2.8 Hz), 136.7, 174.1 (d, 3JPC  6.1 
Hz). 
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Ethyl hydrogen (octadecanamido(thiophen-2-yl)methyl)phosphonate (57e) 
 
Off-white solid (0.14 g, 99%), m.p. 82.5-84.2 °C. ESI-MS, m/z: 486 [M - H]-. HRMS calculated for 
C25H45NO4PS- 486.2812, found 486.2818. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3(CH2)16CO), 1.18 (3H, t, J 7.1 Hz, POCH2CH3), 1.22-1.31 (28H, m, CH3(CH2)14(CH2)2CO), 
1.57-1.63 (2H, p, J 7.1 Hz, CH2CH2CO), 2.25 (2H, t, J 7.5 Hz, CH2CO), 3.86-3.91 (2H, m, 
POCH2CH3), 5.47 (1H, d, J 19.8 Hz, NHCHP), 6.91 (1H, t, J 4.3 Hz, ArH), 7.17 (1H, s, ArH),  
7.21 (1H, d, J 5.1 Hz, ArH); 13C NMR (125 MHz, CD3OD) δ 13.2, 15.9 (d, 3JPC 6.3 Hz), 22.4, 25.7, 
28.8, 28.9, 29.0, 29.15, 29.17, 29.3, 29.40, 29.47, 29.49, 31.8, 35.9, 45.1 (d, 1JPC 162 Hz), 60.9 (d, 
2JPC 6.0 Hz), 123.7 (d, 4JPC 2.6 Hz), 125.5 (d, 3JPC 5.9 Hz), 126.1 (d, 4JPC 2.3 Hz), 136.7, 174.1 (d, 
3JPC  6.0 Hz). 
Ethyl hydrogen ((2-octyloxy)acetamido(thiophen-2-yl)methyl)phosphonate (57f) 
 
Off-white semi-solid (0.10 g, 99%). ESI-MS, m/z: 390 [M - H]-. HRMS calculated for 
C17H29NO5PS- 390.1510, found 390.1519. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3(CH2)7O), 1.18 (3H, t, J 7.1 Hz, POCH2CH3), 1.29-1.39 (10H, m, CH3(CH2)5(CH2)2O), 1.60-
1.66 (2H, p, J 7.0 Hz, CH2CH2CO), 3.49-3.57 (2H, m, CH2O), 3.86-3.92 (2H, m, POCH2CH3), 
3.95 (1H, d, J 44 Hz, OCH2CO), 3.97 (1H, d, J 44 Hz, OCH2CO), 5.48 (1H, d, J 19.8 Hz, 
NHCHP), 6.93 (1H, t, J 4.4 Hz, ArH), 7.17 (1H, s, ArH),  7.23 (1H, d, J 5.2 Hz, ArH); 13C NMR 
(125 MHz, CD3OD) δ 14.4, 17.2 (d, 3JPC 6.3 Hz), 23.7, 27.1, 30.4, 30.5, 33.0, 48.2 (d, 1JPC 147 Hz), 
62.2 (d, 2JPC 6.1 Hz), 70.9, 73.0, 125.3 (d, 4JPC 2.6 Hz), 126.8 (d, 3JPC 5.9 Hz), 127.5 (d, 4JPC 2.3 
Hz), 142.4, 171.8 (d, 3JPC  6.0 Hz). 
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Ethyl hydrogen ((2-hexadecyloxy)acetamido(thiophen-2-yl)methyl)phosphonate (57g) 
 
Off-white solid (0.09 g, 100%), m.p. 72.9-73.3 °C. ESI-MS, m/z: 502 [M - H]-. HRMS calculated 
for C25H46NO5PS- 502.2762, found 502.2747. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 6.9 Hz, 
CH3(CH2)15O), 1.18 (3H, t, J 7.1 Hz, POCH2CH3), 1.28-1.38 (26H, m, CH3(CH2)13(CH2)2O), 1.60-
1.66 (2H, p, J 7.0 Hz, CH2CH2CO), 3.49-3.57 (2H, m, CH2O), 3.86-3.92 (2H, m, POCH2CH3), 
3.95 (1H, d, J 45 Hz, OCH2CO), 3.97 (1H, d, J 45 Hz, OCH2CO), 5.48 (1H, d, J 19.5 Hz, 
NHCHP), 6.93 (1H, t, J 4.3 Hz, ArH), 7.17 (1H, s, ArH),  7.23 (1H, d, J 5.0 Hz, ArH); 13C NMR 
(125 MHz, CD3OD) δ 14.5, 17.2 (d, 3JPC 6.2 Hz), 23.7, 27.1, 30.4, 30.55, 30.59, 30.75, 30.78, 33.1, 
47.9 (d, 1JPC 147 Hz), 62.2 (d, 2JPC 6.2 Hz), 70.9, 73.0, 125.2 (d, 4JPC 2.6 Hz), 126.8 (d, 3JPC 5.9 
Hz), 127.5 (d, 4JPC 2.3 Hz), 142.4, 171.8 (d, 3JPC  6.5 Hz). 
Ethyl hydrogen ((2-octadecyloxy)acetamido(thiophen-2-yl)methyl)phosphonate (57h) 
 
Off-white solid (0.09 g, 99%), m.p. 71.6-73.6 °C. ESI-MS, m/z: 530 [M - H]-. HRMS calculated for 
C27H49NO5PS- 530.3075, found 530.3091. 1H NMR (500 MHz, CD3OD) δ 0.89 (3H, t, J 7.0 Hz, 
CH3(CH2)17O), 1.18 (3H, t, J 7.1 Hz, POCH2CH3), 1.28-1.39 (30H, m, CH3(CH2)15(CH2)2O), 1.60-
1.66 (2H, p, J 7.1 Hz, CH2CH2CO), 3.49-3.57 (2H, m, CH2O), 3.85-3.92 (2H, m, POCH2CH3), 
3.95 (1H, d, J 46 Hz, OCH2CO), 3.97 (1H, d, J 46 Hz, OCH2CO), 5.48 (1H, d, J 19.6 Hz, 
NHCHP), 6.92 (1H, t, J 4.3 Hz, ArH), 7.17 (1H, s, ArH),  7.23 (1H, d, J 5.0 Hz, ArH); 13C NMR 
(125 MHz, CD3OD) δ 13.2, 15.9 (d, 3JPC 6.2 Hz), 22.4, 25.8, 29.2, 29.3, 29.45, 29.47, 29.49, 31.8, 
46.6 (d, 1JPC 147 Hz), 60.9 (d, 2JPC 6.2 Hz), 69.7, 71.7, 123.9 (d, 4JPC 1.6 Hz), 125.6 (d, 3JPC 5.6 
Hz), 126.2 (d, 4JPC 2.3 Hz), 141.2, 170.5 (d, 3JPC  6.5 Hz). 
 
 
H
NP
S
O
HO
EtO
O
O (CH2)15Me
H
NP
S
O
HO
EtO
O
O (CH2)17Me
	   175	  
5.4.2 Kinetic Assays 
All kinetic assays were conducted based on the procedure previously described in Section 2.4.3. 
pPAP was reduced before use in all steady-state assays using 67 mM ferrous ammonium sulfate and 
134 mM BME as the reducing agent. Continuous assays were conducted using p-NPP as the 
substrate, in 0.1 M sodium acetate buffer with 25% DMSO, pH 4.9 (optimum pH for pPAP), at 25 
°C. Kinetic measurements was measured with a UV/Vis spectrophotometer at λ = 405 nm, with 
Δε405 = 342.9 L mol-1 cm-1, and the data were collected at 132-264 seconds. Fully reduced pPAP 
concentration was 20 nM in all assays. 
In screening assays, p-NPP concentration was 5 mM, and inhibitor concentrations used were 1, 10 
and 100 µM. Screening results were calculated as inhibition %. In inhibition assays, p-NPP 
concentrations used were 1, 3, 5, 7.5, 10, and 12.5; and inhibitors’ concentrations used ranged 
between 0 to 10 µM (see Figure 58 to Figure 64 for the concentrations used for 56e,g,h and 
57d,e,g,h). Data were analysed using non-linear regression performed by WinCurveFit (Kevin 
Raner software). 
kcat (s-1) was converted from (Vmax) according to the equation: 
kcat (s-1) = Vmax/60 x molecular weight of enzyme in mg/µmol, 
where: 
Specific activity (Vmax) is the units of activity per mg of protein (U/mg). 
A unit of enzme activity (U) is the release of 1 µmol per product per minute (µmol/min). 
Molecular weight of pPAP is 35000 µmol/mg. 
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Chapter 6  CONCLUSIONS AND FUTURE WORK  
 
Osteoporosis is a highly prevalent systemic skeletal disease especially among elderly people.1-2 
Osteoporosis develops as a result of extensive bone loss, which is primarily caused by higher level 
of bone resorption than bone formation, thus interrupting the balance of the dynamic bone 
remodelling process.1,3-4 The significant increase in the estimated number of osteoporosis patients 
and osteoporosis-related fractures1,5-6 poses a substantial global health threat. Therefore, there is an 
urgent need to manage osteoporosis. The currently prescribed anti-osteoporotic drugs are still 
lacking the desired effectiveness in restoring lost bone mass and in preventing fracture 
incidences,4,7-16 and the many side effects associated with taking the medications1,4,7,17-29 make them 
unfavourable. These unmet needs of osteoporosis patients from the currently available treatments 
signify the need for the development of new drugs with high efficacies and better safety profiles. 
This work has identified the enzyme purple acid phosphatase (PAP) as a suitable and attractive 
target for the development of anti-osteoporotic drugs, due to its postulated role in bone 
resorption.30-44 Evidence in the literature that suggests PAP’s role in bone resorption include (1) 
transgenic mice with osteoclasts that over-expressed the PAP gene developed mild osteoporosis,33 
(2) transgenic PAP-knockout mice developed osteopetrosis (opposite of osteoporosis),33,45 (3) 
osteoporosis patients are found to have elevated PAP serum levels,46 and (4) osteoclastic bone 
resorption was hindered in in vitro bone resorptive assays by either a PAP specific antibody, or if 
molybdate, a potent PAP inhibitor, was used in the assays.37-38  
The strong correlation between PAP and the development of osteoporosis based on the evidence in 
the literature as stated above suggests that inhibiting PAP could halt or delay osteoporosis 
development. Therefore, this work aimed to develop new potent human PAP (hPAP) inhibitors 
towards the development of anti-osteoporotic chemotherapeutics, using the approach of design 
(based on a lead compound), synthesis and testing. In silico docking simulations were employed to 
predict and visualise the predicted binding orientations of the newly designed PAP inhibitors, and 
therefore provided insights for the next round of rational design of PAP inhibitors.   
The starting point of the design of new generation of PAP inhibitors in this work was based on a 
lead compound 26e (see Figure 65) that was a potent PAP inhibitor with Kic value of 8 µM against 
pig PAP (pPAP) and Kic value of 11 µM against red kidney bean PAP (rkbPAP). Compound 26e 
was a potent PAP inhibitor due to the presence of the phosphonate moiety, which was postulated to 
bind to the diiron metal centre in PAPs in a similar way to their endogenous substrate. However, the 
	   179	  
stable C-P bond (unlike the hydrolysable P-O bond in phosphoesters) cannot be hydrolysed by 
PAP, thus inhibiting PAP to carry out the dephosphorylation of bone matrix proteins. It was also 
demonstrated that the presence of the long alkyl chain improved the inhibition potency of the 
compound. 
 
26e 
Figure 65: Tetradecyl derivarive of α-((amido)(naphthyl)methyl)phosphonic acid (26e). Kic = 8 µM 
(pig PAP) and Kic = 11 µM (red kidney bean PAP) 
In chapter 2, a series of new PAP inhibitors were designed based on the lead compound 26e, and 
the derivatives were designed and synthesised to have increasing chain lengths. This was based on 
the previous findings by Schwender et al.47 and our group,48-50 where inhibition potencies of the 
compounds improved as chain length increased, as the chain was postulated to bind to a 
hydrophobic groove adjacent to the active site of PAP. As both the phosphonate moiety and the 
long alkyl chains were essential to result in high inhibition potencies, the lead compound was 
modified to have a smaller ring in the design of the new series of PAP inhibitors as it was 
hypothesised that a smaller rigid component in the compound might contribute to a better affinity to 
the enzyme, hence increased inhibition potency. The derivatives that were synthesised in this 
chapter are listed below.  
Compound R = 
 
33 
33a Me(CH2)8- 
33b Me(CH2)10- 
33c Me(CH2)12- 
33d Me(CH2)14- 
33e Me(CH2)16- 
33f Me(CH2)7OCH2- 
33g Me(CH2)15OCH2- 
 
34g Me(CH2)15OCH2- 
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As the compounds were synthesised as racemates, both isomers of the compounds were docked in 
the crystal structure coordinates of human PAP (hPAP) and pig PAP (pPAP). hPAP is the clinically 
relevant target, but due to the difficulties in obtaining sufficient amount of hPAP from the current 
baculoviral expression system51 to be used in the studies, pPAP was used as a hPAP model in all in 
vitro kinetic studies in this work. pPAP is a valid hPAP model due to (1) the high conservation of 
the seven invariant metal-ligating residues in the active sites, (2) the same catalytic 
mechanism,39,46,48,52-53 and (3) the similar inhibition constants for different inhibitors against both 
PAPs.40,46,52,54-55 This suggests that the kinetic results obtained could be extrapolated to hPAP.  
Docking studies of these compounds predicted that both isomers would have comparable inhibition 
potencies between each other. This agreed with the previous finding in our group, which showed 
that the enantiomerically pure compounds inhibited pPAP at similar inhibition potencies.50 The 
results from the docking studies did not correlate with the hypothesis that longer chain length would 
result in increased inhibition potencies. Nonetheless, the results from the kinetic studies agreed with 
our hypothesis, where the trend of improved inhibition potencies with increasing chain length was 
observed. All of the compounds in this series were potent pPAP inhibitors, exhibiting Ki values in 
the low micromolar and nanomolar range. The most potent compound in this series was compound 
33e with 17 carbons in its alkyl chain, which inhibited pPAP in a competitive mode with a Kic value 
of 168 nM, which was a remarkable improvement in pPAP inhibition potency compared with the 
previous lead compound 26. This is also the most potent pPAP inhibitor reported to date. Docking 
results suggested that the improvement in the inhibition potencies could be due to the phenyl ring in 
compounds 33 binding to one of the small pockets adjacent to the active site of PAP, which might 
not fit the larger naphthalene ring in the lead compound 26.  
Both docking and kinetic results also showed that a methoxy substituent at the para-position of the 
phenyl ring might contribute to improved inhibition potency of the compounds, which was likely 
due to the methoxy group binding to one of the small pockets adjacent to the active site of PAP. 
The main important conclusions that were suggested from both the docking and kinetic results from 
Chapter 2 are (1) the two pockets adjacent to the active site of PAP are good targets to improve the 
design of new generation of PAP inhibitors, (2) a smaller aromatic ring component in the 
compound could result in improved inhibition potency, and (3) a substituent at the para-position of 
the phenyl ring could improve the inhibition potencies of the compounds compared with the 
compound without a substituent on the phenyl ring. It was also demonstrated that docking results 
did not correlate well with the experimentally determined kinetic data, which was similarly found in 
other studies in the literature,56-59 therefore it was important to not rely solely on the docking results 
to determine the inhibition potencies of new inhibitors.  
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Based on the results gathered in Chapter 2, new series of compounds 43 were designed as discussed 
in Chapter 3, where it was hypothesised that improved inhibition potencies on PAP could be 
achieved with a longer alkyloxy group substituted at the para-position of the phenyl ring, as an 
extra carbon would have an extra hydrophobic interaction with the enzyme, particularly at the target 
pocket near the active site of PAP. A total of four derivatives were designed, synthesised and tested 
in this new series 43, as shown below.  
Compound R = 
 
43 
43c Me(CH2)12- 
43d Me(CH2)14- 
43e Me(CH2)16- 
43f 
Me(CH2)7OCH2- 
All four compounds 43c-f were calculated to have high binding affinities to both hPAP and pPAP 
based on the docking results, although the hypothesis might not be correct, as the ethoxy group was 
not predicted to bind to the target pocket near the active site, which was likely due to the ethoxy 
group being too large compared with a methoxy group, to fit into the pocket. Kinetic analyses 
showed that only compounds 43c-e exhibited quite high inhibition potencies on pPAP. This was 
again in contrast with the docking results, where compound 43f was predicted to have the highest 
calculated binding affinity for both hPAP and pPAP, but did not show high inhibition activity when 
screened on pPAP. This further suggests that the docking scores are not accurate representation for 
the binding affinities and thus the inhibition potencies of the designed inhibitors.  
The most potent compound in this series was compound 43d with a Kic value of 606 nM. This 
compound was almost four times less potent than the most potent compound in the previous series 
described in Chapter 2 (33g, Kic = 168 nM on pPAP). As this work aimed to develop potent PAP 
inhibitors to be developed as anti-osteoporotic drug leads, therefore improvement on the inhibition 
potencies of the designed inhibitors was desirable.  
As the hypothesis of having a larger substituent on the phenyl ring did not result in improved 
inhibition potencies in the designed PAP inhibitors, thus another series of compounds were 
designed and developed to test another hypothesis, where a smaller aromatic ring component in the 
compound that is targeted to bind into one of the small pockets near the active site of PAP might 
result in improved inhibition potencies of the compounds. Therefore, compounds 48 as shown 
below were designed to test this hypothesis, as described in Chapter 4. 
P
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48 
The attempts to synthesise compounds 48 were unsuccessful due to the furan ring in 48 being acid-
sensitive, thus the ring could be opened when reactions were carried out in acidic conditions. Base 
hydrolysis of the phosphonate diesters 50 only yielded monoesters 49. The compounds that were 
synthesised and were available to be tested against pPAP in Chapter 4 are as shown below. 
Compound R = 
 
49 
49d Me(CH2)14- 
49e Me(CH2)16- 
 
50 
50c Me(CH2)12- 
50d Me(CH2)14- 
Docking results showed that compounds 48, 49 and 50 were predicted to have favourable binding 
orientations that could yield high PAP inhibition potencies, and that the hypothesis was correct, 
where the furan ring in the compounds were predicted to bind to the target pocket. The kinetic 
studies yielded surprising results, as even the phosphonate diesters 50 exhibited moderate inhibition 
potencies on pPAP. Docking results showed that the phosphonoester groups were not predicted to 
make any interaction with the diiron centre in both hPAP and pPAP, as was expected. But the 
predicted binding orientation of compounds 50, where the long alkyl chain was predicted to bind to 
the hydrophobic groove, and the furan ring predicted to bind into the pocket, were likely to be the 
contributing factors for the inhibition activities observed for compounds 50 against pPAP. 
Furthermore, the potencies improved at least ten-fold when even only one of the ethyl phosphonate 
diesters was cleaved, as exhibited by the lower Kic values (low micromolar) determined for the 
monoesters 49 compared with the Kic values of the diesters 50. In silico docking simulations 
predicted that the desired phosphonic acids 48 would have high binding potencies on PAP, as they 
were predicted to bind to PAP via strong electrostatic interactions between the phosphoryl oxygen 
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atoms and both of the iron ions in the active site. It was therefore very intriguing to investigate if 
compounds with a chemical structure such as 48 would have improved inhibition potencies on 
pPAP.  
Based on the predicted high binding affinities of compounds 48 to both hPAP and pPAP from 
molecular docking studies, compounds 56 were designed to comprise the next series of PAP 
inhibitors in this work, to probe the inhibition activities of compounds with a chemical structure 
similar to that of 48. Furthermore, the monoesters of compounds 56 were also synthesised and 
tested, to directly compare their kinetic parameters with those found for their furan counterpart, 
compounds 49. Therefore, in Chapter 5, twelve new compounds were synthesised and tested for 
their inhibition potencies against pPAP, and the structures of the compounds are as shown below. 
Compound R = 
 
56 
56c Me(CH2)12- 
56d Me(CH2)14- 
56e Me(CH2)16- 
56f Me(CH2)7OCH2- 
56g Me(CH2)15OCH2- 
56h Me(CH2)17OCH2- 
 
57 
57c Me(CH2)12- 
57d Me(CH2)14- 
57e Me(CH2)16- 
57f Me(CH2)7OCH2- 
57g Me(CH2)15OCH2- 
57h Me(CH2)17OCH2- 
All twelve compounds were synthesised without incident, most likely due to the thiophene ring 
being more acid tolerant than the furan ring. Docking results showed that the compounds were not 
predicted to bind in a similar manner to that observed for their furan counterpart. However, both the 
oxygen atom in the furan rings of compounds 48 and 49, and the sulfur atom in the thiophene rings 
of compounds 56 and 57 were not predicted to make any interaction with PAPs. Thus, the reasons 
that could account for the difference in the binding orientations predicted for the compounds were 
not fully understood.   
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Kinetic analysis showed that seven out of the twelve compounds exhibited considerable pPAP 
inhibition potencies, particularly the derivatives with the longer alkyl or alkoxymethyl chains. This 
was a consistent result found throughout this work, where increasing chain length resulted in 
improved pPAP inhibition potencies. However, the docking results obtained for all twelve 
compounds, 56c-h and 57c-h did not correlate well to the results obtained from the kinetic studies. 
This result was consistently found throughout this work. This suggests that the results obtained 
from docking simulations should not be solely relied on when investigating the inhibition activities 
of the designed PAP inhibitors. The most potent compound developed among the phosphonic acid 
series 56 was compound 56h with Kic value of 864 nM, and the most potent compound developed 
among the monoester series 57 was compound 57h with Kic value of 293 nM, exhibiting a mixed-
mode inhibition, which were both less potent than compound 33e from Chapter 2. 
This work has developed the most potent pPAP inhibitor to date, which was compound 33e with Kic 
value of 168 nM. Nonetheless, the compounds in other series developed in this work also exhibited 
quite potent pPAP inhibition potencies, with Ki values mostly in the low micromolar to nanomolar 
range. Although these results were very promising, it is important to also test the inhibition 
potencies of these compounds against the clinically relevant target, human PAP, for further 
development of the compounds as anti-osteoporotic drug leads. Furthermore, as all of the 
compounds were synthesised as racemates, it would be very interesting to see if individual 
enantiomers of the compounds would exhibit different or similar PAP inhibition potencies. While 
previous studies showed that the racemate (25f) was more potent than the individual enantiomers, 
however the difference in the chemical structures of the compounds developed in this work, 
compared with 25f, though small, might still produce different results.  
Throughout this work, it was demonstrated that docking simulations might not be as reliable as we 
would have hoped. Nevertheless, when combined with kinetic results, docking results were quite 
useful in providing a guide towards designing new generations of potential PAP inhibitors with 
improved inhibition potencies.  
The work described in Appendix A provided another important finding in this work, where it 
further substantiated the findings by Myers et al. that incorporating metal-binding components in 
the structure of potential PAP inhibitors resulted in improved inhibition potencies of the 
compounds.60 However, this work had only employed the substrate mimic, the phosphonate moiety 
as the metal-ligating moiety, which resulted in high inhibition potencies of the compounds. It was 
demonstrated through screening of other compounds with other metal-binding components such as 
thiol, carboxylate, nitrile, imidazole or pyrrole groups that the phosphonate moiety is the best 
choice to be used as the metal-binding motif in the structures of the compounds designed as PAP 
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inhibitors, compared with other groups as listed above that only resulted in low inhibition activities, 
or none at all, against pPAP.  
In summary, through design (based on a lead compound), synthesis and testing, new potent pPAP 
inhibitors were successfully developed, in line with the aims of this project. The promising results 
from this work provide an ideal starting point for the next generation of potent PAP inhibitors 
towards the development of anti-osteoporosis chemotherapeutics. 
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Appendix A  SCREENING OF AVAILABLE COMPOUNDS 
AS POTENTIAL PAP INHIBITORS  
A.1  Introduction 
Initially, this project has taken the approach in developing new potent PAP inhibitors based on a 
lead compound. However, it is undeniable that screening more fragments or compounds could also 
lead to potentially successful drug lead discovery. Therefore, this project had also taken the 
approach in screening more compounds that were obtained throughout this research project in order 
to discover more potent PAP inhibitors that could be developed into potential anti-osteoporotic drug 
leads. Thus this chapter will discuss the results from the screening assays performed on pPAP for 
all of the available compounds, which are supplied by Dr Max Massi’s research group from Curtin 
University (Section A.2.1) and those that were synthesised within the McGeary group (Section 
A.2.2). 
A.2  Results and Discussion 
A.2.1  Compounds from Dr Max Massi’s research group in Curtin University 
Screening assays against pPAP were carried out for compounds 61a-k synthesised by Dr Max 
Massi’s research group from Curtin University. This class of compounds were synthesised as 
ligands for metals of various valencies,1 therefore it was of interest to investigate whether they 
would bind to the dimetal centre of pPAP thus inhibiting the enzyme. Table 28 shows the chemical 
structures of the compounds and the summary of the screening assay results. Unfortunately, none of 
the compounds showed good inhibition activity against pPAP, except 61c, with a modest inhibition 
of 21% at 100 µM. However, at lower concentrations-10 µM and 1 µM, the compound showed very 
little pPAP inhibition and no inhibition, respectively. This was a surprising result, as the findings 
from Myers et al. have demonstrated that inhibition potencies of PAP inhibitors were improved by 
up to two orders of magnitude when metal-ligating moieties were incorporated into the compounds2 
(see Section 1.3.1 for details). These results however suggest that not all metal-binding motifs 
would bind to the diiron centre of pPAP, and the results found in this work thus far showed that the 
presence of phosphonic acid moieties in the design of PAP inhibitors resulted in high potencies of 
the compounds against pPAP. 
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Table 28: Screening assay results of 1, 10, 100 µM of compounds 61a-k synthesised by Dr Max 
Massi’s research group from Curtin University1 against fully reduced pig PAP using 5 mM p-NPP 
as a substrate at pH 4.9 with reduction time 132-264 seconds. 
Compound 
 
61 
R = 
Inhibition% 
Concentration of compounds 
100 µM 10 µM 1 µM 
61a 
 
1 ± 1 2 ± 1 No inhibition 
61b 
 
10 ± 2 9 ± 3 No inhibition 
61c 
 
21 ± 2 1 ± 1 No inhibition 
61d 
 
6 ± 2 1 ± 1 No inhibition 
61e 
 
No inhibition No inhibition No inhibition 
61f 
 
5 ± 1 2 ± 1 No inhibition 
61g 
 
9 ± 3 1 ± 1 No inhibition 
61h 
 
5 ± 1 2 ± 1 No inhibition 
61i 
 
9 ± 2 5 ± 2 No inhibition 
61j 
 
4 ± 1 No inhibition No inhibition 
HN
N
N
N
R
N
N
N
N
NH
OO
MeO
Br
N
O
Me
O
MeO
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61k 
 
5 ± 1 4 ± 1 No inhibition 
 
A.2.2  Compounds Synthesised as IMP-1 (a Metallo-β-Lactamase) Inhibitors 
Our research group is not only working on PAPs, but also on another binuclear metallohydrolase, 
namely IMP-1, a metallo-β-lactamase, which confers antibiotic resistance in many bacteria.3-4 
Similar to PAP, IMP-1 is also a binuclear enzyme, but with two zinc ions in the active site.4 
Therefore some of the inhibitors developed for IMP-1 were also designed to have metal-binding 
moieties. As shown by Myers et al.2 and discussed in Section A.2.1, improved PAP inhibition 
potencies could be achieved when incorporating metal binding components in the inhibitors. Hence, 
it was plausible that the compounds developed as IMP-1 inhibitors could also have inhibition 
properties against PAPs. All of the compounds discussed in this section were synthesised by 
members of our research group, and they were found to have inhibition activities against IMP-1. 
A.2.2.1 Mercaptoproline Derivatives 
Ms Yusralina Yusof synthesised compounds 62a-f to be developed as potential IMP-1 inhibitors.5 
Compounds 62a-c were the precursors for the hydrolysed products 62d-f. Therefore, only 
compounds 62d-f had the metal-binding components, which are the thiol group and the carboxylate 
group that were targeted to bind to the two zinc ions in the active site of IMP-1. Table 29 shows the 
structures of compounds 62a-f and the summary of the screening assay results. Interestingly, 
compounds 62a-c had comparable inhibition potencies with compounds 62d-f against pPAP. This 
suggests that neither the thiol nor the carboxylate group binds to the diiron centre in pPAP, as both 
the docking and kinetic results obtained throughout this work have demonstrated that strong binding 
affinities of PAP inhibitors are due to the strong electrostatic interactions between the inhibitors and 
the dimetal centre in the active site of PAP. Another plausible explanation for the comparable 
inhibition potencies between the precursors 62a-d and the hydrolysed products 62d-f is that the 
acetyl groups in the precursors 62a-d were hydrolysed by pPAP during the screening assays. 
Therefore, it was likely that the screening results for compounds 62a-c were actually for those of 
compounds 62d-f. Nonetheless, as can be seen from the screening results of compounds 62a-f 
against pPAP summarised in Table 29, the inhibition potencies of compounds 62 were very 
modest. Therefore, compounds with chemical structure such as 62 are not suitable to be further 
developed as PAP inhibitors.  
N
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Table 29: Screening assay results of 1, 10, 100 µM of compounds 62a-f against fully reduced pig 
PAP using 5 mM p-NPP as a substrate at pH 4.9 with reduction time 132-264 seconds. 
Compound 
 
62 
R1 = R2 = n = 
Inhibition% 
Concentration of compounds 
100 µM 10 µM 1 µM 
62a t-butyl -Ac 1 21 ± 3 4 ± 4 3 ± 4 
62b t-butyl -Ac 2 7 ± 3 2 ± 1 1 ± 2 
62c t-butyl -Ac 3 7 ± 1 3 ± 1 No inhibition 
62d H H 1 8 ± 2 4 ± 3 No inhibition 
62e H H 2 17 ± 1 3 ± 1 1 ± 0 
62f H H 3 16 ± 3 11 ± 3 5 ± 3 
A.2.2.2 2-N-Acyl-4-cyanopyrrole Derivatives 
Mr Daniel Tan synthesised a series of cyanopyrrole derivatives with the chemical structure 63.6 
Table 30 lists the structures of compounds 63a-j and the screening results of these compounds at a 
concentration of 10 µM performed against pPAP. Due to the low solubilities of compounds 63, 
screening assays could not be performed at higher concentrations of the compounds. Although 
metal-binding moieties were present in compounds 63a-j, only several of the derivatives showed 
some inhibition activity against pPAP, albeit at rather low potencies. This suggests that all of the 
compounds 63a-j did not bind to the dimetal centre, but the (low) inhibition activities observed for 
a few of the compounds were likely due to the aromatic components in compounds 63 making 
hydrophobic interactions with the surface residues around the active site of pPAP, thus contributing 
to some binding affinities of compounds 63 to pPAP. These interactions might be similar to that 
observed for several of the derivatives of PAP inhibitors described in Chapters 2, 3, 4 and 5, where 
their alkyl chains were predicted to make hydrophobic interactions with the backbone of the surface 
residues around the active site of pPAP from molecular docking studies. However, without strong 
electrostatic interactions between the compounds and the metals in pPAP’s active site, hydrophobic 
interactions are not sufficient to result in high inhibition potencies of the compounds against pPAP. 
This correlates with the previous findings in the literature.2 
 
O OR1
N
O
O
S R2
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Table 30: Screening assay results of 10 µM of compounds 63a-j against fully reduced pig PAP 
using 5 mM p-NPP as a substrate at pH 4.9 with reduction time 132-264 seconds. 
Compound 
 
63 
R = 
Inhibition% 
Concentration of compound 
= 10 µM 
63a 
 
12 ± 10 
63b 
 
4 ± 2 
63c 
 
4 ± 2 
63d 
 
No inhibition 
63e 
 
5 ± 3 
63f 
 
2 ± 2 
63g 
 
No inhibition 
63h 
 
13 ± 4 
63i 
 
37 ± 3 
N
CNPh
Ph
Ph
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N Ph
O
PhO
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63j 
 
9 ± 8 
 
A.2.2.3 Imidazole Derivatives 
Dr Omid Arjomandi synthesised derivatives of imidazole compounds (64),7 with the chemical 
structures listed in Table 31 along with their results from the screening assays performed against 
pPAP. Unfortunately, none of the derivatives of 64 exhibited any inhibition activity against pPAP. 
This was likely due to the lack of electrostatic interactions between the compounds and the diiron 
centre in pPAP, despite the presence of the imidazole components in compounds 64. Again, similar 
with the results found and discussed in the previous sections, the imidazole component was not a 
suitable metal-binding motif to be used in the design of PAP inhibitors. Thus, the lack pPAP 
inhibition activity observed for these compounds make them unsuitable to be developed as leads for 
PAP inhibitors.  
Table 31: Screening assay results of 1, 10, 100 µM of compounds 64a-t against fully reduced pig 
PAP using 5 mM p-NPP as a substrate at pH 4.9 with reduction time 132-264 seconds. 
Compound 
 
64 
R1 = R2 = 
Inhibition% 
Concentration of compounds 
100 µM 10 µM 1 µM 
64a H 
 
No inhibition No inhibition No inhibition 
64b H 
 
No inhibition No inhibition No inhibition 
64c H 
 
No inhibition No inhibition No inhibition 
N
O
O
Me
Me
MeMe
N N
R1
R2
NO2
NH2.HCl
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64d H 
 
No inhibition No inhibition No inhibition 
64e H 
 
No inhibition No inhibition No inhibition 
64f H 
 
No inhibition No inhibition No inhibition 
64g H 
 
No inhibition No inhibition No inhibition 
64h H 
 
No inhibition No inhibition No inhibition 
64i H 
 
No inhibition No inhibition No inhibition 
64j Me 
 
No inhibition No inhibition No inhibition 
64k Me 
 
No inhibition No inhibition No inhibition 
64l H 
 
No inhibition No inhibition No inhibition 
64m Me 
 
No inhibition No inhibition No inhibition 
64n H 
 
No inhibition No inhibition No inhibition 
Cl
Cl
OH
OMe
Me
NO2
NO2
NH2.HCl
NO2
Cl
NO2
Cl
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64o Me 
 
No inhibition No inhibition No inhibition 
64p Me 
 
No inhibition No inhibition No inhibition 
64q H 
 
No inhibition No inhibition No inhibition 
64r Me 
 
No inhibition No inhibition No inhibition 
64s H 
 
No inhibition No inhibition No inhibition 
64t Me 
 
No inhibition No inhibition No inhibition 
A.2.2.4 3-(2-Alkylthio)-2-arylthiazolidine-4-carboxylic acid Derivatives 
Ms Sara Musaddiq synthesised a series of thiazolidine derivatives 65 and 668 with the structures as 
shown in Table 32, along with their inhibition activities determined from the screening assays 
performed against pPAP. All of the precursors and their hydrolysed product were tested for their 
pPAP inhibition activities. Compounds 65 and 66 have the same metal-binding components to that 
of compounds 62 (see Section A.2.2.1 for details), which are the thiol and carboxylate groups. 
Similarly, compounds 65 and 66 showed very little or no inhibition activity against pPAP (see 
Table 32). This further validated the results as described in Section A.2.2.1 that both thiol and 
carboxylate groups are not suitable motifs to be the metal-binding moieties to incorporate into the 
structures of potential PAP inhibitors.  
From Table 32, it could be observed that some of the derivatives, namely compounds 65t, 65v, 65z 
and 66d exhibited lower inhibition activities compared with their corresponding precursors 65s, 
NO2
NH2.HCl
NH2.HCl
Cl
NH2.HCl
Cl
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65u, 65y and 66c, respectively. This suggests that the free thiol did not play a role in contributing to 
the binding of the compounds to pPAP. Furthermore, compound 65l exhibited the highest pPAP 
inhibition activity among series 65 and 66, with 57% pPAP inhibition at 100 µM, followed by its 
precursor 65k, with 37% pPAP inhibition at 100 µM. Both compounds 65l and 65k had a 
naphthalene component, similar to the lead compounds 25 and 26 (see Section 1.3.1 for details). 
This suggests that the naphthalene ring in compounds 65l and 65k, rather than the thiol or 
carboxylate groups, played a role towards binding of the compounds to pPAP. In silico docking 
studies might provide some insights in regard to the predicted binding orientations of these 
compounds that contributed to their inhibition activities against pPAP. 
Table 32: Screening assay results of 1, 10, 100 µM of compounds 65a-z and 66a-d against fully 
reduced pig PAP using 5 mM p-NPP as a substrate at pH 4.9 with reduction time 132-264 seconds. 
Compound 
 
65 (n=1), 66 (n=2) 
R1 = R2 = 
Inhibition% 
Concentration of compounds 
100 µM 10 µM 1 µM 
65a 
 
-Ac No inhibition No inhibition No inhibition 
65b 
 
H 16 ± 3 No inhibition No inhibition 
65c 
 
-Ac No inhibition No inhibition No inhibition 
65d 
 
H No inhibition No inhibition No inhibition 
65e 
 
-Ac No inhibition No inhibition No inhibition 
65f 
 
H 11 ± 2 No inhibition No inhibition 
65g 
 
-Ac 6 ± 4 No inhibition No inhibition 
NS
O
OH
R1
S
O
n
R2
HO
HO
MeO
MeO
OMe
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65h 
 
H 4 ± 3 5 ± 3 No inhibition 
65i 
 
-Ac 6 ± 2 3 ± 1 6 ± 2 
65j 
 
H 34 ± 8 21 ± 9 16 ± 10 
65k 
 
-Ac 37 ± 5 16 ± 1 9 ± 2 
65l 
 
H 57 ± 5 29 ± 4 7 ± 5 
65m 
 
-Ac 4 ± 1 No inhibition No inhibition 
65n 
 
H 9 ± 3 No inhibition No inhibition 
65o 
 
-Ac 5 ± 2 No inhibition No inhibition 
65p 
 
H 24 ± 6 No inhibition No inhibition 
65q 
 
-Ac 7 ± 1 1 ± 1 No inhibition 
65r 
 
H 24 ± 7 12 ± 4 5 ± 2 
65s 
 
-Ac 10 ± 3 8 ± 2 No inhibition 
65t 
 
H 2 ± 1 No inhibition No inhibition 
65u 
 
-Ac 8 ± 3 4 ± 1 No inhibition 
OMe
Me
Me
OMe
OMe
Br
Br
Br
Br
O
O
OH
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65v 
 
H 2 ± 1 No inhibition No inhibition 
65w 
 
-Ac 10 ± 3 7 ± 2 No inhibition 
65x 
 
H 17 ± 5 7 ± 2 No inhibition 
65y 
 
-Ac 12 ± 3 8 ± 2 No inhibition 
65z 
 
H No inhibition No inhibition No inhibition 
66a 
 
-Ac 15 ± 3 10 ± 1 No inhibition 
66b 
 
H 10 ± 4 9 ± 2 7 ± 3 
66c 
 
-Ac 17 ± 5 12 ± 3 No inhibition 
66d 
 
H 6 ± 2 No inhibition No inhibition 
A.2.2.5 (S)-3-(4-(benzyloxy)phenyl)-2-(2-mercaptoacetamido)propanoic acid Derivatives 
Dr Omid Arjomandi also synthesised another series of compounds 677 which were potent inhibitors 
of IMP-1, therefore it was very exciting to probe whether they show any inhibition activity against 
pPAP. Thus all of the derivatives of 67 were tested for their pPAP inhibition activities. Table 33 
summarises the structures of the derivatives and their inhibition activities determined from the 
screening assays. Compounds 67 also have both a thiol and a carboxylate groups as the metal-
binding components, similar to compounds 62, 65 and 66 (see Table 29 and Table 32 for details). 
Among the derivatives of 67, only compounds 67j and 67k exhibited quite high pPAP inhibition 
activities with 47% and 56% inhibition at 100 µM, respectively. Although their inhibition activities 
are quite high compared with that found for all the other compounds described in this chapter, they 
were still not comparable to that found for the other PAP inhibitors developed in this work, as 
OH
Cl
Cl
F
F
Br
Br
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described in Chapters 2, 3, 4 and 5, where most of them exhibited more than 50% pPAP inhibition 
at 1 µM in the screening assays (data not shown).  The low inhibition potencies for all series of 
compounds 62, 65, 66 and 67 further substantiate the hypothesis that neither a thiol nor a 
carboxylate group is a good metal-binding motif to be incorporated into the structures of the 
compounds when designing future potential PAP inhibitors.  
Table 33: Screening assay results of 1, 10, 100 µM of compounds 67a-k against fully reduced pig 
PAP using 5 mM p-NPP as a substrate at pH 4.9 with reduction time 132-264 seconds. 
Compound 
 
67 
R = 
Inhibition% 
Concentration of compounds 
100 µM 10 µM 1 µM 
67a 
 
3 ± 1 No inhibition No inhibition 
67b 
 
No inhibition No inhibition No inhibition 
67c 
 
55 ± 8 21 ± 5 No inhibition 
67d 
 
21 ± 6 15 ± 2 No inhibition 
67e 
 
17 ± 5 12 ± 3 2 ± 1 
67f 
 
15 ± 2 11 ± 4 9 ± 1 
67g 
 
18 ± 5 11 ± 3 No inhibition 
OH
O
O HN
O
SHR
NO2
NO2
O2N
Br
Br
Me
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67h 
 
35 ± 8 23 ± 2 No inhibition 
67i 
 
29 ± 5 17 ± 1 No inhibition 
67j 
 
47 ± 3 24 ± 4 No inhibition 
67k 
 
56 ± 4 35 ± 3 27 ± 7 
A.3  Conclusion 
Several series of available compounds were tested to determine their inhibition activities against 
pPAP as an alternative to find suitable compounds that can be developed as potential osteoporotic 
drug leads targeting PAP inhibition. Unfortunately, none of the compounds was found to be a 
potential candidate to be developed as potent PAP inhibitor. This work has employed the strategy of 
using a phosphonate moiety that was both a substrate mimic and the metal-ligating component in 
the structures (based on the lead compound). From the screening assays of other types of 
compounds described in this chapter, it was demonstrated that a metal-binding motif is an essential 
element in the structures of the compounds to be developed as PAP inhibitors. This was also 
demonstrated by the results of both docking and kinetic studies throughout this work, where strong 
electrostatic interactions between the compounds and the diiron centre in the active site of PAP 
contributed to the high binding affinities of the compounds thus their high inhibition potencies.  
Another finding from the results of the screening assays of other compounds described in this 
chapter was that other metal-binding motifs such as thiol, carboxylate, nitrile, imidazole, or pyrrole 
groups only resulted in low or no pPAP inhibition activities. Therefore, based on these findings, it 
could be concluded that in the design of potential PAP inhibitors, (1) a metal-ligating component is 
essential, and (2) a phosphonate moiety is a better choice to be incorporated as the metal-binding 
motif, compared with thiol, carboxylate, nitrile, imidazole, or pyrrole groups. 
 
 
Me
Cl
Cl
Cl
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A.4  Experimental 
A.4.1 Kinetic Assays 
All kinetic assays were conducted based on the procedure previously described in Section 2.4.3. 
pPAP was reduced before use in all steady-state assays using 67 mM ferrous ammonium sulfate and 
134 mM BME as the reducing agent. Continuous assays were conducted using p-NPP as the 
substrate, in 0.1 M sodium acetate buffer with 25% DMSO, pH 4.9 (optimum pH for pPAP), at 25 
°C. Kinetic measurements was measured with a UV/Vis spectrophotometer at λ = 405 nm, with 
Δε405 = 342.9 L mol-1 cm-1, and the data were collected at 132-264 seconds. In screening assays, 
fully reduced pPAP concentration was 20 nM, p-NPP concentration was 5 mM, and inhibitor 
concentrations used were 1, 10 and 100 µM (see Table 28 to Table 33 for details). Each 
measurement was carried out in duplicates. Screening results were calculated as inhibition %.  
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Appendix B  X-RAY CRYSTALLOGRAPHY OF RKBPAP-
INHIBITOR COMPLEX 
B.1  Introduction 
As discussed throughout Chapters 2, 3, 4 and 5, molecular modelling is not sufficient to determine 
the precise binding modes of the new potent PAP inhibitors within the enzyme’s active site. 
Therefore, crystal structures of PAP-inhibitor complex are required to determine the actual binding 
modes of the inhibitors in PAPs. Human PAP (hPAP) is the clinically relevant target, but 
mammalian PAPs are innately difficult to crystallise,1-2 especially without any tetraoxoanions such 
as phosphate, tungstate or sulfate bound to their active sites.3 On the other hand, red kidney bean 
PAP (rkbPAP) can be obtained in large quantities from its natural sources4-5 and crystallises more 
readily.6-8 Therefore rkbPAP was the protein of choice to be soaked with the new potent inhibitors 
to obtain PAP-inhibitor complex crystal structures. The use of rkbPAP as a valid hPAP model is 
supported by the observations that: (1) the residues are highly conserved in the active sites of PAPs 
across different sources,9 (2) the substrate-binding pockets are similar,3,5,10-13 and (3) a range of 
structurally different PAP inhibitors were reported to have similar inhibition constants for several 
mammalian and plant PAPs.4,9-10,13-19 
B.2  Results and Discussion 
B.2.1 Soaking of potent pPAP inhibitors 33e and 34g into pre-grown rkbPAP crystals 
The two most potent inhibitors in the series were chosen to be soaked into rkbPAP crystals (pre-
grown by Mr Daniel Feder20), namely compounds 33e and 34g, with Kic values of 168 nM and 242 
nM, respectively (Figure 66 and Figure 67). The two compounds, dissolved in a cryoprotectant 
solution (0.1 M sodium citrate pH 5.0, 0.1 M lithium chloride, 25% v/v polyethylene glycol, 20% 
v/v isopropyl alcohol, 10% v/v glycerol) were successfully soaked with pre-grown rkbPAP crystals 
in collaboration with Daniel Feder. The detailed procedure is discussed in Section B.2.1. X-ray 
diffraction data for the crystals (Figure 66 and Figure 67) was collected at the Australian 
Synchrotron in Melbourne by Associate Professor Luke Guddat.  
Unfortunately, the crystals only diffracted to a very low resolution of 3.2 Å, thus data refinement 
and model building could not be done using the collected X-ray data. 
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Figure 66: rkbPAP crystals soaked with 33e. 
 
Figure 67: rkbPAP crystals soaked with 34g. 
B.2.2 Crystallisation attempts of rkbPAP 
Since the resolution of the rkbPAP crystals soaked with the potent pPAP inhibitors 33e and 34g was 
very low, another attempt was made to obtain the crystal structures of rkbPAP with bound inhibitor 
to determine the actual binding orientations of the inhibitors. There were no remaining pre-grown 
rkbPAP crystals that could be used to be soaked with the potent inhibitors at the time. Therefore, 
attempts were made to grow new hexagonal-shaped rkbPAP crystals, as it was found that only the 
hexagonal-shaped crystals would give good diffraction data.16,20 Attempts were made to grow 
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rkbPAP crystals using the hanging drop vapour diffusion method (see Section B.4.2 for detailed 
procedure). Pure rkbPAP that was used in these attempts was the last remaining stock that was 
previously extracted and purified by a previous member of our group, Dr Annie Kan. 
Unfortunately, none of the different growth conditions employed resulted in large hexagonal-
shaped rkbPAP crystals (see Section B.4.2 for details), and only small diamond-shaped crystals 
were grown. Previous work in the group has found that these small diamond-shaped crystals would 
not give good diffraction data,16,20 therefore more attempts should be made to grow rkbPAP crystals 
that were of sufficient quality. However, since pure rkbPAP in high concentration was not available 
to be used for crystal growth, a new stock of pure and concentrated rkbPAP was required.  
B.2.3 Extraction and purification of rkbPAP 
As discussed in Section B.2.2, a new stock of pure rkbPAP in high concentration was required for 
X-ray crystallographic studies. A well-established procedure was adapted to extract and purify 
rkbPAP.4,16 The detailed procedure is described in Section B.4.3. Ethanol fractionation and 
ammonium sulfate precipitation (47-53%) did not result in pure rkbPAP as the analysis using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) showed that the sample 
contained multiple bands (data not shown). Due to time constraint, further attempts to purify the 
rkbPAP sample had to be halted. 
B.3  Conclusion 
To determine the actual binding orientations of the potent pPAP inhibitors developed in this work, 
experimentally determined data from X-ray crystallographic studies was required, as it was found 
and discussed in the preceding chapters that in silico docking simulations that were employed were 
not sufficient and the results might not be correct based on the contrasting results obtained from the 
docking studies and the kinetic studies. Therefore, attempts to obtain the crystal structures of the 
potent pPAP inhibitors bound to the active site of rkbPAP were made, however no useful result was 
obtained from any of the efforts.  
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B.4  Experimental 
B.4.1 Soaking of potent pPAP inhibitors 33e and 34g into pre-grown rkbPAP crystals 
Inhibitors 33e and 34g were dissolved in cryoprotectant solution containing 0.1 M sodium citrate 
pH 5.0, 0.1 M lithium chloride, 25% v/v polyethylene glycol, 20% v/v isopropyl alcohol, 10% v/v 
glycerol, up to 20 mM. 2 µL of each inhibitor was pipetted into individual hanging drops containing 
pre-grown large, hexagonal rkbPAP crystals. The rkbPAP crystals were pre-grown by Mr Daniel 
Feder, another member of our group. The crystals were then allowed to soak for at least three weeks 
before flash freezing it in liquid nitrogen.  
To prevent inhibitors being displaced from the active site of the rkbPAP crystals, up to 10 mM of 
each inhibitor was added to the corresponding hanging drops before flash freezing of the crystals. 
Each inhibitor dissolved in DMSO was further dissolved in a cryoprotectant solution containing 0.1 
M sodium citrate pH 5.0, 0.1 M lithium chloride, 25% v/v polyethylene glycol 3, 350, 20% v/v 
isopropyl alcohol, 10% v/v glycerol. Around 2 µL of the solutions of each inhibitor was added to 
the corresponding hanging drops around 10 seconds before the pre-soaked crystals was placed in 
the cryostream (100 K). The frozen crystals were then sent for data collection to the Australian 
Synchrotron, Victoria. 
X-ray data collection was undertaken on the MX2 beamline at the Australian Synchrotron, using 
Blu-Ice, and the reflections were integrated and scaled using iMOSFLM. This was done by 
Associate Professor Luke Guddat. 
B.4.2 Crystallisation attempts of rkbPAP 
rkbPAP crystals were grown using the hanging drop vapour diffusion method. The well solution 
contained 1 mL 2.3 M ammonium sulfate and 0.1 M sodium acetate, at pH 4.0, or 1 mL RKBPAP 
WS (left by Mr Daniel Feder on his bench before he left the group). 2 µL of concentrated rkbPAP 
solution was pipetted onto the cover slip, followed by 2 µL of the well solution to the protein drop, 
before the cover slip was inverted to completely cover and seal the well. Where applicable, seeding 
of microscopic crystals (seeds) such as RKBPAP SEED DJC 100 DF, RKBPAP SEED 1/100 (both 
were left by Mr Daniel Feder on his bench before he left the group), or Naomi’s nucleants to fresh 
hanging drops was performed using a whisker from a domestic short-hair cat. A tray was set up 
such as in Figure 68 to determine the best growth condition to obtain rkbPAP crystals large enough 
(> 0.3 x 0.1 x 0.1 mm) and hexagonal in shape to obtain high resolution X-ray diffraction data.  
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Figure 68: Tray set up for crystallisation of rkbPAP, with the conditions listed. WS A is well 
solution containing 2.3 M ammonium sulfate, 0.1 M sodium acetate pH 4.0, while WS B is well 
solution containing RKBPAP WS.  
After 3 days, the tray set up in Figure 68 only produced millions of small diamond-shaped crystals. 
None of them were large enough to give good diffraction. Therefore, another tray was set up 
containing varying amounts of concentrated rkbPAP solution (1.4 – 2 µL) and well solution of 2.3 
M ammonium sulfate, 0.1 M sodium acetate pH 4.0 (WS) with amounts ranging from 2.0 – 2.6 µL 
in the drop and 0.75 – 1.0 mL in the well, to dilute both the protein solution, and the well solution 
(Figure 69). No seeding was performed in this tray set up. 
 
2 µL 
rkbPAP 
2 µL WS 
drop 
1 mL WS 
2 µL rkbPAP 
2 µL WS drop 
0.95 mL WS + 
0.05 mL water 
2 µL rkbPAP 
2 µL WS drop 
0.9 mL WS + 
0.1 mL water 
2 µL rkbPAP 
2 µL WS drop 
0.85 mL WS + 
0.15 mL water 
2 µL rkbPAP 
2 µL WS drop 
0.8 mL WS + 
0.2 mL water 
2 µL rkbPAP 
2 µL WS drop 
0.75 mL WS + 
0.25 mL water 
1.8 µL 
rkbPAP 
2.2 µL 
WS drop 
1 mL WS 
1.8 µL rkbPAP 
2.2 µL WS 
drop 
0.95 mL WS + 
0.05 mL water 
1.8 µL 
rkbPAP 
2.2 µL WS 
drop 
0.9 mL WS + 
0.1 mL water 
1.8 µL rkbPAP 
2.2 µL WS 
drop 
0.85 mL WS + 
0.15 mL water 
1.8 µL 
rkbPAP 
2.2 µL WS 
drop 
0.8 mL WS + 
0.2 mL water 
1.8 µL rkbPAP 
2.2 µL WS 
drop 
0.8 mL WS + 
0.2 mL water 
1.6 µL 
rkbPAP 
2.4 µL 
WS drop 
1 mL WS 
1.6 µL rkbPAP 
2.4 µL WS 
drop 
0.95 mL WS + 
0.05 mL water 
1.6 µL 
rkbPAP 
2.4 µL WS 
drop 
0.9 mL WS + 
0.1 mL water 
1.6 µL rkbPAP 
2.4 µL WS 
drop 
0.85 mL WS + 
0.15 mL water 
1.6 µL 
rkbPAP 
2.4 µL WS 
drop 
0.8 mL WS + 
0.2 mL water 
1.6 µL rkbPAP 
2.4 µL WS 
drop 
0.8 mL WS + 
0.2 mL water 
1.4 µL 
rkbPAP 
2.6 µL 
WS drop 
1 mL WS 
1.4 µL rkbPAP 
2.6 µL WS 
drop 
0.95 mL WS + 
0.05 mL water 
1.4 µL 
rkbPAP 
2.6 µL WS 
drop 
0.9 mL WS + 
0.1 mL water 
1.4 µL rkbPAP 
2.6 µL WS 
drop 
0.85 mL WS + 
0.15 mL water 
1.4 µL 
rkbPAP 
2.6 µL WS 
drop 
0.8 mL WS + 
0.2 mL water 
1.4 µL rkbPAP 
2.6 µL WS 
drop 
0.8 mL WS + 
0.2 mL water 
Figure 69: Tray set up for crystallisation of rkbPAP, with the conditions listed. WS is well solution 
containing 2.3 M ammonium sulfate, 0.1 M sodium acetate pH 4.0. 
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After one day, most drops contained no crystal, but some drops had small diamond-shaped crystals. 
After two days, none of the drops had good crystals that would give good diffraction. In conclusion, 
none of the conditions in both tray setups (Figure 68 and Figure 69) resulted in the growth of 
rkbPAP crystals that were of good quality that would give good diffraction data.  
B.4.3 Extraction and purification of rkbPAP 
The procedure used was based on the established protocol by Dr Annie Kan.16 1.5 kg of Flannery’s 
red kidney bean was placed in -80 °C freezer overnight. The beans were powdered 250 g at a time, 
and were placed back in -80 °C freezer overnight. At 4 °C, 0.5 kg (at a time) of the powdered beans 
was slowly dissolved in 2.25 L of cold 0.5 M NaCl, and stirred for 30 minutes. The extract was then 
filtered through a muslin cloth (double thickness). The filtrates were combined and kept at 4 °C 
overnight. The filtrate was then centrifuged at 7500 rpm for 75 minutes at 4 °C and then filtered to 
remove any insoluble materials. 15% v/v of cold ethanol was slowly added to the supernatant with 
constant stirring, and stirred for a further 30 minutes at 4 °C. The mixture was then centrifuged at 
7500 rpm for 75 minutes at 4 °C. More cold ethanol (33% v/v) was slowly added to the supernatant 
and stirred for a further 30 minutes at 4 °C. The solution was then centrifuged at 7500 rpm for 75 
minutes at 4 °C. The faintly purple pellet was resuspended in ~550 mL of cold 0.5 M NaCl and 
stirred at 4 °C overnight. The resuspended pellet was stirred at room temperature for two hours 
before being centrifuged at 7500 rpm for 75 minutes at 20 °C to give a purplish supernatant. 50% of 
saturated ammonium sulfate was then slowly added to the resulting purplish supernatant at room 
temperature and stirred for 30 minutes, and the solution was centrifuged at 7500 rpm for 90 minutes 
at 20 °C. The faintly purple pellet was resuspended in 75 mL cold 0.5 M NaCl at 4 °C overnight. 
The resuspended pellet was then stirred at room temperature for two hours, after which 47% of 
saturated ammonium sulfate was slowly added to the solution and further stirred for one hour. The 
resulting solution was then centrifuged at 15000 rpm for 60 minutes at 20 °C. After this time, the 
solution remained clear, and the pellet was still quite purple (the supernatant was supposed to be 
purple). Therefore, the purple pellet was then resuspended in 40 mL of cold 0.5 mL NaCl at 4 °C 
overnight. The resuspended pellet was then stirred at room temperature for two hours, after which 
53% of saturated ammonium sulfate solution (pH 8.6) was slowly added to the solution and further 
stirred for one hour, before being centrifuged at 15000 rpm for 120 minutes at 20 °C. The resulting 
purplish pellet was resuspended in 40 mL of cold 0.5 mL NaCl at 4 °C overnight. The resuspended 
purplish pellet was dialysed in cold 0.5 mL NaCl at 4 °C for three changes. SDS-Page analysis of 
the resulting solution showed multiple bands. Previous work by Dr Annie Kan16 showed that after 
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these steps, the resulting solution should yield rkbPAP of sufficient purity. Due to time constraint, 
further purification steps were not attempted.   
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Appendix C  (S)-2-AMINO-3-((2-
PHOSPHONOETHYL)THIO)PROPANOIC ACID  
C.1  Introduction 
Based on crystal structures of pPAP complexed with three fragments, namely acetate, phosphate 
and ethylene glycol (work done by Mr Daniel Feder-unpublished data), the following compound 68 
(Figure 70) was designed, and the docking simulation between 68 and pPAP showed that 68 has a 
favourable binding mode as predicted by docking studies done by Mr Daniel Feder (Figure 71). It 
was predicted that the phosphonate moiety of 68 would make strong electrostatic interactions with 
the diiron centre, and also make hydrogen-bonding interactions with the phenol of Tyr55 (Y55) and 
with the amide proton in the side chain of Asn91 (N91). Furthermore, the oxygen atom of the 
carboxylate group in 68 was predicted to be hydrogen-bonded to the NH of the imidazole side chain 
in His223 (H223). In addition, the amine protons in 68 were also predicted to make ionic 
interactions with side chain carboxylate oxygen atoms of Glu194 (E194) and Asp246 (D246). All of 
these predicted interactions suggested that compound 68 would have a high binding affinity to 
pPAP and therefore high inhibition potency. This will be discussed later in Section C.2.2. 
 
Figure 70: Chemical structure of (S)-2-amino-3-((2-phosphonoethyl)thio)propanoic acid (68). 
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Figure 71: Binding orientation of 68 to the active site of pig PAP as predicted by Molegro Virtual 
Docker (MVD). pPAP electrostatic surface: blue – positive; red – negative; white – neutral. 3D 
residue labels: larger labels – residues that are nearer to the observer; smaller labels – residues that 
are farther away from the observer.  Solid yellow spheres represent the diiron metal centre. Dashed 
lines show the hydrogen bonds and electrostatic interactions. (In silico docking simulation and 
Figure were done by Mr Daniel Feder1) 
C.2  Results and Discussion 
C.2.1 Syntheses of (S)-2-amino-3-((2-phosphonoethyl)thio)propanoic acid hydrochloride (75) 
and (S)-2-amino-3-((2-phosphonoethyl)thio)propanoic acid hydrobromide (76) 
To synthesise the desired compound 68, the first step taken was to synthesise 71, which was 
successfully achieved according to standard procedure2 by reacting 1,2-dibromoethane (69) with 
triethylphosphite (70) under reflux, as shown in Scheme 25. The 1H NMR (proton nuclear magnetic 
resonance) spectrum of 71 was consistent with that described in the literature.2 
 
Scheme 25: Synthesis of diethyl (2-bromoethyl)phosphonate (71). 
Br Br
P
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The next step was to synthesise (S)-2-((tert-butoxycarbonyl)amino)-3-((2-
(diethoxyphosphoryl)ethyl)thio)propanoic acid (74), which was successfully achieved by first 
reducing bis-Boc-cystine (72) using sodium borohydride in isopropanol to generate Boc-cysteine in 
situ. The addition of the synthesised 71 to the mixture allowed the nucleophilic attack of the thiolate 
anion in Boc-cysteine (73) on the bromoethyl group of diethyl (2-bromoethyl)phosphonate (71) to 
afford (S)-2-((tert-butoxycarbonyl)amino)-3-((2-(diethoxyphosphoryl)ethyl)thio)propanoic acid 
(74) in 63% yield, as shown in Scheme 26. All of the spectral data acquired for 74 (1H and 13C 
NMR, LRMS and HRMS (low- and high-resolution mass spectrometry, respectively)) confirmed 
the structure of the product obtained to be that of 74.  
 
Scheme 26: The synthetic route to (S)-2-((tert-butoxycarbonyl)amino)-3-((2-
(diethoxyphosphoryl)ethyl)thio)propanoic acid (74) from bis-Boc-cystine (72). 
The final step to yield the desired (S)-2-amino-3-((2-phosphonoethyl)thio)propanoic acid (68) 
required the removal of both the Boc group and the diester groups in 74. This step was first tried by 
using the method of refluxing 74 in concentrated hydrochloric acid, as shown in Scheme 27. The 
reaction was monitored by thin layer chromatography (TLC), 1H NMR and LRMS. The reaction 
was only complete after four weeks. During this time, another method was tried, using 
bromotrimethylsilane in dry chloroform as the solvent3 for seven days, as shown in Scheme 28. 
Both methods successfully produced the desired 68 in quantitative yields as its hydrochloride salt 
75 (Scheme 27) or its hydrobromide salt 76 (Scheme 28). The identities of both 75 and 76 were 
confirmed by their spectral data (1H and 13C NMR, LRMS and HRMS). 
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Scheme 27: Synthetic route of (S)-2-amino-3-((2-phosphonoethyl)thio)propanoic acid 
hydrochloride (75) from 74. 
 
Scheme 28: Synthetic route of (S)-2-amino-3-((2-phosphonoethyl)thio)propanoic acid 
hydrobromide (76) from 74. 
C.2.2 Kinetic Assays 
Both the hydrochloride and hydrobromide salts of 68 (75 and 76, respectively) were screened 
against pPAP to determine whether they have sufficient pPAP inhibitory activities before 
performing the inhibition assays. Based on the favourable binding of 68 to pPAP as predicted by 
Molegro Virtual Docker (MVD) (see Figure 71), it was then expected that compound 68 would 
have a high inhibition potency against pPAP. Unfortunately, the screening assay results indicated 
otherwise. Both 75 and 76 exhibited very low pPAP inhibition activities, with only 2% inhibition at 
100 µM. At lower concentrations of 75 and 76 (10 µM and 1 µM), no pPAP inhibition was 
observed. This contrasting finding between the results from docking and kinetic studies was 
consistently observed throughout this work, as discussed in Chapters 2, 3, 4 and 5. 
As demonstrated by the series of new PAP inhibitors developed in this work (Chapters 2, 3, 4 and 
5) and as discussed based on the findings in Chapter 6, it was deduced that a phosphonate moiety in 
the structure of a compound would contribute to strong electrostatic interactions with the diiron 
centre in PAP thus resulting in high binding affinity and inhibition potency of the compound 
against PAP. However, the low inhibition potencies observed for compounds 75 and 76 might be 
due to the small size of the compounds, which is more similar to the size of a fragment.  
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C.3  Conclusion 
A compound with a chemical structure 68 was designed based on crystal structures of pPAP with 
three fragments bound (acetate, phosphate and ethylene glycol). The compound was successfully 
synthesised as its hydrochloride and hydrobromide salts (75 and 76, respectively). Despite its 
favourable binding to pPAP as predicted by docking studies, and the presence of a phosphonate 
moiety, the compound exhibited very low pPAP inhibition activity. Hence, this compound was not 
pursued further to be developed as potent PAP inhibitor in this work. 
C.4  Experimental 
C.4.1 Syntheses 
All chemical reagents are of analytical grade unless stated otherwise. Chloroform was dried by 
distillation from phosphorous pentoxide. Light petroleum (LP, b.p. 40-60 °C) was distilled before 
use. Flash column chromatography was carried out with Merck Kieselgel 60 as described in the 
literature.4 NMR experiments were recorded on 400 and 500 MHz spectrometers (Bruker, 
Rheinstetten, Germany). Chemical shifts are reported in parts per million (ppm) on a δ scale, 
relative to the solvent peak (CDCl3 δH 7.24, δC 77.0; CD3OD δH 3.30, δC 49.0; D2O δH 4.79). 
Coupling constants (J) are reported in hertz and peak multiplicities described as singlet (s) and 
doublet (d). High-resolution electrospray ionisation accurate mass measurements were recorded in 
positive and negative modes on a quadrupole – time of flight instrument (Bruker) with an ESI 
source. Accurate mass measurements were carried out with external calibration using sodium 
formate as reference calibrant and/or Agilent tune mix (mw > 500). Low and high-resolution 
electron impact ionization mass measurements were recorded using perfluorokerosene-H as 
reference calibrant. 
Diethyl (2-bromoethyl)phosphonate (71)2  
 
This compound was prepared according to the general procedure described in the literature.2 The 
reaction was carried out under anhydrous conditions. 1,2-Dibromoethane (69) (8 mL, 92 mmol) was 
transferred into a two-necked round-bottomed flask, followed by the addition of triethyl phosphite 
(70) (4 mL, 23 mmol) under stirring, and the mixture was refluxed for 5 hours under argon 
atmosphere. The product was collected via distillation under reduced pressure (2 mmHg, 80-94 °C) 
Br P
O
OEt
OEt
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as clear colourless liquid (4.3 g, 76%). 1H NMR (400 MHz, CDCl3) δ 1.20 (6H, t, J 7.1 Hz), 2.21-
2.30 (2H, m), 3.37-3.43 (2H, m), 3.96-4.02 (4H, m); 13C NMR (100 MHz, CDCl3) δ 16.1 (d, 3JPC 
5.9 Hz), 23.6, 31.0 (d, 1JPC 134 Hz), 61.7 (d, 2JPC 6.6 Hz), consistent with literature.2  
 (S)-2-((tert-Butoxycarbonyl)amino)-3-((2-(diethoxyphosphoryl)ethyl)thio)propanoic acid (74) 
 
The reaction was carried out under anhydrous conditions. To a mixture of bis-boc-cystine (72) (0.13 
g, 0.29 mmol) in 12 mL isopropanol was added NaBH4 (0.044 g, 1.16 mmol) and stirred under 
reflux in argon atmosphere for 30 minutes. Monitoring by TLC showed that the reduction had gone 
to completion. The mixture was then allowed to cool to room temperature, after which 71 (0.1 mL, 
0.88 mmol) and tetrabutylammonium iodide (5 mg, 0.1 mmol) were added to the reaction mixture. 
The reaction mixture was then stirred under argon at room temperature. After 2 hours, precipitate 
formed, and after 3 hours, the reaction was stopped, and isopropanol was then evaporated and the 
precipitate was stirred with EtOAc (10 mL) and water (10 mL). The aqueous phase was then 
acidified to ~pH 3 using 10% citric acid, and the layers were separated and the aqueous phase was 
extracted again with EtOAc (4 x 10 mL). The combined organic extracts was then dried with with 
Na2SO4, and evaporated in vacuo. The product was purified using silica flash column 
chromatography (5-10% MeOH in CHCl3) to give 74 as yellow gum (0.142 g, 63%). Rf: 0.48 (20% 
MeOH in CHCl3, KMnO4 dip). ESI-MS, m/z: 384 [M - H]-. HRMS calculated for C14H27NO7PS 
384.1246, found 384.1257. 1H NMR (500 MHz, CD3OD) δ 1.32 (6H, t, J 7.0 Hz, OCH2CH3), 1.44 
(9H, s, (CH3)3CO), 2.07-2.14 (2H, dt, J 8.1, 18.2 Hz, CH2P), 2.73-2.80 (2H, m, SCH2), 2.88-2.92 
(1H, dd, J 7.1, 13.9 Hz, CHCH2S), 3.01-3.05 (1H, dd, J 4.7, 13.9 Hz, CHCH2S), 4.07-4.17 (4H, m, 
POCH2CH3), 4.23 (1H, m, NHCHCOOH); 13C NMR (125 MHz, CD3OD) δ 16.69 (d, 3JPC 5.6 Hz), 
16.73, 26.0 (d, 2JPC 3.0 Hz), 26.5, 26.6, 27.7, 28.7, 35.4, 55.7, 63.5 (d, 1JPC 6.5 Hz), 63.9 (d, 2JPC 6.5 
Hz), 68.9, 80.6, 157.7, 177.1, 177.3.  
(S)- 2-Amino-3-((2-phosphonoethyl)thio)propanoic acid hydrochloride (75) 
 
74 (0.020 g, 0.05 mmol) was refluxed in conc. HCl (2 mL). The reaction was monitored by TLC, 
NMR, and MS; and the reaction was complete after 4 weeks. The solution was then concentrated 
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under reduced pressure. The residue was then washed with petroleum ether (2 x 3 mL) and 
decanted, which was followed by washing with diethyl ether (2 x 3 mL) and decanted. The product 
was then dried under high vacuum, which gave 75 as an orange hygroscopic solid (0.012 g, 100%). 
Rf: 0.20 (100% MeOH , KMnO4 dip). ESI-MS, m/z: 228 [M - H]-. HRMS calculated for 
C5H11NO5PS 228.0096, found 228.0097. 1H NMR (500 MHz, D2O) δ 1.89-1.93 (2H, m, 
CH2PO(OH)2),  2.70 (2H, dd, J 8.5, 10.1 Hz, SCH2CH2P), 3.02 (1H, dd, J 7.4, 15.0 Hz, CHCH2S), 
3.13 (1H, dd, J 4.4, 15.1 Hz, CHCH2S), 4.14 (1H, m, NH2CHCOOH); 13C NMR (125 MHz, D2O,  
a drop of CD3OD to calibrate) δ 26.4 (d, 2JPC 2.6 Hz), 28.5 (d, 1JPC 130 Hz), 32.3, 53.4, 172.0. 
(S)- 2-Amino-3-((2-phosphonoethyl)thio)propanoic acid hydrobromide (76) 
 
74 (0.020 g, 0.05 mmol) was stirred with TMSBr (8 eq.) in dry chloroform (5 mL) as the solvent 
under argon atmosphere at room temperature for 7 days. Excess TMSBr and chloroform was then 
removed under a stream of nitrogen, and was then concentrated under reduced pressure. The residue 
was then stirred with water (5 mL) for 90 minutes, and water was evaporated in vacuo, which 
yielded the hydrobromide salt of 68 (76) as semi-solid (0.012 g, 100%). The NMR and MS spectra 
for this compound were identical to that of the hydrochloride salt 75. 
C.4.2 Kinetic Assays           
All kinetic assays were conducted based on the procedure previously described in Section 2.4.3. 
pPAP was reduced before use in all steady-state assays using 67 mM ferrous ammonium sulfate and 
134 mM BME as the reducing agent. Continuous assays were conducted using p-NPP as the 
substrate, in 0.1 M sodium acetate buffer with 25% DMSO, pH 4.9 (optimum pH for pPAP), at 25 
°C. Kinetic measurements was measured with a UV/Vis spectrophotometer at λ = 405 nm, with 
Δε405 = 342.9 L mol-1 cm-1, and the data were collected at 132-264 seconds. In screening assays, 
fully reduced pPAP concentration was 20 nM, p-NPP concentration was 5 mM, and inhibitor 
concentrations used were 1, 10 and 100 µM. Each measurement was carried out in duplicates. 
Screening results were calculated as inhibition %.  
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Appendix D  PREDICTED BINDING ORIENTATIONS 
BETWEEN NEW INHIBITORS AND hPAP AND pPAP BY 
MOLEGRO VIRTUAL DOCKER  	  	  	  	  	  	  	  	  	  	  	  	  	  
D.1 Predicted Binding Orientations of Compounds 33a-g and 34g (Chapter 2) in hPAP 
and pPAP 
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(Decanamido(phenyl)methyl)phosphonic acid (33a) in hPAP 
 
R-33a 
 
 
 
S-33a 
 
P
H
N
HO
OHO (CH2)8Me
O
P HN
HO
OHO (CH2)8Me
O
	   225	  
(Dodecanamido(phenyl)methyl)phosphonic acid (33b) in hPAP 
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(Phenyl(tetradecanamido)methyl)phosphonic acid (33c) in hPAP 
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(Hexadecanamido(phenyl)methyl)phosphonic acid (33d) in hPAP 
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(Octadecanamido(phenyl)methyl)phosphonic acid (33e) in hPAP 
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((2-(Octyloxy)acetamido)(phenyl)methyl)phosphonic acid (33f) in hPAP 
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((2-(Hexadecyloxy)acetamido)(phenyl)methyl)phosphonic acid (33g) in hPAP 
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((2-(Hexadecyloxy)acetamido)(4-methoxyphenyl)methyl)phosphonic acid (34g) in hPAP 
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(Decanamido(phenyl)methyl)phosphonic acid (33a) in pPAP 
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(Dodecanamido(phenyl)methyl)phosphonic acid (33b) in pPAP 
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(Phenyl(tetradecanamido)methyl)phosphonic acid (33c) in pPAP 
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(Hexadecanamido(phenyl)methyl)phosphonic acid (33d) in pPAP 
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(Octadecanamido(phenyl)methyl)phosphonic acid (33e) in pPAP 
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((2-(Octyloxy)acetamido)(phenyl)methyl)phosphonic acid (33f) in pPAP 
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((2-(Hexadecyloxy)acetamido)(phenyl)methyl)phosphonic acid (33g) in pPAP 
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((2-(Hexadecyloxy)acetamido)(4-methoxyphenyl)methyl)phosphonic acid (34g) in pPAP 
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D.2 Predicted Binding Orientations of Compounds 43c-f (Chapter 3) in hPAP and 
pPAP 
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 ((4-Ethoxyphenyl)(tetradecanamido)methyl)phosphonic acid (43c) in hPAP 
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((4-Ethoxyphenyl)(hexadecanamido)methyl)phosphonic acid (43d) in hPAP 
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((4-Ethoxyphenyl)octadecanamido)methyl)phosphonic acid (43e) in hPAP 
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((4-ethoxyphenyl)(2-(Octyloxy)acetamido)methyl)phosphonic acid (43f) in hPAP 
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 ((4-Ethoxyphenyl)(tetradecanamido)methyl)phosphonic acid (43c) in pPAP 
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((4-Ethoxyphenyl)(hexadecanamido)methyl)phosphonic acid (43d) in pPAP 
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((4-Ethoxyphenyl)octadecanamido)methyl)phosphonic acid (43e) in pPAP 
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((4-ethoxyphenyl)(2-(Octyloxy)acetamido)methyl)phosphonic acid (43f) in pPAP 
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D.3 Predicted Binding Orientations of Compounds 48c-e, 49d-e and 50c-d (Chapter 
4) in hPAP and pPAP 
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((Furan-2-yl)(tetradecanamido)methyl)phosphonic acid (48c) in hPAP 
 
R-48c 
 
 
 
S-48c 
 
P
H
N
HO
OHO (CH2)12Me
O
O
P
H
N
HO
OHO (CH2)12Me
O
O
	   251	  
((Furan-2-yl)(hexadecanamido)methyl)phosphonic acid (48d) in hPAP 
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((Furan-2-yl)octadecanamido)methyl)phosphonic acid (48e) in hPAP 
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Ethyl hydrogen ((furan-2-yl)(hexadecanamido)methyl)phosphonate (49d) in hPAP 
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 Ethyl hydrogen ((furan-2-yl)(octadecanamido)methyl)phosphonate (49e) in hPAP 
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Diethyl (furan-2-yl(tetradecanamido)methyl)phosphonate (50c) in hPAP 
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Diethyl (furan-2-yl(hexadecanamido)methyl)phosphonate (50d) in hPAP 
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 ((Furan-2-yl)(tetradecanamido)methyl)phosphonic acid (48c) in pPAP 
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((Furan-2-yl)(hexadecanamido)methyl)phosphonic acid (48d) in pPAP 
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((Furan-2-yl)octadecanamido)methyl)phosphonic acid (48e) in pPAP 
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Ethyl hydrogen ((furan-2-yl)(hexadecanamido)methyl)phosphonate (49d) in pPAP 
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 Ethyl hydrogen ((furan-2-yl)(octadecanamido)methyl)phosphonate (49e) in pPAP 
 
R-49e 
 
 
 
S-49e 
 
P
H
N
HO
OEtO (CH2)16Me
O
O
P
H
N
HO
OEtO (CH2)16Me
O
O
	   262	  
Diethyl (furan-2-yl(tetradecanamido)methyl)phosphonate (50c) in pPAP 
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Diethyl (furan-2-yl(hexadecanamido)methyl)phosphonate (50d) in pPAP 
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D.4 Predicted Binding Orientations of Compounds 56c-h and 57c-h (Chapter 5) in 
hPAP and pPAP 
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 (Tetradecanamido(thiophen-2-yl)methyl)phosphonic acid (56c) in hPAP 
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(Hexadecanamido(thiophen-2-yl)methyl)phosphonic acid (56d) in hPAP 
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(Octadecanamido(thiophen-2-yl)methyl)phosphonic acid (56e) in hPAP  
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((2-Octyloxy)acetamido)(thiophen-2-yl)methyl)phosphonic acid (56f) in hPAP 
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 ((2-Hexadecyloxy)acetamido)(thiophen-2-yl)methyl)phosphonic acid (56g) in hPAP 
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((2-Octadecyloxy)acetamido)(thiophen-2-yl)methyl)phosphonic acid (56h) in hPAP 
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Ethyl hydrogen (tetradecanamido(thiophen-2-yl)methyl)phosphonate (57c) in hPAP 
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 Ethyl hydrogen (hexadecanamido(thiophen-2-yl)methyl)phosphonate (57d) in hPAP 
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Ethyl hydrogen (octadecanamido(thiophen-2-yl)methyl)phosphonate (57e) in hPAP  
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Ethyl hydrogen ((2-octyloxy)acetamido(thiophen-2-yl)methyl)phosphonate (57f) in hPAP  
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Ethyl hydrogen ((2-hexadecyloxy)acetamido(thiophen-2-yl)methyl)phosphonate (57g) in hPAP 
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Ethyl hydrogen ((2-octadecyloxy)acetamido(thiophen-2-yl)methyl)phosphonate (57h) in hPAP 
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(Tetradecanamido(thiophen-2-yl)methyl)phosphonic acid (56c) in pPAP 
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(Hexadecanamido(thiophen-2-yl)methyl)phosphonic acid (56d) in pPAP 
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(Octadecanamido(thiophen-2-yl)methyl)phosphonic acid (56e) in pPAP  
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((2-Octyloxy)acetamido)(thiophen-2-yl)methyl)phosphonic acid (56f) in pPAP 
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 ((2-Hexadecyloxy)acetamido)(thiophen-2-yl)methyl)phosphonic acid (56g) in pPAP 
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((2-Octadecyloxy)acetamido)(thiophen-2-yl)methyl)phosphonic acid (56h) in pPAP 
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Ethyl hydrogen (tetradecanamido(thiophen-2-yl)methyl)phosphonate (57c) in pPAP 
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 Ethyl hydrogen (hexadecanamido(thiophen-2-yl)methyl)phosphonate (57d) in pPAP 
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Ethyl hydrogen (octadecanamido(thiophen-2-yl)methyl)phosphonate (57e) in pPAP  
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Ethyl hydrogen ((2-octyloxy)acetamido(thiophen-2-yl)methyl)phosphonate (57f) in pPAP  
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Ethyl hydrogen ((2-hexadecyloxy)acetamido(thiophen-2-yl)methyl)phosphonate (57g) in pPAP 
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Ethyl hydrogen ((2-octadecyloxy)acetamido(thiophen-2-yl)methyl)phosphonate (57h) in pPAP 
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